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SUMMARY
The thesis embodies work designed to investigate the 
acute effects of catecholamines on the hepatic metabolism 
of foreign compounds. Most of the studies were performed 
on the isolated perfused liver of the rat. The historical 
development of the techniques used in the perfusion of the 
liver is reviewed. The literature concerning the properties 
of the hepatic mixed function system responsible for the 
metabolism of foreign compounds has been reviewed. Previous 
work on the effects of catecholamines on drug metabolism is 
also discussed.
The operative procedure and the technique for the per­
fusion of the liver were developed to enable rapid transfer 
of the liver to the perfusion chamber without a period of 
anoxia, which has characterised many previous attempts at 
perfusion of the liver. The liver was perfused with a semi­
synthetic medium. The viability of the liver was assessed 
by a variety of tests of biochemical and physiological function 
and by histological examination. The technique developed 
allowed the liver to be successfully perfused for periods of 
up to 6 h, whilst maintaining a functional integrity.
The metabolism of the type I and the type II substrates, 
hexobarbitone and aniline respectively, were investigated. 
Hexobarbitone is removed by a first order reaction at a rate 
comparable to that previously reported for the liver in vivo.
Aniline metabolism, which has not previously been inves­
tigated in the perfused liver, was studied in some detail. 
Aniline is removed biphasically from the perfusion medium.
ii
Half of the aniline removed is converted to an acid-labile 
conjugate, possibly aniline-N-glucuronide, and a further 25% 
is converted to p-aminophenol and its conjugates. 3H-aniline 
added to the perfused liver could be quantitatively accounted 
for after 3 h perfusion. In agreement with previous findings, 
it was found that p-aminophenol reacts with haemoglobin, thus 
making it impossible to detect free p-aminophenol in the 
perfusion medium. The differences between the pattern of 
aniline metabolism by the perfused liver and by the whole 
animal, where aniline is excreted mainly as p-aminophenol and 
its conjugates, are discussed.
The kinetics of aniline removal have been analysed by 
curve stripping and model fitting. The mathematics of these 
procedures are described separately in Appendix II. In the 
perfused liver aniline is distributed throughout a two- 
compartment system. The first compartment probably repre­
sents the total aqueous phase and aniline is removed from 
this compartment only. The identity of the second compart­
ment is less certain. Several possibilities are discussed 
and in view of evidence obtained with SKF 525-A, an inhibitor 
of drug metabolism, it is suggested that the second compart­
ment may represent the binding of aniline to a non-metabolic 
site of cytochrome P-450.
Both adrenaline and noradrenaline inhibit the metabolism 
of hexobarbitone by the perfused liver but neither catechol­
amine has any effect on the metabolism of aniline. Catechol­
amines do not inhibit the metabolism of either aniline or 
hexobarbitone by the microsomal fraction or by liver slices.
iii
It was thus concluded that catecholamines are not in­
hibiting hexobarbitone removal directly. The possibility that 
their effect is mediated by cyclic AMP, a compound reported 
to inhibit hexobarbitone metabolism by the perfused liver, 
was investigated. Papaverine, an inhibitor Of phosphodiesterase, 
does not potentiate the inhibitory effects of catecholamines 
on hexobarbitone metabolism, nor does it cause them to have 
any inhibitory effect on the metabolism of aniline. Cyclic 
AMP was shown to inhibit drug metabolism by liver slices, 
whereas catecholamines are without effect. The probability 
that cyclic AMP is not important in mediating the effects of
catecholamines on drug metabolism is discussed in some
/
detail.
Both catecholamines increase the portal pressure in the
2 +-perfused liver by over 100%. When Ca is omitted from the
perfusion medium it was found that this pressor effect is
almost totally inhibited. Catecholamines also no longer in-
2+hibit the metabolism of hexobarbitone. The omission of Ca 
leaves the metabolic effects of catecholamines relatively 
unaffected. It was thus suggested that catecholamines might 
be inhibiting hexobarbitone metabolism through an effect on 
the hepatic vasculature.
In a constant flow system, as used in this study, one 
way in which such an effect of catecholamines might manifest 
itself is as a redistribution of perfusate through the liver.
It was found that considerable controversy exists as to 
whether or not catecholamines can cause a redistribution of 
blood flow within the liver. The available evidence is
iv
assessed separately in Appendix II. The effects of adrenaline 
on the intrahepatic distribution of perfusate have been in­
vestigated by X-radiography, and by perfusing the liver with 
Indian ink followed by histology. It was concluded from 
these studies that catecholamines can cause a redistribution 
of blood flow within the liver, away from the periphery of 
the lobes towards more central regions.
Several possibilities involving a redistribution of per­
fusate are considered which might explain the selective in­
hibition of hexobarbitone metabolism by catecholamines. It 
was concluded that it probably results from a hypoxia of 
peripheral cells. This is superimposed on an overall tendancy 
to hypoxia caused by the increased oxygen consumption that 
will result from the stimulation of intermediary metabolism 
by catecholamines. This may then cause an inhibition of 
hexobarbitone metabolism, which is very sensitive to hypoxia, 
while having very little effect on aniline metabolism, which 
is relatively unaffected by even severe hypoxia.
The possible physiological significance of this effect 
of catecholamines on the metabolism of foreign compounds is 
discussed.
Rats were also pre-treated with catecholamines to deter­
mine their in vivo effects on hepatic drug metabolism. Nor­
adrenaline was found to stimulate the metabolism of both 
aniline and aminopyrine by the microsomal fraction whereas 
adrenaline produces an inhibition of the metabolism of both 
types of substrate. It was found that this is not due to a
Vdirect effect of catecholamines on the components of the 
microsomal electron transport chain.
The possibility that the effect is manifest during the 
preparation of the microsomal fraction was studied by washing 
microsomes, after their original preparation, in solutions 
of catecholamines. The results obtained were very similar 
to those found after pre-treating rats with catecholamines. 
However it was found that the apparent stimulation caused 
by noradrenaline is in fact a protection against a loss of 
drug-metabolising activity occurring on washing control micro­
somes.
The effects of washing microsomes were investigated 
further. It was found that EDTA also provides protection 
against the loss of activity caused by washing and even in­
creases the activity compared with unwashed microsomes.
Several possible mechanisms were investigated and these are 
discussed. It was found that one of the main effects of 
washing the microsomes is to stimulate the non-enzymatic 
peroxidation of lipid and to reduce the binding of type I 
substrates to cytochrome P-450. On the other hand, washing 
in EDTA largely prevents the increase of lipid peroxidation 
and gives rise to an increased binding of type I substrates 
to cytochrome P-4 50.
It was concluded that washing the microsomes stimulates 
lipid peroxidation, possibly by the removal of an endogenous 
inhibitor, and this results in the destruction of phosphatidyl­
choline, known to be necessary for the integrity of the type I 
binding site. This then results in a decrease in the metabolism
vi
of type I substrates. EDTA, a known inhibitor of lipid per­
oxidation, prevents these effects.
Washing of the microsomes also almost completely abolishes 
the enhancement of aniline metabolism by acetone. This can 
also be prevented by washing with EDTA. It is suggested that 
the current work supports a previous hypothesis that acetone 
causes enhancement by promoting the binding of type II sub­
strates to type I sites, thus increasing their metabolism.
It is further suggested that washing the microsomes, by de­
stroying type I sites, reduces acetone enhancement.
CHAPTER 1
Introduction
11.1 Historical perspectives of the metabolism of foreign
compounds
Between 1840 and 1900 considerable research was carried 
out on the metabolism of foreign compounds and by the turn of 
the century most of the major routes of metabolism had been 
discovered. After 1900 the discovery of new routes of meta­
bolism was slower and most research was concerned with study­
ing the known routes in detail-, although some work was directed 
towards investigating the underlying mechanisms of metabolism.
As research into the metabolism of foreign compounds was 
progressing during the, first few decades of this century 
simultaneous discoveries were being made on cellular ultra­
structure, with the pioneering work of Claude. In 19 38 he 
isolated a fraction of the cell, later called the microsomal 
fraction (Claude, 1943a), which was shown to be derived from 
the endoplasmic reticulum (Porter, Claude and Fullam. 194 5).
In 194 9 Mueller and Miller reported that the hepatic micro­
somal fraction could metabolise aminoazo dyes by oxidative N- 
ndemethylation." 'This finding stimulated an upsurge in mechan- 
'"ist'i'c interest in metabolic reactions which continues to the 
present day. However the study of the microsomal metabolism 
of foreign compounds was put on a firm basis by Brodie who 
showed that the hepatic microsomal fraction metabolised a wide 
variety of foreign compounds and established that it contained 
a group of low specificity enzymes capable of transforming 
many of the diverse anutrients ingested by the organism (Brodie,
Axelrod, Cooper, Gaudette, La Du, Mitoma and Udenfriend, 1955) . 
Shortly after this classic paper Williams (1959) published an 
enlarged second edition of his book on detoxication mechanisms 
which was to become one of the leading sources of information 
on the subject for many years. He outlined the two phase con­
cept of the metabolism of foreign compounds which rationalised 
the information available to that time and in the light of 
which future discoveries were more easily interpreted. In his 
scheme compounds could undergo either transformation (mainly 
oxidation) reactions or synthetic (conjugation) reactions or 
both.
The previous year Klingenberg (19587) and Garfinkel (1958) 
had discovered a new haemoprotein in the hepatic microsomal 
fraction, later called cytochrome P-450 (Omura and Sato, 1964).
It was soon shown to be essential for microsomal oxidation 
reactions and with the development of more sophisticated spectro- 
photometric techniques considerable information became available 
on the new protein. A scheme for the molecular mechanisms 
involved in the oxidation of foreign compounds was devised by 
Gillette (1963) which included a requirement for cytochrome 
P-450 and an activated oxygen species. Spectrophotometric 
studies on cytochrome P-450 continued and in 1966 Remmer, 
Schenkman, Estabrook, Sasame, Gillette, Narasimhulu, Cooper 
and Rosenthal and Imai and Sato (19 66b) found that foreign 
compounds produced characteristic changes in the difference 
spectrum of the microsomal fraction. Most foreign compounds 
producing such a change could be classified into one of two 
groups, based on the type of spectral change occurring. Sub­
sequent work revealed that the changes were a reflection of
binding to sites on cytochrome P-4 50 and that the significance 
of the distinction into two groups went further than changes 
in the difference spectrum and had ramifications throughout 
almost all aspects of microsomal oxidative reactions (Gillette, 
Davis and Sasame, 1972).
During the past 15 years considerable advances have been 
made towards an understanding of many of the phenomena of 
microsomal oxidative metabolism. Although induction of drug 
metabolism was first reported in 1954 by Brown, Miller and 
Miller the mechanism involved is still not completely under­
stood. Gelboin and Nebert (see review by Gelboin, 1971) have 
recently been examining the molecular mechanisms involved in 
induction and the genetic regulation of induction. Recently 
the importance of induction and metabolism in carcinogenesis 
has been realised (Creaven and Parke, 1966; Miller, 1970;
Lake and Parke, 1972b).
Several groups of workers have recently been investigating 
the phenomenon of enhancement, an increase in the specific 
activity of the microsomal mixed function oxidase occurring 
in vitro. This work stems from findings in the latter half 
of the last-decade by Imai and Sato (1966a) and Anders (1968) 
that several compounds could enhance drug metabolism by the 
hepatic microsomal subcellular fraction. Enhancement provides 
a means whereby the metabolising activity of the liver can be 
increased quickly and reversibly. At•present there is little 
information available as to the mechanisms of enhancement or 
whether it may play a physiological role.
The mechanisms of the mixed function oxidases in the
4liver have received considerable attention and many attractive 
reaction schemes have been proposed to explain the observed 
results (see review by Estabrook, 1971). Although a definitive 
scheme has yet to be devised some of the more recent schemes 
explain most of the observed data. Coon and his associates 
have recently been studying a reconstituted mixed function 
oxidase system. They have identified the components vital to 
the functioning of the system which has led to the realisation 
that cytochrome P-450 and the phospholipid phosphatidylcholine 
are complexed in some way that is responsible for the activity 
of the system (Autor, Kaschnitz, Heidema and Coon, 1973). The 
importance of this association is becoming increasingly 
apparent and recent evidence, over the past two years, impli­
cates it in many of the unexplained phenomena of the oxidative 
metabolism of foreign compounds such as substrate-induced 
changes in the microsomal difference spectrum and the loss of 
metabolising activity that occurs on storage of the microsomes.
i
The hepatic microsomal mixed function oxidase is affected 
by a wide variety of genetic and environmental conditions and 
this aspect of its activity has received much attention. An­
other aspect to be investigated in some detail is the role of 
“several hormones in possible regulatory mechanisms. Many 
“steroids can cause an induction of the enzymes of drug metabolism 
(Conney, 1967) and a sex difference in the activity of the 
mixed function oxidase in rats has been shown to be due to 
androgens (Kato and Onoda, 1970). In contrast, high levels of 
circulating corticosterone result in inhibition of the mixed 
function oxidases (Radzialowski and Bousquet, 1968). Many 
other hormones such as growth hormone (Wilson, 196 9) growth
factors in pregnancy (Neale and Parke,' 197 3) , ACTH and 
thyroxine (Kato and Gillette, 19 65) and glucagon and cyclic 
AMP (Weiner, Buterbaugh and Blake, 1972a) have been shown to 
influence mixed function oxidase activity but the physiological 
role of such effects has still to be.determined.
Early work by Fouts (1962) suggested that an alteration 
in glycogen levels in the liver affected mixed function 
oxidase activity but it was later shown that this was not so 
(Dixon, Rogers and Fouts, 1964). Thus although the effects 
of many hormones in the long term control of drug-metabolising 
enzyme levels have been investigated in detail little is known 
of how the activity of the mixed function oxidase is regulated 
acutely, or even if such regulation occurs.
1.2 The aims of the investigation
A survey of the literature on the metabolism of foreign 
compounds revealed that very little is known of the normal 
physiological mechanisms for the acute regulation of drug 
metabolism. In view of the known acute regulatory effects 
of catecholamines upon other metabolic pathways it was thought 
.possible that they might play some role in any such mechanism. 
The acute interaction of catecholamines and the hepatic mixed 
function oxidase have therefore been studied.
The effects of catecholamines upon drug metabolism were 
first studied in the isolated perfused liver of the rat. The 
perfused liver provided a system that closely resembled the 
liver in vivo while being free of possible complicating factors 
such as the secondary release of other hormones by catechol-
amines or interaction of the substrate with other organs.
The viability of the perfused liver was first established, 
using several tests of hepatic function. The metabolism of 
hexobarbitone, a typical type I compound and aniline, a 
typical type II compound, both hydroxylated by the hepatic 
microsomal mixed function oxidase system, were studied in 
the perfused liver. Although the metabolism of hexobarbitone 
in the perfused liver had been previously reported (Sitzel, 
Anders and Mannering, 1966) the metabolism of aniline had not 
previously been investigated. Thus the metabolism of aniline 
by the perfused liver was first characterised in some detail. 
The effect of the catecholamines adrenaline and noradrenaline 
on the metabolism of these two substrates by the perfused 
liver was studied.
Due to the possible complications of the vasoactive 
effects of catecholamines upon hepatic mixed function oxidase 
activity the effects of adrenaline and noradrenaline on the 
microsomal fraction itself and upon the interaction of sub­
strates with cytochrome P-450 were investigated.
Because it was possible that catecholamines might be 
acting at the level of the intact cell the investigation was 
later expanded to include a study of the effects of catechol­
amines on liver slices, which by their nature are independent 
of changes in blood flow and hypoxia but retain the organis­
ation and compartmentalisation of the intact cell.
It was considered possible that the effect of catechol­
amines upon the activity of the mixed function oxidase of the
7liver might be explained in terms of haemodynamic effects..
Due to the controversy in the literature on the effects of 
sympathomimetics upon liver blood flow the influence of 
adrenaline on flow was investigated in the perfused liver by 
X-radiography and by Indian ink perfusion followed by 
histology.
The effects of the pre-treatment of rats with catechol­
amines was investigated to determine the time course of the 
changes in microsomal metabolism reported by Fouts (1962) and 
to determine if such changes could be due to the effects 
observed in the perfused liver.
The results of this investigation raised the possibility 
that some of the effects of catecholamine pre-treatment were 
due to changes caused in the microsomal fraction during its 
preparation.
Since adrenaline was known to be an inhibitor of lipid 
peroxidation the possible involvement of lipid peroxidation 
with mixed function oxidase activity was investigated. In 
the course of this study it was observed that washing micro- 
somes reduced their drug-met abolishing activity and also 
-abolished acetone enhancement of this activity. This was 
further studied using inhibitors of lipid peroxidation.
In all studies the rat was used as an experimental animal. 
It has been widely used both in studies on the metabolism of 
foreign compounds and in liver perfusion experiments, and its 
use is well documented in these areas. It is easily available,
8cheap and can be maintained with the minimum of attention.
Rat liver is particularly suitable for perfusion since it is 
of a manageable size. The liver of larger animals presents 
problems in the adequacy of the oxygen supply and the relative 
importance of the hepatic artery.
CHAPTER 2
The Metabolism of Foreign Compounds
92•1 Historical introduction to the metabolism of foreign
compounds
For over 120 years it has been known that the organism 
can transform ingested foreign compounds and excrete the 
products. The earliest recorded observation of such a reaction 
was made by Rouelle in 1784 who noticed that animals excreted 
hippuric acid after the ingestion of benzoic acid. However he 
did not propose any causal relationship and it was not until 
1831 that WOhler put forward the idea that after the ingestion 
of benzoic acid the organism actively converted it to hippuric 
acid. It was later shown by Schultzen and Grabe (1867) that 
the formation of hippuric acid was a common metabolic pathway 
for several aromatic acids.
The first reported examples of the oxidation of foreign 
compounds were the hydroxylation of benzene to phenol and the 
hydroxylation of toluene to benzoic acid (Schultzen and Naunyn, 
1867). From this date to the turn of the century most of the 
routes of biotransformation were to be discovered.
Ethereal sulphate conjugation was discovered by Baumann 
in 1876. He observed that these conjugates were much less toxic 
than the parent compound. This was the first suggestion that 
biotransformations were other than simple metabolic conversions 
and from this time the concept of detoxification slowly gathered 
momentum, though it was not until 1895 that it was explicitly 
stated when Neumeister (1895) proposed that the process of 
glucuronide conjugation was one of detoxification.
In 1879 after 2-5 years of accumulated evidence Schmiedeberg
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and Meyer established that glucuronida'tion was one of the 
synthetic reactions of the biotransformation of foreign 
compounds. In the same year Baumann and Preusse (187 9) 
observed that bromobenzene was converted to a mercapturic 
acid and independently Jaffe (1879) also discovered that 
halogenated benzenes formed mercapturic acids.
In 1887 Jaffe and Cohn found that furfural, a heterocyclic 
compound, was converted to pyromucic acid by oxidation, 
followed by conjugation to furoylglycine and furfuracryluric 
acid. They also found that although furfural was oxidised 
to pyromucic acid by hens it was then conjugated with 
ornithine (Jaffe and Cohn, 1888) confirming an earlier finding 
of Jaffe (1877) that hens formed ornithine conjugates only.
His in 1887 reported the transformation of a foreign 
organic compound by methylation, the conversion of pyridine 
to methylpyridinium hydroxide.
In 1893 Cohn discovered that dogs and rabbits fed nitro- 
benzaldehyde excreted acetylaminobenzoic acid and hence dis­
covered the acetylation of aromatic compounds.
An interesting observation by Lang (1894) was that some 
of the hydrocyanic acid fed to dogs was excreted as the 
thiocyanate. This compound is only 0.5% as toxic as the 
parent drug so that this reaction may be regarded as a true 
detoxification mechanism without conjugation.
Discovery of new routes in the metabolism of foreign
11
compounds became slower after the turn of the century, since 
most reactions had been described in the previous 25 years. 
Thierfelder and Sherwin (1914, 1915) observed that phenyl- 
acetic acid could be conjugated with glutamine in some primates. 
Forty years later Myers and Smith (1954) found that phenols 
were conjugated with glucoside in insects.
Thus, by 1920,almost all of the routes of metabolism had 
been discovered and over the next three decades most work was 
concentrated on consolidating these findings. This work 
culminated in the publication of 'Detoxication Mechanisms' by 
R.T. Williams in 1947. The mid 1950's witnessed one of the 
major turning points in the study of drug metabolism. Two 
important proposals were made that were to transform our under­
standing of the drug-metabolising system. The first, by Brodie 
et al in 1955, was that most biotransformation reactions were 
catalysed by a series of enzymes situated in the endoplasmic 
reticulum of the liver cell. The full significance of this 
finding is discussed later. It turned attention towards a 
specific site of metabolism and in the twenty years that 
followed, intensive research has provided much insight into 
the mechanisms operating therein. The second proposal, by 
Williams in a second edition of his book in 1959, was a scheme 
for the progressive metabolism of compounds to active or in­
active products. Metabolic reactions were divided into phase 
I and phase II. Phase I reactions consisted of oxidation and 
reduction involving transformation of existing groups on the 
molecule whereas phase II reactions consisted of conjugation 
reactions involving a synthetic process in which an existing 
molecule was added to a compound. These proposals permitted
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a rationalisation of the metabolic processes that had not been 
possible previously. The different types of biotransformation 
reactions have been discussed at length in several excellent 
reviews (see Williams and Par.ke, 1964; Parke, 1968; Parke 
and Williams, 1969; La Du, Mandel and Way, 1971; Brodie and 
Gillette, 1971; Parke, 1972).
2.2 The metabolism of foreign compounds by the hepatic 
microsomal subcellular fraction
2*2.1 The concept and nature of the microsomal fraction
/
Brodie et al (1955) showed that the hepatic microsomal 
fraction was responsible for the metabolism of many foreign 
compounds. This fraction was first isolated by Claude in 1938 
and was found to consist mainly of a lipoprotein complex 
together with some ribosomal type nucleic acid as well as some 
other proteins (Claude, 1939, 1940; Feulgen and Bersin, 1939).
Although the fraction was of cellular origin, the form 
that the elements adopted occurred during their isolation 
(Claude, 1938, 1939). Claude (1943a) called them 'microsomes' 
to distinguish them from other, natural, cell components. It 
was shown by histological methods and preparative ultracentri­
fugation that the microsomal fraction was derived from an 
important part of the fundamental substance of the cytoplasm 
(Claude, 1943b, 194 6) and further investigations established 
that it was derived from the endoplasmic reticulum (Porter 
et al, 1945; Claude, Porter and Pickels, 1947). Thus in the 
ten years following its first isolation the microsomal fraction
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was characterised as vesicular, with a diameter between 100 
and 150y, derived from the endoplasmic reticulum, and com­
prising mainly lipoprotein.
2.2.2 The involvement of the microsomal subcellular fraction 
in the metabolism of foreign compounds
Shortly after the characterisation of the microsomal
fraction Mueller and Miller (194 9) reported that certain foreign
compounds could be metabolised by this system. However it was
not until 1955 that Brodie et al published their important paper,
with its much wider implications, in which they established
/
that the hepatic microsomal fraction was responsible for the
metabolism of a wide range of foreign compounds. Microsomal
2 +metabolism was found to have a requirement for NADPH, Mg and 
molecular oxygen (Brodie et al, 1955). This placed the enzyme 
system within the external mixed function oxidase classification 
of Mason (1957, 1965) and also in the monooxygenase class-
18ification of Hayaishi (1964). It was shown with labeled 
18and ^ 0  that the oxygen utilised in the hydroxylation of 
acetanilide was derived from molecular oxygen and not from 
water (Posner, Mitoma, Rothberg and Udenfriend, 1961).
The hepatic microsomal fraction was found to catalyse a 
wide variety of oxidative reactions. These were deamination,
N-, 0-, and S- dealkylation, aryl and alkyl hydrocarbon hydroxy­
lation, epoxidation, formation of alkylol derivatives, N- 
hydroxylation, N- and S- oxidation, and dehalogenation (for 
review see Gillette, 1966). This bewilderingly diverse series 
of reactions becomes more comprehensible when viewed in the
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light of a suggestion made by Brodie, Gillette and La Du (1958). 
They pointed out that all of these reactions could be regarded 
as forms of a hydroxylation reaction and this concept was 
supported by further work of Gillette (reviewed 1963, 1966).
The reactions of the hepatic drug-metabolising enzymes situated 
in the microsomal fraction have been reviewed many times in the 
past decade (see Gillette, 1963, 1966, 1969; Mannering, 1968, 
1971; Parke, 1968, 1972; Gillette, Conney, Cosmides, Estabrook, 
Fouts and Mannering, 1969; Brodie and Gillette, 1971; Kratz, 
1973).
2.2.3 The components of the hepatic microsomal electron 
transport system
Brief mention was made in the last section of the involve­
ment of NADPH and molecular oxygen in the metabolism of foreign 
compounds by the microsomal fraction. They are utilised by an 
electron transport system responsible for the oxidation of 
substrates. Chance and Williams (1954) had noticed that more 
NADPH was required to reduce cytochrome b^ in the liver micro­
somal fraction than was theoretically necessary. They postulated 
that in addition to cytochrome b^ there was another electron 
accepting component present. Four years later the development 
of new spectrophotometric techniques by Chance (1957) enabled 
a thorough investigation of the cytochrome pigments observed in 
the microsomal fraction to be carried out. In the following 
year independently, and almost simultaneously, Klingenberg (1958) 
and Garfinkel (1958) announced the discovery of a new carbon 
monoxide-binding cytochrome (haemoprotein) in the microsomal 
fraction. This was confirmed by Omura and Sato (1962, 1964)
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who were first to name the new haemoprotein cytochrome P-4 50 
(Omura and Sato, 19 64). Considerable evidence has now 
accumulated that cytochrome P-450 is vital, and central, to 
the functioning of the microsomal mixed function oxidase and 
it has been extensively reviewed recently (Gillette and Gram, 
1969; Estabrook and Cohen, 1969; Estabrook, 1971; Mannering, 
1971; Gillette et al, 1972). The properties and role of 
cytochrome P-450 are discussed in Section 2.2.5.
Discrepancies in the response of cytochrome P-4 50 to a 
variety of factors led many workers to the conclusion that 
there could be two forms of cytochrome P-450. A second form 
was identified and designated cytochrome P^-450 (Sladek and 
bannering, 1966, 1969a, b; Shoeman, Chaplin and Mannering,
1969; Mannering, Sladek, Parli and Shoeman, 1969). This has 
also been referred to as cytochrome P-448 (Alvares, Schilling, 
Levin and Kuntzman, 1967) and cytochrome P-446 (Hildebrandt, 
Remmer and Estabrook, 1968) though all forms are now thought 
. to be identical (Mannering, 1971). However it is not thought 
to be normally present in the microsomal fraction in any 
appreciable amount (Mannering, 1971).
 Unqualified reference has already been made to another
— cytochrome, cytochrome b^. The existence of this compound was 
first suspected in 1940 by Keilin and Hartree although it was 
not until 1952 that it was possible to show that the unidentified 
pigment was associated with the microsomal fraction of several 
cell types including liver (Strittmatter and Ball, 1952). Two 
years later it was identified and called cytochrome b^ 
(Pappenheimer and Williams, 1954). The studies of Klingenberg 
(1958) and Omura and Sato (1964) revealed that it was the only
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other cytochrome present in the hepatic microsomal fraction 
apart from cytochrome P-450 -and its variants.
Work with the adrenal microsomal fraction, which hydroxy-
lates steroids, led to the discovery that a non-haem iron
protein, adrenodoxin, functions as an electron carrier between
the flavin enzyme, adrenodoxin reductase, and cytochrome P-4 50
in the electron transport system (Suzuki and Kimura, 1965).
Although very little evidence exists to support the hypothesis,
it has been suggested several times that an analogous non-haem
iron protein could function in the transport of electrons to
cytochrome P-450 in the hepatic microsomal fraction (Estabrook
/
and Cohen, 1969). Recently Diplock and Lucy (1973) repeated 
this suggestion and reported that they had identified such a 
protein with selenide in complex with non-haem iron as the 
active centre. Further studies by the same group (Caygill and 
Diplock, 1973; Caygill, Diplock and Jeffery, 1973) support 
this theory and indicate that the protein is normally protected 
from oxidation in vivo by vitamin E, possibly because the 
incorporation of selenium into the protein depends on the 
organisation of the membrane phospholipids.
In 1950 Horecker reported that the enzyme NADPH-cytochrome 
- -C- xeductase could be detected in extracts of whole liver. NADPH- 
cytochrome c reductase activity was later found in microsomal 
fractions (Strittmatter and Velick, 1956) and in 1962 the enzyme 
was conclusively demonstrated to be associated with this fraction 
(Phillips and Langdon, 1962; Williams and Kamin, 1962). The 
prosthetic group was identified as flavine adenine dinucleotide, 
FAD (Williams and Kamin, 1962) so that the enzyme could be
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classified as a flavoprotein. The properties of the enzyme
have been comprehensively reviewed by Kamin, Masters, Gibson
and Williams (1965). Cytochrome c and other electron acceptors
not normally present in the microsomal fraction inhibited the
oxidation of foreign compounds. It was reasoned that since
the enzyme normally catalysed the transport of electrons, and
since a diversion of these electrons to electron acceptors such
as cytochrome c resulted in an inhibition of metabolism, then
a free flow of electrons catalysed by this enzyme must have
been a requirement for metabolism. It was thus suggested that
NADPH-cytochrome c reductase was a component of the microsomal
drug-metabolising system (Gillette, Brodie and La Du, 1957;
/
Gillette, 1966) and was regarded as the most probable agent 
in the transfer of electrons from NADPH to cytochrome P-450, a 
role that is now generally accepted (Kratz, 1973).
After the detection of NADPH-cytochrome c reductase a 
second flavoprotein, NADH-cytochrome b^ reductase, was isolated 
from the hepatic microsomal fraction (Strittmatter and Velick, 
1957a, b; Strittmatter, 1958). This enzyme has been suggested 
to be involved in the reduction of cytochrome P-4 50 by an 
alternative electron-donor pathway via cytochrome b^ (Estabrook 
and Cohen, 1969). Cytochrome b^ may also be reduced by NADPH 
via a so-called NADPH-cytochrome b^ reductase (Strittmatter,
1963). Recently detergent-solubilised NADPH-cytochrome c 
reductase was shown to reduce cytochrome bj- (Satake, Imai and 
Sato, 1972) so that NADPH-cytochrome b^ reductase is possibly 
identical to NADPH-cytochrome c reductase.
The rate of oxidation of foreign compounds is more closely
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related to the rate of cytochrome P-4 50 reduction than to the 
total amount of cytochrome P-450 present or to the rate of 
cytochrome c reduction (a measure of NADPH-cytochrome c 
reductase activity) (Gillette and Gram, 1969; Gillette, 1969; 
Gigon, Gram and Gillette, 1969). This finding led these 
authors to the conclusion that an ’NADPH-cytochrome P-450 
reductase1 was rate limiting in the overall oxidative reaction 
of the microsomal fraction. The existence of such an enzyme 
has been accepted in theory although little is known about it 
except how its activity is affected. The enzyme would be 
responsible for the reduction of oxidised cytochrome P-450.
In a reconstituted microsomal system that hydroxylated 
foreign compounds there was a requirement for an unidentified 
lipid component for maximal activity (Lu and Coon, 1968). The 
factor was heat stable (Lu, Strobel and Coon, 1969) and in some 
way increased the rate of reduction of cytochrome P-450 (Strobel, 
Lu, Heidema and Coon, 1970). It has now been shown to be 
phosphatidylcholine (Strobel et al, 1970; Autor et al, 1973).
2.2.4 The organisation of the microsomal mixed function 
oxidase system
The metabolism of foreign compounds by the microsomal mixed
function oxidase system involves the reduction of some component 
of the- microsomal fraction by NADPH which then reacts with 
molecular oxygen to form an 'active oxygen1 intermediate. The 
'active oxygen1 is subsequently transferred to the substrate 
(Gillette, 1963). In such a mechanism equivalent amounts of 
NADPH, molecular oxygen and substrate would be utilised in the
LPO LP
3+ 2+P-450
TPNH(NADPH)
3+ 2+hvP-450 P-450 P-450CO
CO
SOH
2+
P-450
Y/
cytochrome b DPNH(NADH)
S
P-4503+V
Figure 1 Hypothetical scheme proposed by Estabrook (1971) to 
explain the mechanism of drug metabolism by the hepatic micro­
somal mixed function oxidases.
The substrate is designated S. fpT is the flavoprotein NADPH-
cytochrome c reductase and fpD is the flavoprotein NADH-cyto-
chrome b^ reductase. "X" represents a postulated non-haem iron
protein which is shown to take part in the peroxidation of
lipid (LP). The substrate combines with oxidised cytochrome 
3+P—450 (P—450 ) which is then reduced by one electron from
NADPH, reacts with molecular oxygen and is then further reduced 
by a second electron from either NADH or NADPH. The reduction 
of the oxidised substrate cytochrome P-4 50 complex is thought 
to be rate limiting.
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reaction. A 1:1:1 stoichiometry for the demethylation of 
aminopyrine was observed (Ernster and Orrenius, 1965) but 
later work showed that two moles of NADP were formed for every 
mole of formaldehyde produced (Estabrook and Cohen, 1969).
Thus the overall reaction is more complex than in the scheme 
proposed by Gillette (1963).
In the original description of microsomal metabolism there 
was a requirement for NADH as well as NADPH (Mueller and Miller, 
1949, 1953). From these earliest reports to the present 
time various investigators have reported that NADH can take 
part in microsomal oxidative metabolism (Conney, Brown, Miller 
and Miller, 1957; Nilsson and Johnson, 1963; Ullrich, 1969).
In addition 50% more NADPH was found to be oxidised than 
hexobarbitone was metabolised (Sasame, 1964). These findings 
were rationalised by Estabrook who suggested a mechanism for 
the metabolism of foreign compounds that included a role for 
NADH (Estabrook and Cohen, 1969; Estabrook, 1971).
The more recent scheme (Estabrook, 1971) is illustrated 
in Fig. 1. Hildebrandt and Estabrook (1971) have suggested 
that NADPH preferentially donates the first electron in the 
.reduction of cytochrome P-4 50 and that either NADH or NADPH 
can donate-the second electron, which would be transported via 
cytochrome b^. This was confirmed in studies with antibodies 
to cytochrome b,- which prevented NADH synergism of oxidative 
metabolism but did not affect the reaction when NADPH was the 
only electron donor (Sasame, Mitchell, Thorgeirsson and 
Gillette, 1973). Recent work by Correia and Mannering (1973a,
'b) also confirmed these findings and showed that the second 
electron is donated by NADPH or NADH, both via cytochrome b'^ ,
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with NADH being the more efficient of the two donors of this 
electron only in the metabolism of type I substrates. Some 
form of•interactive mechanism similar to that proposed by 
Estabrook (1971) is almost certainly operative in the micro­
somal fraction.
2.2.5 Properties of cytochrome P-450 and the substrate-
induced spectral changes in the microsomal fraction
Cytochrome P-4 50 was established to be the pigment 
responsible for the activation of oxygen in microsomal mixed, 
function oxidase reactions in the early 1960's (Estabrook, 
Cooper and Rosenthal, 1963; Omura, Sato, Cooper, Rosenthal 
and Estabrook, 1965; Cooper, Levin, Narasimhulu, Rosenthal 
and Estabrook, 1965). It was also found that the addition of 
17-hydroxyprogesterone to the cytochrome P-450-containing 
fraction of adrenal cortical microsomes caused a character­
istic change in the microsomal difference,spectrum (Narasimhulu, 
Cooper and Rosenthal, 1965). Two groups independently found 
that spectral changes also occurred with suspensions of liver 
microsomal fraction on the addition of exogenous substrates 
(Remmer et al, 19 66; Imai and Sato, 1966). . Subsequent work 
(see Gillette et al, 1972) established that these changes were 
due to interactions of the substrates with cytochrome P-450.
Both Remmer and his group (1966) and Imai and Sato (1966) 
classified the different substrates into two groups on the 
basis of the spectral change produced. The groups were named 
type I and type II respectively after the so-called type I and 
type II spectral changes produced. Schenkman, Remmer and 
Estabrook (1967) confirmed this division and added a third
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classification comprising substrates that produced a modified 
type II spectral change.
The type I spectral change may result from substrate 
binding causing a modification of the electronegativity of the 
sixth ligand of the haem-iron moiety attached to the protein 
of cytochrome P-450 (Schenkman and Sato, 1968). A diverse 
range of compounds produce a type I spectral change (Schenkman 
et al, 1967). In contrast only a few compounds cause a type 
II spectral change, and most are amines (Schenkman et al, 1967). 
The type II spectral change may be due to ferrihaemochrome 
formation produced by direct interaction of the haem-iron of 
cytochrome P-450 with the basic nitrogen of the amine substrate 
(Schenkman et al, 1967). The modified type II spectral change 
is the mirror image of the type I spectral change (and is 
sometimes called a reverse type I). A fairly diverse range 
of compounds produce a modified type II spectral change 
(Schenkman et al, 1967). This change may be due to the inter­
action of a substrate with the bound form of cytochrome P-450 
with the same substrate at a site other than the type I site 
(Schenkman, Cinti, Orrenius, Moldeus and Kraschnitz, 1972).
-Digestion of the phospholipids of the membranes of the 
.microsomal fraction by phospholipase C, which degrades 
phosphatidylcholine (Tzur and Shapiro, 1969) resulted in a 
loss of the type I spectral change and thus of type I 
binding (Chaplin and Mannering, 1969, 1970) since it- has been 
shown that a spectral change is synonymous with binding at 
the corresponding site (Mannering, 1971). The type I binding 
site is probably localised in the hydrophobic region of
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cytochrome P-4 50 and associated with membrane phospholipids. 
Although type I binding was-destroyed by phospholipase C 
digestion, the metabolism of some type I compounds was re­
duced by only 40% (Chaplin and Mannering, 1970). Thus it 
appears that the binding of type I compounds is not obligatory 
for their metabolism although it is facilitative. In contrast 
Jefcoate, Gaylor and Calabrese (19 69) have found that type II 
binding does not appear to have any direct role in the meta­
bolism of type II substrates.
Chaplin and Mannering (1970) observed that a destruction
of the type I binding site resulted in an elevation in the
/
magnitude of the spectral change produced by type II compounds. 
One explanation is that normally there is a type I component 
in the spectral change produced by type II compounds. In 1970 
Schenkman confirmed that this was so. Recently Gorrod and 
Temple (1973) and Kamataki, Shimokawa and Kitagawa (1973), 
working independently, also confirmed this‘and in addition found 
that the difference spectrum of type I compounds have a type 
II component.
It has been observed that NADPH-cytochrome P-450 reductase 
-.activity is influenced by the nature of the substrate present 
„ (Gigon et al, 1968, 1969; Gillette, 1969; Gillette and Gram, 
1969). Type II substrates depressed the rate of reduction of 
the substrate-cytochrome P-450 complex while type I compounds 
stimulated the reduction of the complex by"NADPH-cytochrome 
P-4 50 reductase (Gigon et al, 19 68). The rate-limiting step 
in the oxidation of type I substrates may be the rate of re­
duction of the cytochrome P-450-substrate complex by the first 
electron so that the rate of reduction of the oxidised cyto­
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chrome P-450-substrate (type I) complex is then greater than 
that of the uncomplexed oxidised cytochrome P-4 50 (Gigon et al, 
1969; Gillette and Gram, 1969). Gillette and Gram (1969) 
also suggested that the type II substrate-cytochrome P-4 50 
complex may not be reduced at all but that only the uncom­
plexed cytochrome P-450 would be reduced which could then form 
a complex with the type II substrate which would undergo 
subsequent metabolism. Since the type II interaction results 
in the formation of ferrihaemochrome type II compounds may 
compete with oxygen at the oxygen binding site of cytochrome 
P-4 50 and hence such interactions would not be likely to lead 
to further metabolism at this stage (Orrenius, Wilson, von 
Bahr and Schenkman, 19 72).
2.3 Microsomal lipid peroxidation and its relationship to the
metabolism of foreign compounds by the microsomal fraction
Incubation of the microsomal fraction with NADPH and a 
pyrophosphate has been found to cause peroxidation of membrane 
lipid (Hochstein and Ernster, 1963) . Lipid peroxidation in 
the microsomal fraction was not inhibited by carbon monoxide 
(Nilsson, Orrenius and Ernster, 1964) so that cytochrome P-450 
does not appear to be involved in -the reaction. Although NADH 
alone did not support the peroxidation of lipid it enhanced 
lipid peroxidation in the presence of NADPH (De Matteis and 
Sparks, 1973). Oxidative metabolism by the microsomal fraction 
was found to inhibit lipid peroxidation (Orrenius, Dallner and 
Ernster, 1964) and this led to the conclusion that a common 
electron transport system was involved in the mixed function 
• oxidase and in lipid peroxidation. The scheme shown in Fig. 2
NADPH ---- ► cytochrome c reductase  »■ cytochrome P-450
^ ^   »■ Peroxidase?
v.
•V.
NADPH cytochrome reductase >■ cytochrome bj-
2+PPi•Fe
cytochrome b
3+PPi* Fe
LIPID.00H-2+PPi-Fe
Peroxidase? LIPID3+
LIPID-O’ + OH
Figure 2 Hypothetical scheme devised by Bidlack et al (1973) 
to explain the mechanism of hepatic microsomal peroxidation 
of lipids and its interaction with the mixed function oxidase.
3+ 3 +A chelate of a pyrophosphate and Fe (PPi’Fe ) was necessary 
for lipid peroxidation. The initi'al oxidation of cytochrome b^ 
may reflect the reduction of the chelate by NADPH-cytochrome b,. 
reductase which is possibly identical with NADPH-cytochrome c 
reductase. Subsequent activation of oxygen, formation of lipid 
peroxides and their turnover could be due to a simple Fenton's 
type reaction. The second oxidation of cytochrome b^ occurred 
only during active peroxidation and was inhibited by EDTA.
Thus electrons may be drained via peroxides, the iron chelate 
and peroxidase, the drain occurring either after, or directly 
off, cytochrome b^.
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has been devised by Bidlack, Okita and Hochstein (197 3).
The oxidative metabolism of aniline and aminopyrine was 
found to inhibit lipid peroxidation (Orrenius et al, 1964) 
although it was not inhibited by the metabolism of codeine 
and hexobarbitone (Gram and Fouts, 1966). During incubation 
at 37°C of the microsomal fraction, as well as an increased 
lipid peroxidation, there is loss of drug-metabolising 
activity (Gram and Fouts, 1966), and in the pig liver micro­
somal fraction inhibition of lipid peroxidation was found to 
stimulate the epoxidation of aldrin (Lewis, Wilkinson and Ray, 
1967). Although aldrin and lipids may compete for a common 
electron transport system reciprocal inhibition of lipid 
peroxidation by aldrin could not be shown. In these studies
lipid peroxidation in the microsomal fraction was measured in
2 +the absence of exogenous Fe or pyrophosphate so that 
2 +sufficient Fe may remain in the microsomal pellet to 
stimulate lipid peroxidation.
Although lipid peroxidation can be inhibited with EDTA 
there is still loss of drug-metabolising activity during 
microsomal incubation at 37°C (Gram and Fouts, 1966; Carpenter, 
1972). In contrast Kamataki and Kitagawa (1973) have recently 
reported that inhibition of lipid peroxidation with low con­
centrations of EDTA prevents the loss of type I and type II 
drug-metabolising activity that occurs during incubation.
2.4 The effect of catecholamines upon the hepatic microsomal 
metabolism of foreign compounds
Lamson, Grieg and Hobdy (1951) reported that an injection
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of adrenaline into guinea pigs recovering from barbiturate 
anaesthesia re-induced sleep. In the mouse adrenaline had 
similar effects although the effects of noradrenaline were 
less-pronounced (Lamson, Grieg and Williams, 1952). Mazel 
and Bush (1969) found that noradrenaline was active only at 
ten times the dose of adrenaline employed. The effect was 
not due to an increase in brain barbiturate levels nor was 
it due to anaesthesia induced by adrenaline itself (Mazel 
and Bush, 1969). Since adrenaline has many effects including 
the release of ACTH, corticoids, insulin, thyroid hormone and 
glucose, any of these may be involved in the effect (Mazel 
and Bush, 1969).
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In the early 1960's Fouts investigated the possibility 
that the effects of catecholamines on drug metabolism were 
related to their glycogen depleting ability. At first only 
adrenaline was used (Fouts, 1962) but later he used nor­
adrenaline (Dixon et al, 1964) since Vrij,'Cho, De Groot and 
Weber (1956) had found that it was more specific and more 
potent in depleting liver glycogen in the rat.
A single injection of either adrenaline (Fouts, 1962) or 
noradrenaline (Dixon et al, 1964) depleted liver glycogen 
within 12 h but did not alter the microsomal metabolism of 
either type I or type II substrates. Pre-treatment with 
noradrenaline caused no alteration in microsomal 2- or 4- 
biphenyl hydroxylase activity (Parke and Rahman, 1970).
Fouts1 (1962) results showed however that there was a signifi­
cant increase of 35% in the metabolism of type I compounds 
1 h after an injection of adrenaline although no mention of
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this was made in the text. In the later paper the same 
author found an increase of 50 to 60% in the metabolism of 
type I substrates 2 h after an injection of noradrenaline 
although this increase was not significant (Dixon et al,
1964) .
Repeated injections of either catecholamine caused 
inhibition in the microsomal metabolism of both type I and 
type II substrates (Fouts, 1962; Dixon et al, 1964). Although 
glycogen levels returned to control values shortly after the 
last injection of noradrenaline the metabolism of both type I 
and type II compounds remained inhibited for some time (Dixon 
et al , 1964).
Kato and Gillette (1965) reported that adrenaline pre­
treatment inhibited the metabolism of only type I substrates 
in male rats and that drug metabolism was not affected at all 
in female rats after catecholamine pre-treatment.
It was concluded that when glycogen was depleted such 
that the amount of smooth-surfaced microsomes in the liver was 
reduced then drug metabolism was inhibited. A single injection 
of catecholamine would not deplete glycogen sufficiently to 
alter the amount of microsomal fraction in the liver so that 
drug metabolism would not be affected (Fouts, 1962; Dixon 
et al, 1964). Thus any relationship between the effects of 
catecholamines on liver glycogen levels per se and inhibition 
of drug metabolism appears to be indirect at least.
Although adrenergic blocking agents prevented noradrenaline
from depleting liver glycogen they did not prevent it from 
inhibiting drug metabolism. • However some adrenergic blocking 
agents were also capable of inhibiting drug metabolism oh 
their own (Dixon et al, 1964). Peters (1972) suggested that 
alprenolol and other 3-blockers may inhibit microsomal meta­
bolism by interacting allosterically with the mixed function 
oxidase.
All adrenergic blocking agents were found to increase
hexobarbitone sleeping time in mice although not all inhibited
the in vitro microsomal metabolism of foreign compounds
(Mullen and Fouts, 1965). Adrenergic blocking agents may in-
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crease hexobarbitone sleeping time by lowering body temperature 
and some may, in addition, directly inhibit the hepatic micro­
somal metabolism of barbiturates. When the ambient temperature 
was increased so that the body temperature of hexobarbitone- 
anaesthetised mice was maintained at normal only those 
adrenergic blocking agents that directly ihhibited microsomal 
drug metabolism in vitro prolonged hexobarbitone sleeping time 
(Mullen and Fouts, 1965).
Noradrenaline has been reported to stimulate C-21 hydroxy- 
lation of steroids by bovine adrenocortical homogenates but 
-not to affect 11-hydroxylation (Cooper and Rosenthal, 1962a, 
b). Steroid C-21 hydroxylase is a microsomal enzyme (Pincus, 
1958). Lewis et al (1967) suggested that stimulation of C-21 
hydroxylation of steroids by catecholamines was due to in­
hibition of peroxidation of endogenous lipids which may other­
wise compete for electrons from NADPH. Adrenaline is known 
to inhibit the peroxidation of lipid (Privett, 1962).
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Recently Gielen and Nebert (1972) have reported that 
high concentrations of catecholamines (1 mM) induced benz- 
pyrene hydroxylase activity in foetal rat liver cells in vitro. 
The effect was not stereospecific nor was it prevented by a- or 
3- blocking agents. They speculated that the in vivo admin­
istration of catecholamines might produce both monooxygenase 
induction and toxicity, or a marked pharmacological response, 
so that any stimulation would be masked by the toxic or 
pharmacological effect (Gielen and Nebert, 1972). They also 
suggested that the rise in hydroxylase activity occurring 
during the first week of neonatal life was due to release of
biogenic amines through the stress of the birth process.
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2.5 Effect of cyclic 31, 5*-adenosine monophosphate (cyclic 
AMP) on the hepatic microsomal metabolism of foreign 
compounds
Considerable evidence now exists that pre-treatment of 
rats with cyclic AMP can inhibit the metabolism by the hepatic 
microsomal fraction of some substrates (Weiner, Blake and 
Buterbaugh, 1970; Weiner et al, 1972a, b; Weiner, 1973; Ross 
and Oppelt, 1970, 1971, 1973; Ross, Simrell and Oppelt, 1973). 
Cyclic AMP also inhibited the metabolism of foreign compounds 
by the isolated perfused liver (Weiner et al, 1970, 1972a) and 
in liver slices (Weiner et al, 1972b), but it was without 
effect when added directly to the microsomal fraction (Weiner 
et al, 1972b; Ross and Oppelt, 1970).
Cellular integrity appeared to be a pre-requisite for 
cyclic AMP to exert any inhibitory effect upon the metabolism
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of foreign compounds (Weiner et al, 1972b) and the presence 
of an inhibitor in the post-microsomal supernatant of rats 
previously treated with cyclic AMP has been shown by Weiner 
et al (1972b). The inhibitory factor was later found to be 
dialysable and heat stable so it was concluded that it was 
unlikely to be a protein (Weiner, 1973). Its molecular 
weight was estimated at less than 5,000. It has been suggested 
(Weiner, 1973) that cyclic AMP may be acting by the stimulation 
of liver lipase to cause the liberation of free fatty acids 
which would meet the characteristics of the inhibitor as out­
lined above. It had already been shown that free fatty acids 
can cause inhibition of the microsomal metabolism of foreign 
compounds (Di Augustine and Fouts, 1969). This suggestion 
at present remains an attractive, but unproven, hypothesis 
for the mode of action of cyclic AMP.
2.6 The enhancement of the microsomal metabolism of foreign
compounds
Enhancement is an increase in the specific activity of 
the mixed function oxidase occurring in vitro in the presence 
of the enhancing agent. It was first reported by Imai and 
Sato in 1966 who found that ethyl isocyanide stimulated the 
in vitro metabolism of aniline by the rabbit liver microsomal 
fraction. Ethyl isocyanide also stimulates the metabolism 
of aminopyrine, a property that no other enhancing agent 
appears to share (Imai and Sato, 1966). Ethyl isocyanide may 
act by binding to oxidised cytochrome P-450 in competition 
with aniline, at a non-metabolic site, and the oxidised cyto­
chrome P-450-ethyl isocyanide complex would be reduced by 
NADPH more rapidly than either un-complexed cytochrome P-4 50
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or the cytochrome P-450-aniline complex (Imai and Sato, 1968).
Acetone also enhances the metabolism of aniline but in­
hibits the metabolism of type I substrates (Anders, 1968).
Only acetone and 2-pentanone of many solvents investigated 
produced enhancement. Acetone enhancement differed from that 
of ethyl isocyanide (Anders, 1968). Acetone may act prefer­
entially on one of two postulated aniline hydroxylases to 
reveal one of higher activity or it may increase the rate of 
breakdown of enzyme-substrate complex by forming an acetone- 
enzyme-substrate complex (Anders, 1968). It does not appear 
to act by inhibiting microsomal lipid peroxidation (Anders,
1969).
Acetone does not produce its effect by altering the 
relative amounts of cytochrome P-450 and cytochrome P-448 
present in the microsomal fraction (Anders, 1972).
In the presence of acetone low concentrations of aniline 
produced a type I spectral change (Vainio and Hanninen, 1973). 
Phospholipase C abolished the acetone enhancement of aniline 
metabolism but reduced the metabolism of aniline in the 
absence of acetone by only 20% (Vainio and Hanninen, 1972).
The enzyme phospholipase C causes degradation of lipids, 
mainly phosphatidylcholine (Tzur and Shapiro, 1969), a 
necessary component of the reconstituted mixed function 
oxidase system (Strobel et al, 1970) and related to the type
I binding of substrates (Chaplin and Mannering, 1970). Thus 
acetone may cause enhancement by promoting the binding of type
II substrates to the type I site of cytochrome P-4 50 since
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type I binding has already been shown to produce an increased 
rate of metabolism (Gigon et al, 1968).
a, a'-bipyridyl enhances the metabolism of aniline in 
trout liver microsomes (Buhler and Rasmusson, 1968). It also 
enhances aniline metabolism in the rat liver microsomal fraction 
(Anders, 1969) where its effect is probably due to a metabolite 
(Anders, 1972). Like acetone, a, a'-bipyridyl inhibited the 
metabolism of type I compounds (Anders, 1969). The only 
other chelator found to enhance metabolism was 1,10-phenanthro- 
line (Anders, 1969). Although a, a'-bipyridyl inhibits lipid 
peroxidation, Anders (1969) excluded this as a possible 
mechanism for enhancement. However it has recently been 
shown that these chelators at low concentrations enhance the 
metabolism of type I compounds, apparently by inhibiting lipid 
peroxidation (Kamataki and Kitagawa, 1973). These authors 
also found that the metabolism of aniline was enhanced. It 
is not possible at present to evaluate the significance of the 
results of Kamataki and Kitagawa (1973). It may be that 
chelators have two distinct effects on drug metabolism, one 
due to inhibition of lipid peroxidation and the other due 
to direct interaction with the mixed function oxidase.
In 1969 Leibman reported that metyrapone enhanced the 
metabolism of type II substrates by the microsomal fraction, 
and like other enhancing agents inhibited the metabolism of 
type I compounds. Unlike most other compounds metyrapone 
binds to the reduced form of cytochrome P-450 (Hildebrandt, 
Leibman and Estabrook, 1969). Metyrapone could be acting 
by altering the equilibrium between two forms of cytochrome
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P-450 (Hildebrandt et al, 1969). However there is little 
evidence to support the idea of distinct forms of cytochrome 
P-450 for each of type I and type II binding.
Several volatile anaesthetics including halothane and
methoxyfluorane enhanced the metabolism of aniline while
inhibiting that of aminopyrine (Van Dyke and Rikans, 1970).
These anaesthetics may be acting by selective inhibition of
one of two forms of aniline hydroxylase revealing one of
higher activity (Anders, 1971, 1973) or they may bind to the
type I site and shift electrons to the type II site (Korten
and Van Dyke, 1973). Both hypotheses are poorly supported
/
by the experimental evidence of other work and the volatile 
anaesthetics may act in the same way as acetone.
Pre-treatment of rats with safrole caused an increase 
in the metabolism of 2-biphenyl by the microsomal fraction 
(Parke and Rahman, 1970). Although this is, in part, due to 
induction (Parke and Rahman, 1970, 1971) there appears to be 
activation of existing enzyme (Parke and Rahman, 1970; Lake 
and Parke, 1972a).
. .Recently Schenkman, Ritchie, Cha and Sartorelli (1974) 
reported that urethane enhances aniline metabolism in rat 
liver slices. It does not act directly on microsomes so it 
differs in action from other enhancers. The authors showed 
that the effect was on phase I metabolism and may be due to 
inhibition of an alternative pathway of aniline metabolism, 
permitting p-aminophenol formation to increase.
Paraoxon, a cholinesterase inhibitor, enhances the
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metabolism of aniline (Stevens, McPhillips and Stitzel, 1971) 
and it inhibits the metabolism of type I compounds (Stevens 
et al, 1972). Its effect is not dependent upon its meta­
bolism (Stevens et al, 1972) and it probably acts by a differ­
ent mechanism from acetone. Paraoxon could be interacting 
with aniline aromatic hydroxylase to alter its three- 
dimensional structure thereby increasing its activity in 
some undefined way (Stevens et al, 1972).
With the exception of ethyl isocyanide it is not possible
with the. results available at present to suggest any probable
mode of action for any one of the above enhancers on the
/
microsomal metabolism of foreign compounds.
CHAPTER 3
The Technique of Liver Perfusion
3.1 The advantages of the perfused liver
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Perfused organs have many advantages over other pre­
parations in several types of investigations. The system may 
be defined to a very high degree, particularly when using a 
semi-synthetic perfusion medium, and conditions can be altered 
to an extent that would not be tolerated by the whole animal. 
The cells are intact and study can be extended for several 
hours in stabilised conditions, unlike many other in vitro 
preparations.
The liver was chosen being the major organ involved in 
the metabolism of foreign compounds. Most previous studies 
on the metabolism of foreign compounds have been performed 
either on intact animals or on the hepatic microsomal fraction. 
In vivo the rate of metabolism is affected by the amount of 
substrate reaching the liver and this.depends upon the uptake 
and distribution of the compound. The perfused liver over­
comes these problems providing a system that is functionally 
integrated and compartmentalised as in vivo but which is not 
influenced by complicating factors such as secondary hormone 
release or reflex nervous activity. The perfused liver also 
overcomes the disadvantages of an in vitro preparation, such 
as the microsomal fraction, which operates under optimal co­
factor concentrations which may differ considerably from the 
situation in vivo.
An isolated perfused liver system was preferred to an 
in situ system since the former enables more complete control 
• to be maintained over the organ in perfusions lasting several
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hours.
3.2 His.torical introduction to liver perfusion
During the 17th and 18th centuries it was debated whether 
or not the organs of the body were capable of independent 
existence. Willis (1664) maintained that the viscera could 
only function under control of the cerebellum. It was not 
until 1753 that von Haller suggested that organs could be 
maintained extra-corporeally. Le Gallois (1812) took this 
further and proposed that many organs could be kept function­
ing indefinitely by artificial perfusion. Forty years later
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Bernard (1855) suggested the use of isolated organs in meta­
bolic studies.
The earliest attempt to put these theories into practice 
was that of Loebell (1849) who attempted to perfuse the kidney 
of the pig. In 1868 Ludwig and Schmidt carried out the first 
successful isolated perfusion, of a hind limb muscle. Attention 
then turned to the liver and early experiments involved larger 
animals which were easier to manage with the available surgical 
techniques. Luschinger (1875) first perfused a liver and was 
soon followed by von Frey and Gruber (1885).
Despite the comparatively widespread use of liver perfusion 
at the start of this century these early experiments are of 
little scientific value because of the deficiencies in the 
techniques employed but are of considerable historical 
importance. One of the most successful attempts was by Grube 
(1903) who used the apparatus devised by Brodie (1903). This
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included two glass-wool filters which almost undoubtedly 
contributed to the success of these experiments. Grube (1903) 
perfused' cat livers through the portal vein with a mixture of 
defibrinated cat and sheep blood by gravity-feed. The liver 
was maintained for 2 h during which time glucose was con­
verted to glycogen. Several comprehensive reviews were 
published around this time in which the theoretical aspects 
of liver perfusion expounded are still valid (Skutul, 1908; 
Baglioni, 1910; MUller, 1910).
Very few experiments with the isolated liver in metabolic
studies were reported between 1910 and 1950. One possible
/
explanation (Trowell, 1942) is that researchers had turned to 
the tissue slice technique of Warburg (1923) which was more 
reliable, reproducible and economical. It was not until 1941 
that Corey and Britton reported attempts to perfuse rat liver, 
with oxygenated Krebs bicarbonate buffered saline. The 
immediate extensive glycolysis was probably indicative of the 
deteriorating condition of the organ. Trowell (1942) perfused 
the liver retrogradely with buffered saline, to increase the 
flow rate and maintain adequate oxygenation. Although he 
claimed that the liver could be maintained for up to 4 h 
D 1Silva and Neil (1954) subsequently found that there was 
-considerable potassium efflux and oedema within 2 h. Various 
other attempts at perfusion with oxygenated buffered saline 
have met with only partial success (Brauer and Pessotti, 194 9; 
Dawkins, Judah and Rees, 1959; Bristow and Kerly, 1964; 
Nestruck and Furneaux, 1972a, b).
In 1951 independently, and almost simultaneously, Brauer,
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Pessotti and Pizzolato and Miller, Bly, Watson and Bale 
successfully perfused the isolated rat liver. The systems 
were essentially similar, homologous blood diluted with 
bicarbonate buffered saline being perfused at constant pressure 
into the portal vein. Outflow was from a cannula in the vena 
cava. Perfusion medium was oxygenated in a film oxygenator 
and recycled. Both systems included mesh filters to remove 
small clots from the medium. The main differences were the 
aseptic conditions and the addition of antibiotics to the 
perfusion medium by Brauer et al (1951). However most 
techniques of isolated liver perfusion have been modelled on 
that of Miller et al (1951) since such precautions are un­
necessary except for long perfusion periods (Bartosek, Guaitani 
and Garattini, 1972b).
Many modifications of the basic perfusion method of 
Miller et al (1951) have been introduced. Most notable of 
these are replacement of homologous blood with washed 
heterologous erythrocytes in a buffered saline albumin medium 
and perfusion of the liver in situ at a constant flow rate 
(Mortimore, 1961; Exton and Park, 1965), an approach that 
had been attempted earlier by Archdeacon and Brucer (1952). 
Powis (1970) based a constant flow system for rat liver on 
that used by Blakely and Brown (1963) for perfusion of the 
cat spleen. Recently a comprehensive review on the various 
forms of perfusion technique in use at the present for small 
animals has been published (Ross, 1972).
3.3 The experimental approaches adopted to liver perfusion
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3.3.1 Should the hepatic artery be perfused in addition to
the portal vein
No more than 20% of the blood normally reaching the liver 
is supplied by the hepatic artery (Fischer, 19 63). Several 
workers have attempted to perfuse the rat liver via both the 
hepatic artery and the portal vein (Brauer, Shill and Krebs, 
1959; Ross, Hems, Freedland and Krebs, 1967; Abraham and 
Dawson, 1967; Powis, 1970). Their results were recently 
compared (Ross, 1972) with those of Schimassek (1962a, b) and 
Hems, Ross, Berry and Krebs (1966) who perfused the liver via 
the portal vein only. No significant difference in the tests 
of function measured was apparent and, in the rat, perfusion 
via the portal vein alone is totally adequate.
3.3.2 Choice of perfusion medium
Although whole homologous blood, either fresh or diluted, 
would appear to be the most suitable perfusion medium its 
major disadvantage is the 'early outflow vascular block1 often 
observed particularly in larger animals (Miller et al, 1951; 
Brauer, Leong and Pessotti, 1953; Eiseman, Knipe, Koh, Normell 
and Spencer, 1963). This is characterised by an increase in 
hepatic vascular resistance, swelling and cyanosis. Several 
methods have been partially successful in overcoming this 
problem by removing the vasoconstrictor substance from the 
perfusion medium (Felts and Mayes, 1966). Vasoconstriction 
does not occur when a semi-synthetic perfusion medium is used 
(Ross, 1972).
There is a requirement for an oxygen carrying constituent
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in liver perfusion media (Bock, Frohling and Schlote, 1972). 
This is usually fulfilled by haemoglobin and the concentration 
can be varied from 16 g% to 2.5 g% and still provide adequate 
oxygenation (Hems et al, 1966). With oxygenated buffered 
salt solutions there is an inadequate oxygenation and greater 
loss of cell function (D1 Silva and Neil, 1954; Nestruck and 
Furneaux, 1972a, b).
As an alternative to the whole blood media previously 
used Schimassek (1962a) devised a semi-synthetic medium of a 
defined solution of salts, washed bovine erythrocytes and 
bovine serum albumin. Hems et al (1966) described a similar 
medium with human erythrocytes in place of bovine red cells, 
and an altered salt composition. When diluted rat blood 
medium (Miller et al, 1951) and a semi-synthetic perfusate 
(Schimassek, 1962a, 1963a, b) were compared the latter main­
tained the liver in the more viable state as judged by the 
tissue distribution of the media, glucose metabolism and 
degree of haemolysis (Meiers, Flammann, Albaum and Staib, 1966). 
Thus the semi-synthetic media appear more suitable than either 
haemoglobin-free or whole blood media (Ross, 1972). Most semi­
synthetic media include bovine serum albumin between 3 to 5 g% 
(w/v) as an osmotic colloid although Hems et al (1966) found 
that varying the concentration between 1.5% and 6% had no 
deleterious effect. Dextran caused aggregation of the red 
cells (Hems et al, 1966). A totally synthetic system com­
prising sonicated fluorocarbons has been described (Brown and 
Hardison, 1972); first introduced by Sloviter and Kamimoto 
(1967) for perfusion of brain, but this medium causes hepatic 
sinusoidal swelling due to flocculation of the fluorocarbons.
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3.4 Determination of the functional status and viability of
the perfused liver
3.4.1 The appearance of the liver
The macroscopic appearance of the liver provides a useful 
initial indication of the extent of perfusion (Brauer et al, 
1951; Exton and Park, 1967). Inadequacies of perfusion are 
revealed by the appearance of petachiae on the surface of the 
liver and less frequently a collapsed smaller lobe (Miller et 
al, 1951).
Light microscopy of sections of liver taken immediately 
after the experiment provides evidence of the morphological 
integrity and viability of the organ after perfusion. Histo­
logically the liver appears indistinguishable from that of 
freshly killed rat when perfusion is adequate (Miller et al, 
1951; Brauer et al, 1951).
Electron microscopy is also a useful means of judging 
the integrity of the liver after perfusion. After an adequate 
perfusion electron micrographs of the liver reveal no 
differences to those of unperfused organs (Bock et al, 1972).
3.4.2 Blood flow and blood pressure of the perfused liver
Blood flow and portal venous pressure are routinely 
monitored during perfusion. In vivo the portal venous flow 
rate in the rat is 8 to 12 ml/min or 1 ml/g of liver/min 
(Brauer et al, 1951). The minimum flow rate is unimportant
if adequate oxygenation is achieved (Ross, 1972). Normal 
portal pressure is 12 to 14 cm water (Brauer et al, 1951) .
A pressure of 15 to 25 cm of water is required in constant 
pressure systems to achieve a flow rate of 1 ml/g/min. In 
constant flow systems (Mortimore, 1961; Powis, 1970) a 
pressure of about 12 cm water is observed when the flow is 
set at 1 ml/g/min. Sudden changes in pressure in a constant 
flow system may reflect inadequate perfusions due to factors 
such as emboli.
\
3.4.3 The production of bile in the perfused liver
Bile production is used as an indication of the functional 
integrity of the liver due to ease of measurement and its 
Synthetic nature, i.e. the liver must actively produce bile 
to secrete it, (Brauer et al, 1951). Bile flow in vivo is 
between 0.5 ml/h (Ostashever, Gray and Graff, 19 60) and 1.0 
ml/h (Brauer et al, 1951). Within a group of experiments 
carried out under the same conditions it should be possible 
to establish a typical bile flow pattern during adequate 
perfusion, deviation from this would be a sign of abnormal 
liver function.
3.4.4 The efflux of K+ during perfusion of the liver
4-
Loss of K may be a sign of cell damage (Krebs, Eggleston 
and Terner, 1951) and many liver perfusions have included
-j- '
determinations of K efflux into the perfusion medium as a 
measure of cell viability (Frimmer, Gries and Hegner, 1967).
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Mortimore (19 61) showed that increases in perfusate K+ in
his experiments were not due to red cell haemolysis although
Craig (19 66) found that in his experiments the slight net
*4“increase in perfusate K could be accounted for almost 
quantitatively by haemolysis. However increases in perfusate 
K+ normally provide some indication of the degree of cell 
damage and the metabolic activity of the remaining intact 
liver cells.
3.4.5 Levels of glucose in the perfusate
Glucose is involved in several metabolic reactions in 
the liver such as gluconeogenesis, glycolysis and glycogenolysis 
so that determination of free glucose levels in the medium 
will provide some indication of the metabolic integrity of 
the liver. The liver sheds glucose into the medium after 
commencement of perfusion followed by a slow ‘decline in con­
centration (Ostashever et al, 1960; Exton and Park, 19 63;
Craig, 1966; Hems et al, 1966; Bartosek et al, 1972). Non- 
glycolysing cells as were employed in the present study use 
no glucose (Hems et al, 19 66). All the changes in glucose 
levels are thus attributable to the liver. Contrary to 
previous belief, shedding of glucose over the initial period 
of perfusion is a sign of the functional integrity of the 
liver, not of deteriorating function, and is probably induced 
by the trauma of isolation (Selkurt, 1964; Shimazu and 
Amakawa, 1968; Mondon and Burton, 1971; Bartosek et al,
1972b).
3.4.6 The lactate;pyruvate ratio of the perfusion medium
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One of the most sensitive measures of liver function is 
the ratio of lactate to pyruvate in the perfusion medium. 
Schimassek (1963b) has demonstrated that the functioning 
liver maintains the ratio of these substrates in a fixed 
proportion by their interconversion and reflects the balance 
of NAD to NADH within the liver. After perfusion for 2 h a 
ratio of 10:1 is found in the perfusate similar to that 
observed in vivo (Schimassek, 1963b). Although similar 
values have been reported by other workers (Exton and Park, 
1967; Woods and Krebs, 1971; Seglen, 1972) a wider range 
of values,has been taken as within physiological levels. The 
ratio increases considerably in anoxia (Schimassek, 1963b) 
or during inadequate perfusion (Woods and Krebs, 1971). This 
test is a critical test of the redox state of the liver and 
is a very reliable guide to adequacy of perfusion.
3.4.7 Selection of tests of liver viability during perfusion
The tests selected should be relatively easy to perform 
and of preference should be carried out on the perfusate rather 
than the liver tissue itself so that continuous monitoring of 
the state of the liver can be carried out over the duration of 
an experiment. By combining several tests, it is possible to 
..obtain an accurate picture of the functional state of the 
liver.
3.5 The metabolism of foreign compounds by the isolated
perfused rat liver
The perfused liver is achieving an increasing use in
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investigations of the metabolism of foreign compounds and 
the influence that modifying agents have on drug metabolism 
(von Bahr, Alexanderson, Azarnoff, Sjoqvist and Orrenius,
1970). Among substrates that have been investigated are 
ethanol (Van Harken and Mannering, 19 69; Lindros, Vihma 
and Forsander, 1972; Theorell, Chance, Yonetani and Oshino, 
1972), methanol (Van Harken, Tephly and Mannering, 1965), 
desmethylimipramine (Bickel and Minder, 1970; von Bahr 
et al, 1970), imipramine (Bickel and Minder, 1970), phenyl­
butazone, antipyrine, oxotremorine and nortriptyline (von 
Bahr et. alt 1970), pentobarbitone (Kaiser, Kelly, Forbes and 
Randolph, 1969; Bartosek, Guaitani and Donelli, 1972a), 
erythromycin estolate and other derivatives (Kendler, Anuras, 
Laborda and Zimmerman, 1972), chlorpramazine and related 
psychotropic drugs (Cordelli, Ferrari and Savonitto, 1969), 
diazepam (Kvetina, Marucci and Fanelli, 1968), procarbazine 
(Baggiolini, Dewald and Aebi, 1969; Dewald, Baggiolini and 
Aebi, 1969), 2-acetamidofluorene (Miyata, Noguchi and Enomoto, 
1972), deptropine methiodide (Lavy, Hespe and Meijer, 1972), 
2-PAM (Way, 1962) and halothane (Van Dyke and Wood, 1973).
Many substrates are removed from the perfusion medium 
following first order kinetics (von Bahr et al, 1970) 
although some compounds such as propranolol follow complex 
clearance kinetics (Evans, Wilkinson and Shand, 1973). A 
detailed study into the effects of hypothermia on the meta­
bolism by the perfused liver of atropine (Kaiser, Kelvington, 
Randolph and Santomenna, 1965), sulphanilamide (Kaiser, 
Kelvington and Randolph, 1968), procaine (Kaiser, Kelvington, 
Kunig and Randolph, 1968), and pentobarbitone (Kaiser et al,
1969) has been carried out.
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Hexobarbitone metabolism has been widely studied in the 
perfused liver (Stitzel et al, 1966; Stitzel, Tephly and 
Mannering, 1968; Cumming and Mannering, 1970). The substrate 
is removed linearly from the perfusate (Stitzel et al, 1966) 
and its removal is reduced by hypoxia (Cumming and Mannering,
1970) and perfusion with haemoglobin-free medium (Bock et al, 
1972). The studies of Stitzel and his co-workers have played 
an important role in determining the mode of action of in­
hibitors of drug metabolism such as SKF 525-A (Stitzel et al, 
1966, 1968). It was also shown that some compounds which did 
not inhibit drug metabolism in vivo, such as morphine, did 
produce an inhibition in the perfused liver (Stitzel et al,
1968).
In addition to the metabolism of foreign compounds the 
perfused liver has been used to investigate the metabolism of 
many endogenous compounds such as calcitonin (Greenberg, Martin, 
Melick, Jablonski and Watts, 1972), hydrocortisone (Bartosek, 
Marc, Guaitani and Garattini, 1973), methylprednisolone (Kuster 
and Woods, 1972), thyroid hormone (Flock and Owen, 1965), 
androstenedione and progesterone (Eriksson, Gustafsson and 
Pousette, 1972), mestranol (Bolt and Remmer, 1973), testo­
sterone (Staib, Sonnenschein and Staib, 1970), L-DOPA (Tyce 
and Owen, 1972) , and insulin (Stoll, Touber, Menahan and 
Williams, 1970).
The isolated perfused liver has played an important part
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in elucidating some of the mechanisms of induction of drug 
metabolism. 3,4-benzpyrene causes induction in the perfused 
liver with peak activity at the same time as after an in vivo 
injection of the compound (Juchau, Cram, Plaa and Fouts, 1965). 
Thus enzyme inducers are acting directly on the target cells 
and need not act through any endogenous compound such as a 
hormone (von Bahr et al, 1970).
The perfused liver also exhibits enhancement of the 
metabolism of type II substrates by metyrapone (Kahl, Minck 
and Netter, 1973).
The major components of the microsomal mixed function 
oxidase, cytochrome P-450, cytochrome b^ and NADPH-cytochrome 
c reductase, are stable during perfusion of the liver under 
optimal conditions (Bock et al, 197 2). However the metabolism 
of type I substrates by the 9,000 x G fraction was reduced in 
livers perfused for 4 h although the metabolism of type II 
substrates was almost unaffected (Bartosek, Guaitani, Garattini 
and Simonazzi, 1974).
3.6 The effect of catecholamines upon the isolated perfused
liver
Adrenaline decreased glycogen levels in the perfused liver 
of the dog (Bodo and Marks, 1928) and of the cat (Sokal, Miller 
and Sarcione, 1958) with a concomitant increase in liver and 
perfusate glucose. Adrenaline also increased perfusate levels 
of glucose in the perfused liver of the rat due to an activa­
tion of liver phosphorylase (Northrop and Parks, 1964). It
47
has been suggested that the normal hepatic glycogenolytic 
activity of adrenaline may be due to the release of glucagon 
since this hormone is 350 times as potent as adrenaline in 
the perfused liver at producing glycogenolysis (Ezdinli and 
Sokal, 1966). Adrenaline also inhibits glycogen synthetase 
I in the perfused liver thus preventing re-conversion of 
glucose back to glycogen (HOstmark, 1973).
The glycogenolytic activity of adrenaline in liver has 
been reviewed in depth by Sutherland and Robison (Sutherland 
and Robison, 1966; Robison, Butcher and Sutherland, 1968).
Catecholamines stimulate gluconeogenesis in the perfused 
rat liver, increasing conversion of non-carbohydrate precursors 
such as lactate, into glucose. Although low doses of adrenaline 
have no effect, at higher concentrations catecholamines in­
crease glucose production by 100% (Exton and Park, 1968). 
Glucagon and cyclic AMP have also been reported to stimulate 
gluconeogenesis from lactate in the perfused liver (Exton and 
Park, 1968, 1969).
Adrenaline causes a loss of K+ with a concomitant increase 
in Na+ in hepatocytes of perfused liver (Lambotte, 1968). In 
the dog this caused depolarisation of liver cells (Lambotte,
1970, 1971). Stimulation by a-agonists causes a rapid increase
+ +in Na permeability with depolarisation and exchange of Na
+
for K . 3-receptor stimulation causes a slower decrease in 
+Na permeability and hyperpolarisation (Lambotte, 1971). In 
contrast stimulation of either a-receptors (Friedmann, Somlyo 
and Somlyo, 1971; Haylett and Jenkinson, 1972) or 3-receptors
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(Haylett and Jenkinson, 1972) in the guinea pig liver resulted 
in hyperpolarisation. Isoplenaline caused hyperpolarisation 
in the rat liver (Haylett and Jenkinson, 1969).
Noradrenaline can stimulate an hepatic lipase in the 
isolated perfused liver of the rat to cause increased levels 
of non-esterfied fatty acids in the perfusion medium (Lemberg, 
Wikinski, Izurieta, Halperin, Paglione and de Neuman, 1972).
/
CHAPTER 4
Materials and Methods
TABLE 1
Chemicals used, their sources and quality
Chemical Supplier Quality
All inorganic salts 
Calcium chloride 
Magnesium chloride 
Barium chloride 
Manganese chloride 
Ferrous chloride 
Hydrochloric acid
B.D.H.
B.D.H.
Hopkin and Williams 
B.D.H.
B.D.H.
B.D.H.
Hopkin and Williams
AnalaR
Volumetric solution
AnalaR
AnalaR
AnalaR
Lab reagent
AnalaR
Acetylacetone 
Isoamyl alcohol 
Acetone
Petroleum spirit(60-80°C) 
Liquid paraffin, light 
Absolute alcohol
B.D.H. Lab reagent
Hopkin and Williams General Purpose Peagent
B.D.H. AnalaR
B.D.H. AnalaR
B.D.H. Lab reagent
James Burrough Ltd. BPC
Folin and Ciocalteau's 
Phenol Reagent
N-l-(Naphthyl)-ethylene- 
diamine dihydrochloride
Phenol
Trichloroacetic acid
2-Thiobarbituric acid 
Trizma buffer 
Semicarbazide 
Nicotinamide 
Sucrose
Uranyl acetate 
Hydrazine sulphate 
Glycine
Triethanolamine hydrochloride
Pyruvic acid
Lactic acid
Perchloric acid
Glucose
Bovine Serum Albumin
B.D.H.
Koch-Light
B.D.H.
Hopkin and Williams
Sigma
Sigma
Sigma
Sigma
Hopkin and Williams
Boehringer
Sigma
Sigma
Boehringer
Sigma
Sigma
Boehringer
B.D.H.
Miles Lab. Ltd.
Lab reagent
Pure A.R.
AnalaR
AnalaR
PFS
Reagent Grade
PFS
PFS
AnalaR
PFS
PFS
Standard solution 
Standard solution
AnalaR 
Fraction V
TABLE 1 (cont'd)
Chemical
Glucose-6-phosphate
dehydrogenase
Glucose-6-phosphate disodium 
salt
Isocitric dehydrogenase
DL-isocitric acid trisodium 
salt
3-NADP disodium salt 
(3-NADPH tetrasodium salt 
3-NAD
3-NADH disodium salt
Lactate dehydrogenase
Biochimica Test Combination; 
Glucose
Cyclic 3 *:51 adenosine 
monopho sphate
N^-2‘*'-0-dibutyryl cyclic 3': 5' 
adenosine monophosphate 
monosodium salt
Cytochrome c
Halothane
Aminopyrine
p-aminophenol
Aniline hydrochloride
Formaldehyde
Hexobarbitone sodium
EDTA disodium salt
D-a-Tocopherol
D-a-Tocopherol acetate
D-a-Tocopherol acid succinate
Butylated hydroxytoluene
1,.2-di (2-aminoethoxy) ethane- 
N,N,N',N'-tetraacetic acid 
£GT$
Ascorbic acid
Histamine acid phosphate
Supplier
Boehringer
Boehringer
Sigma
Sigma
Boehringer
Boehringer
Boehringer
Boehringer
Boehringer
Boehringer
Boehringer
Boehringer
Sigma
I.C.I. Ltd.
Ralph N. Emanuel
Koch-Light
B.D.H.
B.D.H.
May and Baker
Hopkin and‘Williams
Sigma
Sigma
Sigma
Sigma
B.D.H.
Koch-Light
B.D.H.
Quality
Grade II
Type IV 
Type I
Grade II 
Grade II 
Grade II 
Analytical
Type II-A - 
BP
Lab reagent
AnalaR
BP
AnalaR 
Type II 
Type III 
Type IV 
PFS
AnalaR
Puriss
BP
TABLE 1 (cont'd)
Chemical Supplier Quality
Oxytoc in
Papaverine hydrochloride 
Adrenaline hydrogen tartrate 
Vasopressin
Noradrenaline bitartrate 
Angiotensin amide 
Heparin 
SKF 525-A
Conray 280 
Eosin solution 
Indian ink
Parke-Davis
Merck
B.D.H.
Parke-Davis
Koch-Light
CIBA
Evans Medical Ltd.
Smith, Kline and 
French Labs. Ltd,
May and Baker
George T. Gurr
George T. Gurr
BP
Biochemical
BP
BP
BP
BP
Medicinal Product 
Special Micro
3H-aniline 
3H-noradrenaline
Radiochemical Centre 
Radiochemical Centre
4.1 Chemicals used and their sources
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The various drugs, reagents and biochemical compounds 
used in the course of this investigation are listed in Table 
1 together with their source and quality. All solutions were 
made with glass distilled water.
4.2 Composition of biological salt solutions
The composition of the bicarbonate buffered saline used 
in the preparation of the medium for perfusion of the liver 
was based on that of Krebs and Henseleit (1932). The composi­
tion in mmol/1 was Na+ 148.8; K+ 4.5; Mg2 + 1.0; Ca2 + 1.25; 
Cl" 127; SP42” 1.0; phosphate pH 7.4, 2.0; HC03" 2.5;
glucose 11.1. The solution was gassed by bubbling with 95% 
air + 5% C03 for at least 15 min.
The phosphate buffered saline used to incubate the
liver slices was based on that of Krebs and Henseleit (1932)
+ +and had the following composition in mmol/1: Na 148.6; K
4.5; Mg2 + 1.0; Ca^+ 1.25; Cl 137; SO^2 1.0; phosphate 
pH 7.4, 10. The medium was buffered by the phosphate system 
and was gassed with 100% oxygen for at least 15 min before 
use. No glucose was added to the medium.
4 - 3 The perfused liver
4.3.1 The vascular perfusion medium
The perfusion medium was based on that of Hems et al
Pressure
Transducer
Perfusion
BoxBubbleTrap)
Liver
Water
Jacket DropCounter □□
Bile
Collection Venous Outflow 
Collection
Bubble 
, TrapFilter Air
Buffer
Pump
Oxygenator- 
„ Reservoir
Figure 3
Diagram of the perfusion apparatus. Direction of perfusion medium flow 
is indicated by the heavy arrows.
1 11 2 3
1 2 11 3 4
Figure 4
Photograph of the perfusion apparatus. 1, oxygenator-reservoir; 2,
bubble trap 5 ml; 3, pump; 4, filter; 5, air buffer 10 ml; 6, 
heating jacket; 7, pressure transducer 500 mmHg; 8, bubble trap 1 ml; 
9, venous outflow; 10, liver; 11, bile drop counter.
Upper plate, low power general view and lower plate, higher power view 
of the arrangement of the liver.
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(1966) although several modifications were introduced., the
most significant of which was to increase the haematocrit to
25% (v/v). Oxygen carrying capacity was primarily provided
by aged human red cells, stored at 4°C for a minimum of 4
weeks. The cells were washed by suspending in 4 volumes of
Krebs bicarbonate buffered saline, pH 7.4, and separated by
centrifuging for 8 min at 2,000 x G at 20°C, three times.
Bovine serum albumin (Cohn Fraction V powder), 4.5 g, was
dissolved in 1 0 0  ml of the buffer to give a final concentration
of 3 g% (w/v) in 150 ml of perfusion medium._ Washed red cells
40 ml, were added to the albumin solution and the volume made
up to exactly 150 ml with fresh buffer. The final glucose
/
concentration of the medium was about 0.15 g% (w/v) and the
haematocrit was between 20 and 25% (v/v). This semi-synthetic
perfusion medium caused no vasoconstriction of the hepatic 
*
vasculature.
4.3.2 The perfusion apparatus
The perfusion apparatus was based on that of Powis (1970) 
which itself was derived from the constant flow perfusion 
system devised by Blakely and Brown (1963) for the perfusion 
of the cat spleen. The apparatus is illustrated diagramatic- 
ally in Fig. 3 and photographically in Fig. 4.
The oxygenator, which also functioned as the reservoir, 
consisted of a 500 ml polyethylene bottle inclined at an 
angle of 30° from the horizontal, rotating at 60 rev/min. 
Perfusion medium from the venous outflow dripped in at the 
upper end of the oxygenator and filmed out over the wall
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where it was equilibrated with a 95% air + 5% CO2 gas mixture 
that had been moistened by passage through a flask of 0 .9 % 
saline. This gas mixture was used in preference to 95% 
oxygen + 5-s CO2 si-nce the higher oxygen tensions had been 
shown to cause degenerative changes due to an increase in 
lysosomal activity of the liver (Abraham, Dawson, Grasso and 
Goldberg, 1968). Samples of perfusion medium for analyses 
were removed from the reservoir and additions to the perfusion 
medium were made into the reservoir.
Perfusion medium was drawn from the reservoir through a 
bubble trap consisting of a 5 ml disposable plastic syringe 
with a hole drilled through the wall at the upper end. The 
pump was a Watson-Marlow HR constant flow peristaltic roller 
type (MHRE 22) which compressed a short length of silicone 
rubber tubing (Silescol TC 156/1, 4.5 x 0.8 mm).
Oscillations in perfusion pressure due to the roller pump 
were damped by an air buffer consisting of a 1 0 ml disposable 
plastic syringe attached to a T-piece next to the pump. The 
medium then passed through a filter to remove any small clots 
or debris. The filter consisted of a compressed stack of 
twenty V75 'Micronyl' nylon photographic water filter discs 
with a filtration degree of 13-45 y (Rellumit Ltd.).
The polyethylene tube through which the perfusion medium 
was flowing then ran for 2 m through a wider P.V.C. tube 
(10 x 14 mm) carrying a flow of water at 38 C, which served 
us an efficient heat exchange unit. After passing through a
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srcia.ll bubble trap (1.0 ml) fashioned, from Peirspex and sealed 
with a silicone rubber bung the medium enterred the liver 
through a cannula in the portal vein. The portal venous 
pressure was recorded from a polyethylene Y-piece between the 
bubble trap and cannula, through a saline filled Tygon tube, 
by a Pye Ether UP4 pressure transducer (± 500 mm Hg) connected 
to a potentiometric recorder (Smiths Servoscribe).
The perfusion chamber consisted of a Perspex box with 
two holes drilled through the wall at one end to carry the 
tubes containing water from the inflow and outflow of the 
vinyl heat exchange unit (Baxter, Fenwal plastic blood warming 
unit) which formed a false floor to the chamber and on which 
the liver rested. Another two holes, one at each end of the 
chamber, sealed with rubber stoppers drilled through their 
centres, carried the polyethylene tubes transporting the 
perfusion medium to and from the liver. The rubber stoppers 
permitted adjustment of the cannulae because of the security 
of grip they provided when the cannulae were set in position. 
The whole chamber was filled with liquid paraffin at 37°C which 
kept the liver warm and moist and prevented compression oedema 
by partially floating the lobes apart.
Bile flow was recorded from a cannula in the bile duct 
running through an electronic drop counter connected to the 
potentiometric recorder or, in initial experiments, by timing 
flow in a capillary tube. Bile was collected at 10 cm 
negative pressure in a small test tube clamped below the 
perfusion chamber.
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The portal venous circuit could be extended by making 
use of the length of Tygon tubing normally connected to the 
pressure•transducer. Thus perfusion of the liver could be 
started while the organ was still in the animal on the 
operating table below the perfusion chamber. After transfer 
of the liver to the perfusion chamber this extension tube 
could be re-connected to the pressure transducer and the 
cannula in the portal vein attached to a shorter tube from 
the Y-piece.
Venous blood drained from the liver at 5.0 cm negative
pressure through a cannula in the inferior vena cava into a
/
polycarbonate collecting tube and then back into the reservoir 
for re-oxygenation and re-cycling.
Portex polyethylene tubing was used throughout for the 
perfusion circuit (PP 270, 2 x 3  mm) and for the bile duct 
cannula (PP 10, 0.28 x 0.61 mm). The portal vein cannula 
consisted of a short length of polyethylene tubing (PP 270) 
drawn out over a bunsen flame to a diameter of 2 mm and cut 
square at the tip. The venous outflow cannula was of a 
similar design except that a 30° bevel at the end was necessary 
to pierce the right atrium of the heart. All connections 
were push fit or by means of short lengths of silicone rubber 
tubing (Silescol). All tubing inside the perfusion chamber 
was of S-50-HL Tygon (2.5 x 4 mm) which provided flexibility 
without risk of compression. The total dead space of the 
circuit was 14.0 ml.
The perfusion medium came into contact with only
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polyethylene, nylon, silicone rubber, Tygon and Perspex.
It was thus unnecessary to siliconise any exposed surface 
as is necessary with rubber or glass. The filter elements, 
bubble traps and T-pieces were washed overnight in RBS 25 
non-ionic detergent (Chemical Concentrates Ltd.) after each 
perfusion and then rinsed in several volumes of distilled 
water before re-assembly. These parts of the apparatus were 
replaced periodically or if showing signs of wear. All 
polyethylene and silicone rubber tubing was discarded after 
each perfusion and replaced with fresh material.
4.3.3 Operative procedure
Male albino Wistar rats (220-300 g) were allowed free 
access to a standard laboratory diet (Diet 41, Herbert C. Styles) 
and water prior to the operation. Anaesthesia was induced by 
Halothane (I.C.I.) 3% in an O^jN^O mixture (1:3) and was main­
tained on 1% Halothane in the same gas mixture delivered 
through a cannula in the trachea. A midline incision was made 
from the pubic symphisis to the xiphoid process along the 
bloodless linea alba and the skin and abdominal muscle coats 
were retracted to either side. The intestines were dis- 
-placed to the left of the rat between layers of tissue kept 
.moist with 0.9% saline preheated to 37°C. The superior mesen­
teric artery was identified and ligated and the inferior 
mesenteric artery was tied off by ligating the colon proximal 
to its junction with the rectum. The superior mesenteric 
vein was ligated by tying' off the duodenum above the entry of 
the bile duct at the sphincter of Oddi. At this stage of the 
operation 250 I.U. heparin were injected into the animal
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through the ventral penile vein. The bile duct was cannulated 
with a length of polyethylene tubing cut to a sharp point, 
which was inserted to a point distal to the fusion of the 
left and right bile ducts to form the common bile duct. Bile 
flow commenced immediately upon insertion of the cannula into 
the duct.
The viscera and intestines were then reflected to the right 
so that the abdominal aorta could be ligated below the coeliac 
axis. After again reflecting the viscera to the left, the 
inferior vena cava was dissected free of the connective tissue 
and tied below the liver above the right renal vein. The 
superior pancreatico-duodenal vein was cleared and cut between 
ties where it entered the portal vein. Loose ligatures were 
placed around the hepatic artery and the portal vein, just 
distal to their points of entry into the liver tissue. Further 
loose ties were placed around the splenic vein at its point of 
entry into the portal vein and around the portal vein distal 
to the splenic vein. The middle colic vein was ligated close 
to the portal vein which was then cleared between this tie and 
the splenic vein. The portal vein was ligated distal to the 
splenic vein.
The rat was then transferred to the perfusion table 
below the perfusion chamber. The liver was at this point 
receiving blood from the hepatic artery and the splenic vein 
via the portal vein. The splenic vein was then ligated1 The 
portal vein was cut proximal to the middle colic vein and a 
saline-filled cannula inserted.and tied into the vein. After 
all air bubbles had been removed from the cannula the perfusion 
circuit, via its extension tube, was attached and perfusion
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commenced at 2 to 3 ml/min. The hepatic artery was then 
ligated.
The thorax was opened and two loose ties placed around 
the inferior vena cava above the diaphragm. The vena cava 
was cannulated by piercing the wall of the right atrium with 
a sharp-pointed cannula and guiding- this down the length of 
the vein to its point df passage through the diaphragm. The 
cannula was then tied in place. At this stage all of the 
blood from the rat itself had been cleared from the liver by 
perfusion with the semi-synthetic medium. Collection of the 
venous outflow after cannulation of the vena cava thus enabled 
the volume of circulating artificial medium to be maintained 
without contamination by rat red blood cells.
The liver was now totally isolated from the circulation 
of the rat but was still attached physically. The colon was 
cut below the ligature around it, the bile duct and portal 
vein dissected free from the surrounding mesentery and the 
hepatic artery cut distal to its tie. The stomach and spleen 
were carefully cut free of their attached ligaments and the 
oesophagus cut near the stomach. The inferior vena cava was 
_cut above the right renal vein but below the ligature around 
it. The intestines, stomach and spleen could then be dissected 
out of the rat leaving the liver attached only to the diaphragm 
by several ligaments and the vena cava. The inferior vena 
cava with attached cannula was cut free from the heart and 
the diaphragm dissected round the vein to leave a cuff of 
diaphragmatic tissue. The remaining ligaments to the liver 
were cut and the liver transferred to the perfusion chamber.
The venous outflow was adjusted to provide optimum flow, 
at a slight negative pressure. The tubing attached to the 
portal vein was disconnected from the cannula and attached to 
the pressure transducer while the previously sealed shorter 
tube from the Y-piece at the pressure transducer was filled 
with perfusion medium, connected to the cannula and opened 
to permit perfusion to continue. The perfusion flow rate was 
adjusted to 1 0 ml/min (approximately 1 ml/g of liver/min) and 
the position of the portal cannula adjusted to give the lowest 
pressure reading indicating that the inflow was not occluded. 
The pressure was normally 8 to 12 cm H20. The end of the bile 
duct cannula was positioned over the collection vessel and 
bile collection commenced. The chamber was filled with liquid 
paraffin previously warmed to 37°C. The perfusion medium 
collected between cannulation of the vena cava and transfer- 
of the liver was then returned to the reservoir.
4.3.4 Operative protocol
The entire operative procedure took 30 min. Half-way 
through the operation the apparatus was primed with the 
perfusion medium, care being taken to expel all air bubbles, 
-and the medium slowly re-cycled through the apparatus, being 
„oxygenated in the process. After isolation of the liver it 
could be attached to the perfusion circuit by means of an 
extension tube of Tygon as described above, so that transfer 
of the liver from the operating table to the perfusion 
chamber could be carried out without any interruption in 
blood flow to the organ. The liver was normally left to 
equilibrate for 60 min except in viability studies.
4.3.5 Experimental procedures
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4.3.5.1 Assessment of viability
After a few minutes equilibration 3 ml aliquots of 
perfusion medium were removed from the reservoir at 15 min 
intervals over the first 90 min and every 30 min thereafter 
up to 6 h, for the determination of glucose, lactate and 
pyruvate or the degree of haemolysis and K+ levels. Bile 
flow rate was determined by timing the period taken to fill 
a 20 pi capillary tube. In some perfusions 5 ml aliquots 
of perfusion medium were taken for the determination of the 
level of bacterial contamination, pH or oxygen content. 
Similar samples were taken in control perfusions in which 
perfusion medium was re-cycled in the circuit in the absence 
of a liver. Any medium leaking from the 'liver was collected 
and measured at 15 min intervals.
After completion of perfusion the appearance of the 
liver was noted and the liver weight recorded. In some 
instances sections of liver were removed for electron micro­
scopy together with sections cut from the livers of freshly 
killed rats.
In calculating the removal or appearance of compounds 
in the perfusion medium a correction both for removal of 
the compound during sampling and for loss occurring from 
leakage of medium from the liver vasculature, normally 0 to 
2 ml/h, has been made.
4 .3.5.2 Hexobarbitone metabolism
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Livers were equilibrated for 60 min after transfer to 
the perfusion chamber to permit a constant rate of conversion 
of substrates of intermediary metabolism to be established 
(Ross, 1972). Hexobarbitone sodium, dissolved in 0.9% saline 
was added to the reservoir to give an initial concentration 
of 1 ymol/ml. The two pulse protocol of Stitzel et al (1966) 
was followed in which, 90 min after the addition of the first 
pulse of hexobarbitone, a second similar pulse of the sub­
strate was added. Aliquots of perfusion medium, 1 ml, were 
removed at 15 min intervals. Noradrenaline or adrenaline 
bitartrate, dissolved in saline, was added to the reservoir 
85 min after the first pulse of hexobarbitone and 5 min before 
the second pulse to give an initial concentration of 6.0 yM.
4.3.5.3 Aniline metabolism
Livers were equilibrated for 60 min and aniline hydro­
chloride dissolved in saline added to the reservoir to give 
an initial concentration of 1 ymol/ml. Aliquots of perfusion 
medium, up to 2.6 ml, were removed at 15 or 30 min intervals 
up to 4 h and assayed for free aniline and acid-labile aniline 
conjugate. In some perfusions free and conjugated p-amino- 
phenol were also measured. Aliquots of bile were collected 
over 1 h periods and also assayed for aniline and its meta­
bolites. Adrenaline or noradrenaline bitartrate dissolved in 
saline was added 60 min after the addition of aniline to give 
an initial concentration of 6.0 yM.
4 .3.5.4 Blood pressure studies
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The vasoactive properties of a variety of compounds 
were tested in the perfused liver. Ba2 + / K+, vasopressin, 
histamine, papaverine and angiotensin II were administered 
directly into the reservoir and angiotensin, Ba"1"*", vasopressin 
and K infused in saline at a constant flow rate of between 
11 yl/min and 44 yl/min into the portal venous bubble trap.
4.3.5.5 X-radiography of the liver
After equilibration for 60 min the liver was perfused 
for 3 min with a 10% (v/v) solution of the radio-opaque 
contrast medium Conray 280 in perfusion medium by a separate 
perfusion circuit which allowed an almost square wave pulse 
of contrast medium to be delivered. X-radiographs were 
taken with a Newton Victor Model K, Type 5 X-ray Machine 
placed 32 cm above the liver at 30 KeV, with 3 sec exposure, 
on to 3M type S X-ray film placed 3 cm below the liver.
During perfusion of the contrast medium and for 5 to 10 min 
afterwards the perfusion medium was not re-circulated. 30 
min later the liver was perfused with medium containing 
adrenaline, 6.0 yM and when the increased portal pressure 
had reached a plateau perfusion with medium containing Conray 
280 as well as adrenaline was commenced and X-radiographs 
were taken as before.
4.3.5.6 Perfusion of the liver with Indian ink
After 30 min equilibration the liver was perfused with 
medium containing Indian ink, particle size < 3 y, 10% (v/v)
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through the portal vein for 2 mm. Perfusion was stopped and 
sections of liver immediately removed from deep central and 
peripheral regions of the lobes and placed in Helly's fluid 
(Disbrey and Rack, 1970) as a fixative. In another group of 
livers after the equilibration period the medium was changed 
to one containing 6.0 yM adrenaline and perfusion was continued 
until the portal pressure response reached a plateau when 
Indian ink 10% (v/v) was added to the medium and sections taken 
as above.
4.3.6 Chemical and biochemical analytical techniques
4.3.6.1 Determination of L (+)-lactate
The concentration of lactate in the perfusion medium was 
determined by the lactate dehydrogenase method of Hohorst 
(1963). Aliquots of perfusion medium were deproteinised with 
2 volumes of ice cold 0.6 M perchloric acid immediately after 
sampling and the deproteinised supernatants assayed after 
storage overnight at -20°C. The only significant modification 
of the assay was to increase the amount of enzyme by 50%. The 
accuracy of the assay was ± 0.014 ymol/ml.
4.3.6 .2 Determination of pyruvate
Pyruvate in the perfusion medium was assayed by a method 
based on the lactate dehydrogenase method of BUcher, Czok, 
Lamprecht and Latzko (1963), modified by BUcher (1970). Aliquots 
of perfusion medium were deproteinised with an equal volume of 
ice cold 1 M perchloric acid immediately upon collection and 
the deproteinised supernatants stored overnight at -20 C. Ihe
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accuracy of the assay was ± 0 . 0 0 2 ymol/ml.
4.3.6.3 Determination of glucose
The total blood glucose of the perfusion medium was 
determined by the GOD-Perid method of Werner, Rey and 
Wielinger (1970) with a commercially available test com­
bination (Boehringer), the manufacturer's instructions being 
followed exactly. Samples were deproteinised and stored 
overnight at -20°C. The accuracy of the assay was ± 0.25 
ymol/ml (± 5 mg%).
4.3.6 .4 Estimation of haemolysis
The extent of haemolysis in samples of perfusion medium 
was determined on duplicate samples of the synthetic plasma 
obtained by centrifugation of the medium at 2,000 x G for 10 
min. The plasma was stored overnight at -20°C prior to assay. 
The plasma samples were diluted with 3 volumes of glass dis­
tilled water and the absorbance at 416 my measured. An 
aliquot of perfusion medium haemolysed by the addition of 1 0 0  
volumes of distilled water served as a reference standard. 
Haemolysis was expressed as a percentage of the haemolysed 
-Standard.
4.3.6 .5 Determination of haematocrit
The haematocrit of the perfusion medium was determined 
on samples of medium before starting perfusion of the liver. 
The samples were centrifuged in glass Wintrobe tubes at 2,000
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x G for 15 min and. the haematocrit expressed as per cent 
packed cell volume in the sample.
4.3.6.6 Determination of serum potassium
The concentration of K was determined in cell free 
samples of perfusion medium prepared by centrifugation at 
2,5000 x G for 15 min and stored overnight at -20°C. Samples 
were diluted with 3 volumes of distilled water and K+ content 
determined on an EEL Model 100 direct reading flame photo­
meter. Duplicate samples were sprayed in a randomised order 
with a standard solution after every third sample to allow 
for any drift of the photocell. The accuracy of the assay 
was ± 0.0025 yM/ml.
4.3.6 .7 Determination of pH and oxygen content of the 
perfusion medium
Samples of perfusion medium were collected under liquid 
paraffin and the pH at 37°C determined immediately on a Metrohm 
direct reading pH meter, model E 512, with a saturated KCL 
combination glass electrode (Russell). In later determinations 
the perfusion medium samples were collected and sealed in 
plastic syringes and the pH determined on a Radiometer blood 
gas analyser. The perfusate P and P were determined on
C°2 2
the same samples as were used for the pH determination on the 
blood gas analyser. Total oxygen content of the medium was 
estimated in. samples sealed in glass syringes and assayed on 
a Lex-O^-Con total oxygen analyser.
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4 •3 . 6 • 8 Determination of bacterial contamination of the 
perfusion medium
Aliquots of perfusion medium were removed at hourly 
intervals and sealed in glass tubes. Possible bacterial 
contamination was checked by culturing the sample on both 
solid and liquid media, using routine microbiological 
techniques for the identification of any bacterial growth 
(Cruikshank, 1968).
4.3.6 .9 Preparation of tissue for electron microscopy
Sections of liver taken for electrorf microscopy were 
fixed for 1 h in a glutaraldehyde-cacodylate fixative con­
sisting of 0.1 M sodium cacodylate with 2% glutaraldehyde,
1.7% (w/v) sucrose and 1 mM Ca.Cl^r pH 7.2 and osmolarity 
400 mosmol/1. After a minimum of a 2 h wash in 5.9% (w/v) 
sucrose in 0.1 M sodium cacodylate, pH 7.2 the sections were 
post-fixed for 1 h in osmium cacodylate fixative. This was 
0.1 M sodium cacodylate with 1% (w/v) and 5.1% sucrose,
pH 7.2 and osmolarity 400 mosmol/1. After fixing, the sections 
were dehydrated in a series of graded alcohols, embedded in 
araldite and 400 A sections cut on a LKB ultramicrotome.
These sections were stained with saturated alcoholic uranyl 
acetate and Reynolds' lead citrate (Reynolds, 1963). The 
stained sections were examined with an AEI EM6B electron 
microscope and micrographs taken on Ilford EM4 plates.
4.3.6.10 Preparation of tissue for histological examination
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Small sections of tissue were removed and fixed for 24 h 
in Helly s fluid (Disbrey and Rack, 1970) and then dehydrated 
using a Histokinette automatic tissue processor. The sections 
were finally embedded in paraffin wax (Paraplast) and blocked 
out. Sections 6 y thick were cut on a Jung microtome and 
mounted on glass slides which were dried overnight. The 
slides were cleared of wax in xylene and were examined either 
unstained -or after light background staining in aqueous eosin. 
Examination was carried out under both low and high power 
objectives of a Leitz (Wetzlar) Orthoplan microscope and 
sections were photographed with FP4 film (Kodak) .
4.3.6.11 Protocol for the estimation of aniline and its 
metabolites
Samples of perfusion medium were haemolysed by storage 
overnight at -20°C. Bile samples collected over periods of 
1 h were also stored at -20°C. 1 ml aliquots of the medium
and all of the bile in a sample were extracted with 2 x 5 ml 
light petroleum ether and 1.5% isoamyl alcohol and the free 
aniline thus removed extracted back into 2 ml of 2N HC1. and 
-assayed by the method of Bratton and Marshall (1939). The 
efficiency of the extraction was 95%. The extracted residue 
was deproteinised by the addition of half a volume of ice 
cold 20% (w/v) TCA and centrifuged at 2,000 x G for 10 min.
The supernatant was assayed for aniline liberated from acid- 
labile conjugates by the method of Bratton and Marshall (1939).
A second aliquot of medium or the previously extracted 
bile sample was deproteinised with a half volume of ice cold 
20% (w/v) TCA and centrifuged at 2,000 x G for 10 min. The .
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supernatant was assayed for free p—aminophenol by the method 
of Schenkman et al (1967). An aliquot of supernatant was 
hydrolysed with an equal volume of IN HC1 in a boiling water 
bath for 60 min. These conditions were found to be optimal 
for the liberation of p-aminophenol with least degradation. 
Higher concentrations of acid or more prolonged periods of 
hydrolysis both resulted in a lower recovery of p-aminophenol. 
The acid hydrolysate was assayed for total p-aminophenol and 
for total aniline. The accuracy of the aniline assay was 
± 0 . 0 0 1  ymol/ml and of the p-aminophenol assay ± 0.0005 ymol/ml.
4.3.6.12 Assay of hexobarbitone
/
Aliquots of perfusion medium were haemolysed by storage 
overnight at -20°C. The samples were then assayed for un­
metabolised hexobarbitone by the method of Brodie, Burns, Mark, 
Lief, Bernstein and Papper (1953). The efficiency of the 
extraction was 94% and the accuracy of the assay was ± 0.003 
ymol/ml.
4.4 Liver slices
4.4.1 Preparation of liver slices
Slices were prepared from the livers of adult male Wistar 
rats (200-300 g) by a modification of the method of Umbreit, 
Burris and Stauffer (1964). Rats were killed by decapitation 
and exsanguinated. The livers were quickly removed and placed 
in ice cold 0.9% saline. Slices of liver (0.4 to 0.6 mm) 
were cut by hand between a ground glass plate and a frosted
67
glass microscope slide with a razor blade. The slices were 
cut on ice and kept in ice cold saline at all times.
4.4.2 Incubation of liver slices
The incubation conditions were based on those of Cooper, 
Axelrod and Brodie (1954) and consisted of 4 ymol of hexo­
barbitone or 2 ymol of aniline in Krebs phosphate-buffered 
saline in a total incubation volume of 5 ml. The media were 
pre-warmed to 37°C for 5 min and the reaction started by the 
addition of approximately 0.5 g of liver slices which had 
been blotted and weighed accurately. Incubation was at 37°C 
in a shaking water bath in an atmosphere of 1 0 0 % oxygen for 
3 h. Aliquots of incubation medium, 0.5 ml, were removed at 
various time intervals and stored at -20°C. Unmetabolised 
aniline was determined, after extraction, by the method of 
Bratton and Marshall (1939) and unmetabolised hexobarbitone 
by the method of Brodie et al (1953).
4.5 Metabolism by the microsomal subcellular fraction
4.5.1 Preparation of the microsomal fraction
The microsomal fraction was prepared from the livers of 
adult Wistar rats (150-200 g) by a method based on that of 
Ernster, Siekevitz and Palade (1962). Rats were at all times 
permitted free access to standard laboratory rat food (Diet 
41, Herbert C. Styles) and water.
Rats were killed by decapitation and exsanguinated,
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between 9,JO am and 10,00 am, to avoid diurnal variation in 
drug metabolism (Jon  ^Di Sails and Santini, 1971) . Livers 
were removed and immediately placed in ice cold 0 .9% saline. 
The livers were then homogenised in 4 volumes of 0.25 M 
sucrose and 0,05 M Tris buffer, pH 7.4 in a 55 ml Thomas 
glass homogenising vessel fitted with a Tri-R teflon pestle 
providing a clearance of 0.40 to 0.45 mm. Homogenisation was 
for 12 strokes at 6,000 rpm on a Tri-R homogeniser (model 
S 63C). The microsomal fraction was prepared as described 
by Ernster et al (1962), using a hand operated 4 ml teflon 
and glass horaogeniser, clearance 0.08 to 0.13 mm (Thomas &
Co.) to resuspend the microsomes in sucrose.
4.5.2 Incubation systems
• 4.5.2.1 Incubation system used in studies on the effects of
catecholamines
The incubation system employed in these studies was based 
on that of Orrenius (1965) and consisted of 150 ymol Tris 
buffer, pH 7.-4 at 37°C, 15 ymol MgCl2, 50 ymol nicotinamide,
20 ymol DL-isocitrate, 2 units of isocitrate dehydrogenase,
1 ymol NADP, and 0.2 ymol aniline, 0.6 ymol hexobarbitone or 
10 ymol aminopyrine and 10 ymol semicarbazide. The medium was 
pre-incubated for 10 min at 37°C to start the generation of - 
NADPH. The reaction was started by the addition of 4 to 5 mg 
- microsomal protein to make the final incubation volume 2 ml.
Samples were incubated in a shaking water bath at 37 C
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for 30 min in an atin.osph.ere of air. The reactions were 
stopped by the addition of 0.5 ml ice cold 25% (w/v) ZnS0 4 
followed by 0.5 ml saturated Ba(0H) 2 when aminopyrine was 
the substrate and either 3 ml or 5 ml of light petroleum 
ether and 1.5-s isoamyl alcohol when hexobarbitone and aniline 
were the substrates respectively.
4.5.2.2 Incubation systems used in studies on the effects of 
washing the microsomal fraction
4.5.2.2.1 Incubation system employing NADPH-generating system
This incubation system was based on that of Kato and
Gillette (1965) and consisted of 75 ymol Tris buffer, pH 7.4
at 37°C, 15 ymol MgCl2, 50 ymol nicotinamide, 1 ymol NADP,
26.2 ymol glucose-6-phosphate, 1.4 units of glucose-6-phosphate 
dehydrogenase and 5 ymol aniline or 10 ymol aminopyrine with
10 ymol semicarbazide. These reagents were in a volume of 1 ml. 
A further 0.5 ml of distilled water was added, in which could 
be dissolved any test substances.
The samples were pre-incubated as before and the reaction
started by the addition of 4 to 5 mg microsomal protein, the 
final incubation volume being 2 ml. Incubations were carried 
out at 37°C as before. The reaction was stopped by the addition 
of 1 ml of ice cold 20% TCA or 0.5 ml ice cold 25% ZnS04 
followed by 0.5 ml saturated Ba(0H)2 when aniline and amino­
pyrine respectively were substrates.
4.5.2.2.2 Incubation system employing chemically reduced NADPH
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In some experiments the effects of chelators on micro­
somal drug metabolism were investigated and it was not 
possible to use an ion-dependent enzyme system for the 
generation of NADPH. Instead, chemically reduced NADPH was 
added directly to the incubation system which consisted of 
200 ymol Tris buffer, pH 7.4 at 37°C, 5 ymol aniline or 10 
ymol aminopyrine with 1 0 ymol semicarbazide, three separate 
additions of 2 ymol NADPH at 0 min, 10 min and 20 min and 
4 to 5 mg microsomal protein. The total incubation volume 
after the final addition of NADPH was always 1.8 ml. The 
reaction was started by the addition of the first 2 ymol 
of NADPH and the samples were incubated at 37°C for 30 min 
in a shaking water bath under air. The reactions were 
stopped as described in Section 4.5.2.2.1.
4.5.3 Washing the microsomes
The microsomal pellet was obtained as described in Section 
4.5.1. The pellet was rinsed with 3 x 3 ml of the sucrose 
buffer, drained briefly, re-suspended in 12.5 ml using a hand 
operated 4 ml teflon homogeniser (Thomas & Co.) and incubated 
at 2°C for 30 min then re-centrifuged at 105,000 x G for a 
further 65 min at 2°C. The washed' microsomal pellet obtained 
was again rinsed in 3 x 3  ml sucrose and re-suspended in 3 ml 
of the sucrose as before. This overall procedure is hereafter 
referred to as washing of the microsomes. All assays were 
carried out on the same day as preparation.
4.5.4 Chemical and biochemical assays.
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4 . 5 • 4 .3. Assay of aniline and its metabolite p-aminophenol
Catecholamines were found to inhibit the indo-phenol 
reaction used for the detection of p-aminophenol. Thus when 
catecholamines were included in the incubation medium, micro­
somal aniline metabolism was measured by determining the 
amount of free substrate remaining. . Aniline was assayed 
colourimetrically by the method of Bratton and Marshall (1939).
In other experiments aniline metabolism was followed by 
measuring the formation of its hydroxylated metabolite p- 
aminophenol. The assay used was that of Schenkman et al
(1967). Standards were prepared in 6.7% TCA.
4.5.4.2 Assay of formaldehyde
Aminopyrine metabolism was determined by measuring the 
formation of one of the metabolites, formaldehyde, which was 
trapped in solution as a semicarbazone. The assay used was 
the Cochin and Axelrod (1959) modification of the method of 
Nash (1953). The accuracy of the assay was ± 0.0002 ymol/ml.
4.5.4.3 Assay of hexobarbitone
Hexobarbitone was assayed by the method of Brodie et al 
(1953).
4.5.4.4 Determination of protein
Microsomal protein was determined by the method of Lowry,
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Rosebrough, Farr and Randall (1951). Crystalline bovine 
serum albumin (Cohn Fraction V) in concentrations of 0 to 
100 yg/ml was used as the standard. The accuracy of the 
assay was ± 0 . 0 0 0 2  yg/ml.
4.5.4.5 Assay of thiobarbituric acid reacting substance 
(malonaldehyde)
Lipid peroxidation was measured by determining the 
formation of a thiobarbituric acid reacting substance 
recently shown to be malonaldehyde (Bidlack and Tappel, 197 3). 
The assay was that described by Bidlack et al (197 3) .. Results 
have been expressed as absorption change per mg microsomal 
protein.
4.5.4.6 Determination of cytochrome b  ^ and cytochrome P-450 
content of the microsomal fraction
The microsomal content of cytochrome b^ and cytochrome 
P-450 was determined on the same sample by the method of 
Dallner (1966). The microsomal fraction was diluted to a 
protein concentration of 2 mg/ml in 0.05 M Tris buffer pH
7.4 and 5 mM MgC^.
The extinction coefficient of cytochrome b5 between 500
2 -1mu and 42 3 mu was taken as 171 cm umol and of cytochrome
2 -1P-450 between 450 mu and 480 mu as 91 cm umol . Cytochrome 
content has been expressed in mumol/mg protein.
4.5.4.7 Assay of microsomal activity of NADPH-cytochrome c 
reductase
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The NADPH-cytochrome c reductase activity of the micro­
somal fraction was determined by the method of Mazel (1971).
The extinction coefficient of cytochrome c at 550 my was
2 -1
taken as 19.1 cm ymol and activity has been expressed as 
mymol cytochrome c reduced/mg protein/min.
4 .5.4.8 Assay of microsomal activity of NADPH-cytochrome 
P-450 reductase
The NADPH-cytochrome P-450 activity of the microsomal 
fraction was determined by the method of Gigon et al (1969).
The microsomal suspension was diluted to 5 mg protein/ml in 
0.02 M Tris buffer pH 7.4, and the NADPH-generating system 
consisted of 1.5 ymol MgCl^ f 40 ymol isocitrate and 0 . 0 2  
units isocitrate dehydrogenase in 0.02 M Tris buffer pH 7.4.
The change in absorbance was calculated for the initial
rapid phase of cytochrome P-450 reduction over the first
minute. The activity of NADPH-cytochrome P-450 reductase
has been expressed as mymol cytochrome P-450 reduced/mg
protein/min, using an extinction coefficient for cytochrome
2 -1P-450 at 4 50 my of 91 cm ymol
4.5.4.9 Determination of the substrate-induced difference 
spectrum of the microsomal fraction
The change in the difference spectrum of the microsomal 
fraction caused by the addition of substrate was measured by 
the method of Schenkman et al (19 67) on a Pye Unicam SP 8000 
dual beam recording spectrophotometer. The microsomal fraction 
was diluted to 3 mg protein/ml with 0.10 M Tris buffer pH 7.4.
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4 . 5 In vivo studies
Male.Wistar rats (150-200 g) were pre-treated with either 
adrenaline or noradrenaline (1 mg/Kg) dissolved in 0.9% 
saline, administered by i.p. injection. Animals were killed 
at various times after administration. Liver microsomal 
fraction was prepared as described in Section 4.5.1 and the 
metabolism of aniline and aminopyrine determined as described 
previously. The microsomal content of cytochromes bj-, and 
P-450 and the activity of the enzyme NADPH-cytochrome c 
reductase, were determined as previously described.
4.7 Treatment of results
In studies with the perfused liver, and with liver slices, 
substrate half-lives have been calculated with the aid of a 
Fortran programme. This calculated gradient, m and intercept,
C of the regression line of a plot of logarithm amount of free 
substrate against time of sampling. The half-life was then 
calculated from the expression:
t , log 10C / 2  - C
h = 10
m
Comparison of results was carried out by means of Student's 
t test for samples of unequal size (Snedecor and Cochran, 1968) 
and were regarded as differing significantly if the P-value 
was less than 5 %.
CHAPTER
Results
5.1 Viability of the perfused liver
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5 .1 . 1 Macroscopic appearance
Within a few minutes of commencing perfusion, the liver 
became uniformly coloured a dark red, very similar to the 
colour observed in vivo. At higher oxygen tensions in the 
perfusion medium the liver became abnormally light and more 
pink in colour. After 6 h of perfusion the liver was almost 
invariably evenly coloured, although occasionally paler un­
perfused patches became apparent, particularly at the edge of 
the lobes. Sometimes a clear exudate was visible on the 
surface of the lobes, particularly at higher perfusion 
pressures.
5.1.2 Perfusion pressure
The perfusion medium flow rate was constant throughout 
an experiment and varied between 0 . 8 and 1 . 2 ml/g/min (mean 
1.0 ml/g/min) over twenty perfusions. The difference was due 
to the variations in liver weight since the flow rate was 
initially set at 1 0 ml/min and could only be corrected for 
liver weight at the end of the experiment. The perfusion 
-pressure corresponding to these flow rates was 8 to 12 cm H^O
(mean 10 cm H20). The pressure increased proportionally with
the flow rate.
The perfusion pressure did not normally change
significantly over the duration of an experiment. A typical
record of the portal pressure during a control perfusion is.
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shown in Fig. 16. In a few perfusions the pressure started 
to increase steadily, at any time after commencing perfusion, 
finally resulting in an increase of up to 6 cm Such
perfusions were normally characterised by the appearance of 
unperfused areas at the edges of the lobes. These perfusions 
were rejected.
5.1.3 Adequacy of perfusion
In several livers the introduction of Indian ink (particle 
size < 3y) into the perfusion medium after up to 6 h of 
perfusion revealed an even distribution of carbon granules 
throughout the liver within 2 min, indicating that the medium 
was perfusing all areas of the organ.
X-radiographs of livers perfused with the radio-opaque 
contrast medium Conray 280, at a concentration .of 10% (v/v) , 
also revealed an even perfusion of the liver, as shown in 
Fig. 24. The contrast medium was evenly distributed through­
out the organ, the edges being evenly outlined. Many fine 
branches of the portal venous tree were visible and the 
background was evenly dense, indicative of uniform sinusoidal 
filling.
5.1.4 Extent of haemolysis
The amount of haemoglobin detectable in the cell free 
fraction of the perfusion medium stayed constant over the first 
30 min of perfusion and thereafter increased almost linearly 
with time at a rate corresponding to an average rate of
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Figure 5
Extent of haemolysis in the perfusion medium during perfusion of the 
isolated rat liver. Measurements were started 5 min after transfer of 
the liver to the perfusion chamber. Values obtained with a liver in the 
circuit (•) are mean of four perfusions. Bars represent S.E. of mean. 
Values obtained with no liver in the circuit (■) are mean of two 
perfusions.
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Figure 6
Increase in plasma K+ concentration during perfusion of the isolated liver. 
Measurements were started 5 min after transfer of the liver to the 
perfusion chamber. Values obtained with a liver in the circuit (•) are 
mean (± S.E.M.) of four perfusions. Values obtained with medium alone (■). 
are mean of two perfusions.
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Figure 7
Perfusion medium glucose concentration during perfusion of the isolated 
rat liver. Measurements were started 5 min after transfer of the liver 
to the perfusion chamber. Values obtained with a liver in the circuit 
(•) and with no liver in the circuit (■) are means (± S.E.M.) of four 
perfusions.
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haemolysis of 0.2-s/h (Fig. 5) . Haemolysis occurred at the 
sums rate whether or not there was a liver in the circuit.
Thus it would appear that almost all the rupture of red 
cells was caused by the physical characteristics of the 
perfusion system, probably by the roller pump. However in 
view of reported values of haemolysis in the perfused liver, 
varying between 0%/h (Exton and Park, 1967) and 2%/h (Craig, 
1966) this low level of haemolysis was regarded as acceptable.
+
5.1.5 Accumulation of K in the medium
With no liver in the circuit the concentration of K+ in 
the perfusion medium plasma did not change appreciably over 
6 h as shown in Fig. 6. In view of the low level of haemolysis 
reported above and the fact that non-glycolysing red cells
-f
were employed an increase in plasma K would not be expected.
The inclusion of a liver in the circuit resulted in an 
increase in plasma K+ levels, which was found to average 10 
ymol/g/h. The increase in plasma K+ was almost linear with 
time up to 6 h.
5.1.6 Changes in perfusion medium glucose levels
As shown in Fig. 7, in the absence of a liver in the 
circuit glucose levels in the medium were not altered sig­
nificantly over 5 h of perfusion. Thus aged red cells do 
not appear to be capable of glycolysis, in agreement with 
the findings of Hems et al (1966) . When rat liver was per­
fused it was found to shed large amounts of glucose during
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the first 60 min after isolation. Blood, glucose lsvsls 
plateaued after 2 h and thereafter declined up to 5 h, the 
longest period over which measurements were made. This 
represents an average rate of glucose utilisation over the 
latter part of the perfusion of 22 ymol/g/h.
5.1.7 Perfusion medium pH and oxygen content
It was found that when the liver was perfused for periods
of up to 6 h the pH of the perfusion medium remained between
7.3 and 7.4. When gassed with 95% air + 5% C00 the P of the2 02
perfusion medium was 187 mm Hg. The total oxygen content of
/
the medium was 8.6 vol%.
5.1.8 Bacterial contamination of the medium
In several perfusions samples of medium were cultured 
for possible bacterial contamination. In all such tests no 
significant bacterial contamination was detectable for the 
3 h after commencing perfusion. In one perfusion no bacteria 
were found for a further hour, the longest period over which 
sampling had been carried out for that experiment. However 
in two other perfusions a few bacteria were found after 3 h 
of perfusion, most being the species S. faecalis. It was 
concluded that since perfusions were to be carried out for a 
maximum of 4 h the inclusion of antibiotics in the medium to 
combat the slight contamination usually present at^  this time 
was unnecessary.
5.1.9 Perfusion medium ratio of lactate:pyruvate
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Figure 8
245 305 365
Lactate:Pyruvate ratio in the perfusion medium of the isolated perfused 
rat liver. Measurements were started 5 min after transfer of the liver 
to the perfusion chamber. Values obtained with a liver in the circuit 
(•) are mean (± S.E.M.) of four perfusions. Values obtained in the 
absence of a liver (■) are mean (± SjE.M.) of three perfusions.
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Figure 9
Rate of bile production by the isolated perfused rat liver. Measurements 
were started 5 min after transfer of the liver to the perfusion chamber. 
Values are mean (± S.E.M.) of four perfusions.
Electron micrographs of section of liver removed from deep 
central regions of the lobes of livers. Upper plate, liver 
of animal sacrificed just prior to fixation and lower plate, 
that had been perfused for 4 h. Nucleus, N; nuclear 
membrane, NM; glycogen, G; endoplasmic reticulum, ER; 
mitochondrion, M; bile cannuliculus, BC? cell junction,
CJ. Magnification 20,000x.
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Figure 10
Electron micrographs of sections of liver removed from 
peripheral regions of the lobes of livers. Upper plate, 
liver of animal sacrificed just prior to fixation and lower 
plate, that had been perfused for 4 h. Nucleus N; nuclear 
membrane, NM: glycogen, G; endoplasmic reticulum, ER;
mitochondrion, M: bile cannuliculus, BC; cell junction,
CJ. Magnification 20,000x.
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Fig. 8 shows that the perfusion medium contained both 
lactate and pyruvate, initially in the ratio 20:1. With no 
liver present this ratio remained unaltered over 6 h of 
perfusion. However when a liver was included in the system 
the ratio decreased to 13 within 60 min and was maintained 
between 8 and 12 for the remainder of the experiment. Thus 
the liver appears to act to reduce the lactate:pyruvate ratio 
from its initial high values and to maintain it at a value of 
around 10. This is the physiological ratio of these two 
substrates, which the liver maintains in the blood in vivo 
(Schimassek, 1963b).
5.1.10 Bile flow
After commencing perfusion, the bile flow rate was 0.7 
ml/h. However, as may be seen from Fig. 9, the flow rate fell 
rapidly over the first 60 min and then plateaued between 0.2 
and 0.3 ml/h over the next 4 h. After this the rate of bile 
flow again declined, and was less than 0.1 ml/h after 6 h of 
perfusion.
5.1.11 Electron microscopy of the perfused liver
Electron micrographs of liver from freshly killed rats 
and livers that were perfused for 4 h are shown in Figs. 10 
and 11. Tissue was taken from both the centre and the periphery 
of the lobes. Comparison of the micrographs reveals no signs 
of necrosis or cell degeneration after perfusion. Character­
istic signs of degeneration are disruption of the nuclear 
membrane, distortion of cell junctions, depletion of liver 
glycogen, excessive lysosomal activity and swelling of the
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Figure 12
Hexobarbitone metabolism by the isolated perfused rat liver. Removal of 
hexobarbitone during the first pulse of control perfusions. The upper 
panel shows the amount of hexobarbitone remaining in the perfusion medium, 
and the lower panel the same values plotted logarithmically. Values are 
mean (± S.E.M.) of twelve perfusions.
TABLE 2
Effect of catecholamines on the half-life of hexobarbitone in the perfused
liver
Hexobarbitone, 150 ymol, was added to the perfusion medium at the start 
of the first and second pulses. Catecholamines were added 5 min prior to 
the second pulse of hexobarbitone. - No drug added. Values are mean 
± S.E.M.
*P < 0.05 **P < 0.01 compared with the corresponding first or second
pulse of the control.
Half-life,min 
n First Pulse .Second Pulse
Control
- 5 29.7 ± 2.0 — 39.6± 4.3
Drugs #
- 4 32.6 ± 1.6 Adrenaline, 6yM 87.1 ±
**
8.0
— ■ 4 30.4 ± 2.3 Noradrenaline, 6yM 72.4 ±
**
7.8
Papaverine, 80uM 3 82.5 ±36.8 * Papaverine, 80yM 152.1±
*
51.9
2+0 Ca 3 37.4 ± 2.4*
2+
0 Ca ,
Adrenaline, 6yM
55.2 ± 11.0
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Figure 13
The rate of hexobarbitone metabolism by the isolated perfused rat liver. 
-Values are mean (± S.E.M.) of four perfusions for the first (•) and 
second (o) pulses.
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endoplasmic reticulum (Abraham et al, 1968; Bock et al, 1972). 
One of the earliest signs of inadequate perfusion or hypoxia 
is swelling of the mitochondria (Schimassek, 19 62a; Bock et al, 
1972). However no such swelling was visible after 4 h of 
perfusion.
5.2 Metabolism of drugs by the perfused liver------------------          r— t—
5.2.1 The metabolism of hexobarbitone
Hexobarbitone was removed by the liver from the 
perfusion medium and the amount fell exponentially after 
the first dose of substrate (Fig. 12). Plotting these 
results logarithmically reveals that the reaction is first 
order. The removal of hexobarbitone during the second 
pulse of substrate in control perfusions was also first 
order. The half-life of hexobarbitone during the first 
pulse was 2 9.7 min (Table 2) and during the second pulse it 
was increased significantly by 32% (P < 0.05).
The rate of hexobarbitone removal was initially 3.51 ±
0.25 ymol/g/15 min and 2.66 ± 0.14 ymol/g/15 min during the 
first and second pulse respectively, a reduction of 24% 
during the second pulse. This may be due to depletion of 
some important co-factor from the liver. In both cases the 
rates decreased almost linearly with time as the substrate 
concentration decreased, in accordance with first order 
kinetics (Fig. 13).
Although hexobarbitone could be detected in the bile
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Figure 14
Aniline metabolism by the isolated perfused rat liver. Amount of free 
aniline (•), acid-labile aniline conjugate (■) and p-aminophenol conjugate 
(A) formed during perfusion of the isolated rat liver. Values are mean 
(± S.E.M.) of four perfusions. Thehistogram shows the distribution of 
label amongst aniline and its metabolites 3 h after the addition of 150 
ymol of 3H-aniline (two experiments).
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after 3 h of perfusion it accounted for only 0.40 ± 0.03%
(n = 5) of the substrate added to the medium.
5*2.2 The metabolism of aniline
Fig. 14 shows that the amount of aniline in the medium 
in control perfusions followed an exponential decline. Also 
shown in this figure is the accumulation of a p-aminophenol 
conjugate, which did not appear in the medium in significant
quantities until 60 min after the addition of aniline. An
acid-labile conjugate of aniline was found from the start of 
the experiment and its formation levelled off after 150 min.
In perfusions with no liver in the* circuit there was 
almost no change in the amount of aniline in the medium so 
that aniline was not being lost from the circuit, for example 
by adsorption. It was. very quickly found that no free p- 
aminophenol could be detected in the medium, even after 4 h 
of perfusion. This was surprising since the major normal 
product of aniline metabolism in vivo is p-aminophenol (Parke, 
1960). Acid hydrolysis of the protein-free medium super­
natant was found to liberate p-aminophenol, presumably from 
some conjugated form. These findings led to- a more detailed 
investigation into the measurement and detection of p-amino­
phenol. The outcome of the study was the finding that some 
component of the red cells prevented p-aminophenol from being 
measured at low concentrations. At high concentrations there 
was a reduction in the amount of p-aminophenol that could be 
assayed in a suspension of red cells when compared with the 
assayable concentration in a solution of bovine serum albumin.
TABLE 3
Aniline and its metabolites accumulated in bile by the perfused liver
Values are the amount of aniline and its metabolites accumulated in the 
bile after 3 h perfusion. Initial amount of aniline added was 150 ymol, 
Figures are mean ± S.E.M. of four perfusions.
ymol %total
Free aniline 1.92 ± 0.25 20.49 ±3.28
Labile aniline conjugate 5.38 ± 1.36 47.25 ±5.05
Other aniline conjugates 2.68 ±0.40 26.46 ±4.38
Free p-aminophenol 0.03 ± 0.01 0.31 ±0.23
p-aminophenol conjugates 0.56 ±0.09 5.49 ±1.38
Total 10.57 ± 1.78 100
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It was finally concluded that haemoglobin could interact 
with p-aminophenol to form a complex that was not detected 
by the methods used in this study.
Most of the aniline removed from the perfusion medium 
could be detected as an acid-labile complex, probably 
aniline-N-glucuronide. This acid-labile conjugate was not 
formed in the perfusion medium when there was no liver 
present.
The accumulation of aniline and its metabolites in bile 
is shown in Table 3. As in the perfusion medium most of the 
aniline was recovered as the acid-labile conjugate. A trace 
of free p-aminophenol was also detectable, supporting the 
hypothesis that some free p-aminophenol was being formed but 
which, in the blood, interacted with haemoglobin.
In two experiments aniline was replaced by 3H-an.iline so 
that the distribution of label could be measured. The results 
are shown in the histogram in Fig. 14 which was obtained after 
3 h of perfusion in the presence of labelled aniline. After 
this time 30 ymol of aniline remained unmetabolised, 4 9 ymol 
of the acid-labile conjugate of aniline had been formed and 
-only 19 ymol of p-aminophenol conjugate. A further 12 ymol 
of label was bound to haemoglobin, probably from p-aminophenol 
as discussed previously. There was still 12 ymol of label 
unidentified in the blood, possibly as other more stable 
conjugates or metabolites of aniline. In total 122 ymol of 
label was recovered from the medium. A further 3.5 ymol was 
in the homogenised liver, which had been flushed clear of
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Figure 15
Aniline metabolism by the isolated perfused rat liver. Results are plotted 
semi-logarithmically. Free aniline (•). The residual curve (o) is obtained 
after stripping the second exponential, shown by the broken line, from the 
combined curve as described in Appendix I. Acid-labile aniline conjugate 
(O). Values are mean (± S.E.M.) of four perfusions.
TABLE 4
Half-life of aniline in the perfused liver
Aniline was added in an initial amount of 150 ymol, and drugs at the 
concentrations shown, added as described in the text. The half-lives 
of aniline -were calculated by curve stripping as described in Appendix 
I. Subscript s refers to the slow phase of removal and subscript 1 to 
the faster phase. Figures are mean ± S.E.M. of at least three deter­
minations .
*P < 0.05 **P < 0.01 compared to control perfusions.
2 1 Half-life min Half-life min
Control
Noradrenaline, 6yM
Adrenaline, 6yM
Papaverine, 80yM 
adrenaline, 6yM
SKF 525-A, 200yM
108.7 ± 3.0
100.5 ± .5.8 
101.6 ± 6.1
122.1± 8.7
383.8 ± 120.2
23.4 ± 3.1 
20.3 ± 1.9 
20.6 ± 3.9
11.3 ± 0.8 
19.9 ± 5.3
* *
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perfusate. A significant proportion of the label was 
excreted into the bile, 11 ymol, and a further 12 ymol could 
be recovered from other sources, 8 ymol surprisingly from 
the liquid paraffin in the perfusion chamber. When the 
polyethylene and silicone rubber of the circuit were extracted 
at 37°C for 5 days with Soluene a total of 1 ymol of label 
could be recovered, so that neither aniline nor its metabolites 
were adsorbed on to the surface of the material used in the 
perfusion system to any extent. The rest of the label, 4 ymol, 
was detected in the pipettes and glassware used in the 
collection of perfusion medium samples. A total of 149.5 ymol 
of the label could be accounted for.
When* the aniline remaining in the perfusion medium was 
plotted semi-logarithmically as in Fig. 15 it was found that 
its removal was biphasic. The initial phase was obtained after 
curve stripping of the combined plot as described in Appendix
I. The formation of acid-labile conjugate of aniline was non­
linear on the semi-log plot. In the initial phase aniline 
had a half-life of 23.4 ± 3.1 min (Table 4). This phase of 
removal was almost complete after the first 60 min. In the 
second phase of removal aniline had a half-life of 108.7 ±
3.0 min. This was a continuous process throughout the 
experiment but during the initial 60 min it was masked by 
the faster first phase of removal. SKF 525-A 200 yM, an 
inhibitor of drug metabolism (Cooper et al, 1954), increased 
the half-life of aniline during the second phase to 383.8 ±
12.2 min (P < 0.001) (Table 4). However it did not affect 
the half-life of aniline during the first phase. The first 
phase of aniline removal may thus be a non-metabolic process 
and thus catecholamines were not added in these perfusions
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Figure 16
Effect of catecholamines on the portal pressure of the isolated perfused 
rat liver. The traces shown represent typical results. Adrenaline or 
noradrenaline, 6 yM, was added at the point indicated (t).
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Effect of catecholamines on hexobarbitone-metabolism by the isolated perfused 
rat liver. Adrenaline, 6 yM (A) or noradrenaline, 6 yM (■) was added at O 
min. Control perfusions (o). All the results are of second pulses. Values 
are mean (± S.E.M.) of four perfusions in each case.
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until 60 min after the addition of substrate so that their 
effects upon the metabolic •component of aniline removal 
could be more clearly studied.
5.3 Effect of catecholamines in the perfused liver
5.3.1 Effect on perfusion pressure
In control perfusions the portal pressure remained
%
relatively constant for the duration of the experiment with
a value of 10 ± 2 cm K^O. Fig. 16 shows that the addition
of either adrenaline or noradrenaline to the perfusion medium
/
at an initial concentration of 6 yM, which was supramaximal, 
caused a rapid rise, within 2 min, in the perfusion pressure 
of 13.7 ± 1.2 cm H^O (n = 3) and 11.4 ± 0.4 cm ^ 0  (n = 3) 
respectively. The pressure then fell towards control levels, 
the half-life of the fall after adrenaline being 16.1 ± 1.2 
min and with noradrenaline 23.5 ± 5.2 min; these values not 
differing from each other significantly at the 5% level.
This fall in pressure is probably a reflection of the rapid 
metabolism of catecholamines known to occur in the perfused 
liver (Lightman and Hems, 1973).
5.3.2 Effect on hexobarbitone metabolism
The effects of adrenaline and noradrenaline, at an 
initial concentration of 6 yM, on the rate of hexobarbitone 
metabolism by the perfused liver are shown in Fig. 17. For 
clarity only the second pulse, in the presence of catechol­
amine, is shown and is compared with the second pulse from 
control perfusions.
TABLE 5
Effect of catecholamines on excretion of hexobarbitone into bile
Hexobarbitone accumulation was measured in the bile of livers perfused for 
3 h, after two additions of 150 ymol hexobarbitone at 0 min and 90 min 
respectively. Catecholamines were added at 85 min, initial concentration 
6yM. Figures are mean ± S.E.M. of three perfusions.
*P < 0.05 compared to control perfusions.
Hexobarbitone ymol 
Total « Per g liver
Control
Adrenaline 6yM 
Noradrenaline 6yM
1.187 ±0.115 0.100 ±0.014
1.473 ±0.082 0.167 ±0.032
1.085 ±0.053 0.110 ±0.010
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Both catecholamines inhibited hexobarbitone metabolism
within the first 30 min, by a maximum of 62% (P < 0.005)
with adrenaline and 54% (P < 0.005) with noradrenaline.
Inhibition with adrenaline was apparent within 15 min. Since
adrenaline markedly inhibited the metabolism of hexobarbitone
over the first 30 min there was a higher concentration of
hexobarbitone remaining after 60 min in these perfusions
compared with the concentration in corresponding control
perfusions. The rate of metabolism after 60 min when the 
%
effects of adrenaline had worn off was thus higher than in 
the control perfusions.
/
The half-life of hexobarbitone in the perfusion medium 
was calculated between 0 min and 90 min. In perfusions in 
which catecholamines were added this method of calculating 
half-lives will result in a slight underestimate of the true 
effect of catecholamines because it includes a period when 
the effect of the catecholamines had worn* off. In control 
perfusions the half-life of hexoba.rbitone was 3 9.6 ± 4.3 min 
(Table 2). Adrenaline increased this by 167% (P < 0.005) 
and noradrenaline increased the half-life by 138% (P < 0.005). 
However the half-life of hexobarbitone in the presence of 
adrenaline was not significantly different' from that in the 
presence of noradrenaline.
Neither adrenaline nor noradrenaline had any significant 
effect upon the amount of hexobarbitone accumulated in the 
bile although adrenaline did produce a 67% increase in the 
amount removed in this way (Table 5).
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Figure 18
Effect of catecholamines on aniline metabolism by the isolated perfused 
rat liver. Adrenaline, 6 yM (A) or noradrenaline, 6 yM (■) was added 60 
min after the addition of aniline as indicated ( + ) . Control perfusions 
(o). Values are mean (±S.E.M.) of four perfusions.
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5.3.3 Effect on aniline metabolism
Neither adrenaline nor noradrenaline, at initial con- *
centrations of 6 yM, caused any significant alteration in 
the rate of aniline metabolism in the 60 min following their 
addition (Fig. 18). At no time did the rate of aniline 
metabolism change significantly from the control in the 
presence of noradrenaline. However with adrenaline there 
was a 62% (P < 0.01) increase in the rate of aniline meta­
bolism at one point 75 min after the addition of the 
catecholamine. Catecholamines did not affect the rate of 
formation of aniline metabolites or their accumulation in 
the bile (results not shown).
In control perfusions the half-life of removal during 
the second phase was 108.7 ± 3.0 min (n = 6) and in the 
presence of noradrenaline or adrenaline it was decreased only 
slightly (Table 4). With both catecholamines the probability 
of the results not differing significantly from the control 
was greater than 20%.
5.3.4 Effect of papaverine on drug metabolism
Papaverine is a potent inhibitor of phosphodiesterase 
(Goren and Rosen, 1972) and it should potentiate the effects 
of any cyclic AMP liberated by catecholamines. It should 
thus be possible to determine if the effects.of catecholamines 
on hexobarbitone metabolism in the perfused liver were due 
to cyclic AMP, which itself has been reported to inhibit
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Figure 19
Effect of adrenaline in the presence of papaverine on hexobarbitone 
metabolism by the isolated perfused rat liver. During the first pulse 
papaverine, 80 yM -(A) and during the second pulse papaverine, 80 yM 
and adrenaline, 6 yM (A) were added at 0 min. Values are mean (± S.E.M.) 
of three perfusions. The broken line is the mean of the first pulse of 
11 control perfusions and is included for comparison.
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Effect of adrenaline in the presence of papaverine on aniline metabolism 
by the isolated perfused rat liver. Adrenaline, 6 yM (A) or adrenaline,
6 yM and papaverine 80 yM (o) were added to the perfusion medium, adrenaline 
60 min after the addition of aniline as indicated, and papaverine at the 
same time as the addition of aniline. Values are mean (± S.E.M.) of three 
experiments.
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hexobarbitone metabolism in the perfused liver (Weiner et al, 
1972a).
During the first pulse papaverine itself, at an initial 
concentration of 80 yM, inhibited the rate of hexobarbitone 
metabolism (Fig. 19), maximally at 15 min by 77 ± 3%. Overall 
the half-life of hexobarbitone was increased by 178% (P < 0.05) 
(Table 2). Adrenaline at an initial concentration of 6 yM, 
during the second pulse inhibited hexobarbitone metabolism in 
the presence of papaverine even further. At 30 min the rate 
of hexobarbitone metabolism was reduced by 61% compared with 
the rate during the first-pulse in the presence of papaverine 
alone. This was a similar magnitude of inhibition as that 
observed when adrenaline was added alone compared with the 
appropriate control. The half-life of hexobarbitone was 
also increased by adrenaline to a similar extent as previously 
(Table 2). Thus papaverine appeared not to potentiate the 
inhibitory effects of adrenaline upon hexobarbitone removal.
In the presence of papaverine, 80 yM, adrenaline at an 
initial concentration of 6 yM did not cause any significant 
change in the rate of aniline removal as compared to the 
rate of removal in the presence of adrenaline alone as shown 
.in Fig. 20 or as compared to the control perfusions.
5.3.5 Effect of vasoactive compounds in the perfused liver
In order to investigate whether the effects of catechol­
amines on hexobarbitone metabolism in the perfused- liver were 
due to an effect on blood flow, rather' than a direct metabolic
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effect, several compounds were studied with a view to finding 
one that would produce a similar pressor response as 
catecholamines, but by a non-adrenergic mechanism. In this 
way it was hoped to produce vasoconstriction in the perfused 
liver by a compound lacking the metabolic effects of 
catecholamines.
Neither oxytocin nor vasopressin, added directly to the
reservoir to give initial concentrations of up to 0.14 U/ml,
had any effect upon the perfusion pressure. The addition of
BaC^/ to give initial concentrations from 0.004 yM to 27.3
yM, produced, at most, a maximum increase in the perfusion
/
pressure of 0.5 cm f^O and even infusion of BaC^ directly
into the portal vein, at a rate of 0.18 ymol/min, increased
the portal pressure by only 0.2 cm 1^0. Thus vasopressin,
2 +oxytocin and Ba were unsuitable.
Infusion of KC1 into the portal vein-, at 44 ymol/min, 
caused an increase of the portal pressure of only 0.5 cm 
H^O. When KC1 was added to the reservoir, to produce an 
initial concentration of 5,000 yM, the portal pressure in­
creased by 10 cm 1^0 and returned to 50% above the control 
value within 10 min. In view of the high concentration of 
K necessary to produce this response, because of its short 
duration of action and since catecholamines are known to 
cause alterations in hepatic cells by the release of K+ 
(Haylett and Jenkinson, 1972) it was decided that KC1 was 
unsuitable.
The addition of angiotensin II to the reservoir, to give
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an initial concentration of 1.9 yM, caused an increase in 
portal pressure of 11.0 cm J^O, although this increase in 
pressure was very short-lived. However infusions of angio­
tensin directly into the portal vein at rates as low as 
0.007 ymol/ml caused increases in perfusion pressure of 3.5 
cm H^O. As the rate of infusion increased the pressure in­
creased proportionately, to an increase of 9.0 cm ^ 0  at an 
infusion rate of 0.031 ymol/min. However even at these 
higher rates of angiotensin infusion, at which the magnitude 
of the pressor response was similar to that obtained with 
catecholamines, the increase was not maintained for more than 
5 min and even when the rate of infusion was increased to 
0.122 ymol/min the increase in portal pressure could not be 
maintained. When infusion was stopped for 10 min and then 
recommenced, the perfusion pressure was immediately increased 
by 11.0 cm EL^ O, but again this was not maintained. Thus 
angiotensin was not suitable for providing a maintained 
pressor response in place of catecholamines in the perfused 
liver.
This approach was then abandoned in favour of finding 
a compound that would inhibit the pressor effects of catechol- 
--amines while not affecting their metabolic effects.
5.3.6 Inhibition of the pressor effects of catecholamines 
in the perfused liver
It was not possible to use either a - or 3-adrenergic 
blockers since these compounds have been shown to inhibit 
drug metabolism themselves (Mullen and Fouts, 1965).
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2+Effect of adrenaline on. portal pressure in the absence of Ca in the
isolated perfused rat liver. Traces are typical results. Adrenaline,
6 yM was added at the time indicated (t). The upper panel shows the
2+effect of adrenaline in the presence of Ca ,1.25 mM and the lower 
panel the effect of adrenaline when the perfusion medium was prepared 
without Ca^+.
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Figure 22
2+
Effect of an absence of Ca on hexobarbitone metabolism by the isolated 
perfused rat liver. First pulse of perfusions with medium containing 
normal calcium, 1.25 mM (•) and with no calcium (T). Values are mean 
(± S.E.M.) of four perfusions.
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Papaverine, as well as an inhibitor of phosphodiesterase, 
is a smooth muscle relaxant (Daniel, 1964). However rather 
than antagonise vasoconstriction caused by catecholamines, 
papaverine, at initial concentrations of 80 yM, was found 
to prolong the pressor response of adrenaline and noradrenaline.
Histamine, added to the reservoir to give an initial 
concentration of 10.9 yM, reduced the portal pressure, pre­
viously increased by adrenaline, by 1.5 cm ^0. Even at 
higher concentrations of histamine no pronounced antagonism 
to vasoconstriction by adrenaline could be produced. Neither 
papaverine nor histamine was thus suitable as an antagonist 
of vasoconstrictor activity in the perfused liver.
When the perfusion medium was prepared with Krebs
2 +bicarbonate buffer in which all Ca had been replaced by 
2 +Mg the pressor effect of adrenaline was almost completely
abolished as may be seen in Fig. 21. Thus the removal of 
2 +Ca provided a method whereby the metabolic effects of 
catecholamines could be investigated in the absence of 
possible complications caused by changes in hepatic vascular 
resistance.
.5.3,7 Effect of adrenaline on hexobarbitone metabolism in
2 +the absence of Ca
2 +In perfusions in which the perfusion medium Ca had 
been omitted the rate of hexobarbitone metabolism was 19% 
less over the first 30 min than in the corresponding control 
(Fig. 22) and the half-life of hexobarbitone in these
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Figure 2.3
2+Effect of adrenaline on hexobarbitone metabolism, in the absence of Ca , 
by the isolated perfused rat liver. Only the second pulses are shown
for clarity. Adrenaline, 6 yM was added at O min in the presence of
2+ 2+- Ca , 1.25 mM (A) or in the absence of Ca (V). Control perfusions (o)
are shown by the broken line for comparison. Values are mean (± S.E.M.)
of four perfusions.
Figure 24
X-radiographs of the isolated rat liver perfused with adrenaline. 
Photographs are typical of results obtained. Weight of liver 9.3 g. 
The upper plate shows a liver after control perfusion with 10% (v/v) 
Conray 280 in the perfusion medium. The lower plate shows a liver 
after adrenaline, 6 yM was perfused until the pressure reached a 
plateau then Conray 280 was perfused with adrenaline. The lines in 
the background are due to the opacity of the heat-exchange unit.
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perfusions was increased by 26% (P < 0.05) (Table 2).
As shown in Fig. 23 when adrenaline was added in the 
24-absence of Ca the rate of hexobarbitone metabolism was no
longer reduced by the 62% normally observed after 30 min but
was only reduced by 21%. Even this decrease can be accounted
2 +for entirely in terms of a lack of Ca
24-In the absence of Ca the half-life of hexobarbitone, 
after the addition of adrenaline, 6 yM, was increased by 3 9% 
compared with the second pulse of control perfusions (P > 0.05).
This increase is of the same magnitude as that observed in
24- ythe absence of Ca when compared with the first pulse of
24-control perfusions. Thus in the absence of Ca adrenaline 
had no significant effect upon either the individual rates 
of hexobarbitone metabolism or its half-life over 90 min in 
the perfused liver.
5*3.8 X-radiography of the liver
From the previous section it was apparent that catechol­
amines may have been producing an inhibition of hexobarbitone 
metabolism through their effect on hepatic vascular resistance.
When livers were perfused with contrast medium, at the 
peak of the pressure response to adrenaline, 6 yM, X-radiographs 
similar to that shown in Fig. 24 were obtained. Similar re­
sults were obtained in each of four separate perfusions. The 
liver was no longer evenly dense, many lighter areas being 
apparent, probably due to incomplete sinusoidal filling.
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Effect of Conray 280 on the portal pressure in isolated perfused rat liver. 
Weight of liver 8.4 g. Unmarked bar; perfusion with Conray 280, 10% (v/v) 
in the perfusion medium. Adrenaline, 6 yM perfused where shown.
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Distribution of carbon particles after perfusion of the isolated rat liver 
with Indian ink, 10% (v/v) in the perfusion medium. A typical result. 
Upper plate, sections from deep central and lower plate, from peripheral 
regions of the lobes were taken from livers perfused for 2 min with 10% 
(v/v) Indian ink in the perfusion medium. Magnification lOOx.
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The edges of the lobes were not as clearly defined as before 
and some of the smaller lobes were under-perfused by up to 
50%. Many of the fine branches of the portal venous tree 
previously visible could no longer be seen.
Unfortunately the contrast medium itself had some vaso­
constrictor activity as shown in Fig. 25. Conray 280, 10%
(v/v) caused an increase in perfusion pressure of 4 to 6 cm 
1^0, both alone and superimposed upon the maximum vaso­
constriction caused by adrenaline, 6 yM. Thus is was difficult 
to interpret the X-radiographs unequivocably, particularly at 
the lobular level. For this reason further studies on portal 
vasoconstriction by adrenaline were instituted involving 
perfusion of the liver with Indian ink with subsequent 
histology.
5.3.9 Vasoconstrictor effect of adrenaline revealed by Indian 
ink
In control perfusions, shown in Fig. 26, distribution of 
carbon granules from Indian ink was even, both within small 
areas of the liver and between sections taken from the peri­
phery and centre of lobes. Although only one micrograph is 
shown from each area at least three separate tissue sections 
were examined from peripheral and central areas of each liver. 
Perfusions were carried out on three separate control and three 
adrenaline perfused livers. In control perfusions many small 
blood vessels were visible and the lobular pattern of the 
liver was discernable.
Effect of adrenaline on the distribution of carbon particles after perfusion 
of the isolated rat liver with Indian ink, 10% (v/v) in the perfusion medium. 
A typical result. Upper plate, sections from deep central and, lower plate, 
from peripheral regions of the lobes were taken from livers first perfused 
with adrenaline, 6 yM and then, at the peak of the pressure response, with 
adrenaline, 6 yM and Indian ink, 10% (v/v) in the perfusion medium. 
Magnification lOOx.
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Perfusion with adrenaline, 6 yM caused narked changes 
in the pattern of distribution of carbon granules. In 
sections from the centre of the lobes (Fig. 27) the dis­
tribution of granules was much denser than in corresponding 
control sections. In contrast, in those sections taken from 
the edge of the lobes, the distribution of granules was much 
less dense than in either sections from the centre of the 
lobes or in corresponding control sections. The lobular 
structure of the liver in these sections was not as evident 
as in the other sections and in addition most of the carbon 
granules appeared concentrated in the lumen of larger vessels. 
This corresponded to the macroscopic appearance of livers 
perfused with adrenaline and Indian ink, the surface of which 
became mottled within a few minutes, as if small areas of 
the liver were not being perfused with carbon granules, 
particularly at the edges of the lobes.
High power microscopy of all sections revealed that the 
granules from the Indian ink were exclusively located within 
the lumen of blood vessels, none of the particles having been 
taken up by reticulo-endothelial cells in the short time in 
which they were exposed to the ink. Indian ink, at the con­
centrations employed, was totally devoid of any pressor 
activity in the perfused liver.
It was concluded from this study that adrenaline could 
cause a change in the distribution of blood flow within the 
liver, resulting mainly in a shunting of perfusate away from 
peripheral areas to more central areas.
5.4 Drug metabolism in liver slices
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Figure 28
Hexobarbitone metabolism in liver slices. Liver slices were incubated
-3 -3with substrate alone (o), with adrenaline'10 M (A), noradrenaline 10 M
-3 -3(□), dibutyryl cyclic 3'; 51 AMP 10 M (?) or SKF 525-A, 10 M (V).
Values are mean (± S.E.M.) of three determinations.
TABLE 6
Hexobarbitone and aniline metabolism by liver slices
Liver slices were incubated with the compound shown. Figures are mean 
half-lives ± S.E.M. of substrates shown. /
*P < 0.05 **P < 0.01 compared to control liver slices.
• Half-life, min
Hexobarbitone Aniline
Control
-3
Adrenaline 10 M
-3Noradrenaline 10 M
n
3 81.7± 5.6
4 91.3± 7.4
3 99.6 ± 18.1
-3
Dibutyryl cyclic AMP 10 M 3 131.7 ±13.8
SKF 525-A 10~3M 3 362.8 ± 7.5
* *
n
6 84.4 ±10.6
6 77.5 ± 7.0
5 88.2± 5.6
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Since catecholamines were shown to cause a redistribution 
of blood flow in the perfused liver this was thought a 
possible mechanism for their inhibition of hexobarbitone 
metabolism in this preparation. To test this hypothesis 
further, the effect of catecholamines on drug metabolism in 
liver slices was investigated. Liver slices provide a whole 
cell system which, by its nature, is free from the complica­
tions of a blood supply since oxygenation is achieved by 
diffusion from the incubation medium into the slices.
Both hexobarbitone (Fig. 28) and aniline were removed 
exponentially by a first order reaction in liver slices. 
Substrate metabolism has thus been expressed in terms of 
half-life over 2 h as shown in Table 6. SKF 525-A, a potent 
inhibitor of drug metabolism (Cooper et al, 1954), was in­
cluded to test the integrity of the system. It cuased a 
pronounced inhibition of hexobarbitone metabolism (Fig. 28), 
the half-life increasing by 344% (P < 0.01).
In agreement with the findings of Weiner et al (1972b) 
dibutyryl cyclic AMP inhibited the metabolism of hexobarb­
itone by liver slices, the half-life increasing by 51% (P < 
0.05).
-3
Neither adrenaline nor noradrenaline, 10 M produced 
any significant alteration in the metabolism of either hexo­
barbitone or aniline. It thus appears that catecholamines, 
even at high concentrations, do not release sufficient cyclic 
AMP to inhibit drug metabolism in intact cells.
TABLE 7
Influence of origin of NADPH on drug metabolism
NADPH was supplied directly or by a generating system. Figures are mean 
± S.E.M. of six determinations.
Aniline metabolism Aminopyrine metabolism 
mymol/mg protein/30 min miimol/mg protein/30 min
NADPH 13.4 + 1.5
Generating system, glucose-
6-phosphate dehydrogenase 6.7 ±0.3
Generating system, DL-
isocitrate dehydrogenase 6.6±0.7
87.6 ± 10.1 
56.9± 7.8 
67.3± 7.3
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5.5 Effect of catecholamines on drug metabolism by the 
microsomal subcellular fraction
5.5.1 Co-factor requirements
Before proceeding with this aspect of the investigation 
drug-metabolising activity was compared in the different 
NADPH-generating systems employed. The effect of varying 
the concentrations of the different constituents of the 
incubation system was also investigated to determine the 
optimum conditions for drug metabolism. When NADPH was 
generated by either glucose-6-phosphate dehydrogenase or DL- 
isocitrate dehydrogenase there was no significant difference 
in the microsomal metabolism of either aniline or aminopyrine 
(Table 7). However when NADPH was added direct the rate of 
metabolism of both aniline (P < 0.01) and aminopyrine (P <
0.05) was significantly higher.
When NADP, isocitrate dehydrogenase or the substrate in 
the NADPH-generating system was omitted there was an almost 
total loss of metabolising activity, showing that the micro­
somal fraction contained none of the normal endogenous com­
ponents of the NADPH-generating system. When the concentration 
of any of the co-factors was halved, or doubled, there was no 
significant change in microsomal drug-metabolising activity 
with either aniline or aminopyrine as substrate. Thus 
optimum concentrations were being employed for a microsomal 
concentration of 4 mg/ml.‘ Similar results were obtained with 
the glucose-6-phosphate dehydrogenase system.
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2 +Optimum concentrations of Mg and Tris buffer were 
determined and used in subsequent incubations. The concen­
tration of nicotinamide employed was slightly inhibitory 
but was included as a precaution against NADP degradation.
The rate of drug metabolism increased as the concentration 
of microsomal protein decreased. A fixed concentration of 
4 mg/ml microsomal protein was therefore used throughout 
the study.
5.5.2 Effect of adrenaline on the assay of p-aminophenol
-4
When adrenaline, 10 M was included in a standard
/
solution of p-aminophenol, 0.05 mM, the magnitude of the 
change in absorbance produced for the indo-phenol complex 
was reduced by 26% and the time taken for maximum colour 
development was increased by 138%. It was thus considered 
undesirable to measure p-aminophenol formation by this assay 
as an index of aniline metabolism in the presence of catechol­
amines.
For this reason, in these studies, aniline metabolism 
was determined by assaying unmetabolised substrate by the 
method of Bratton and Marshall (1939) and calculating the 
amount metabolised. In the presence of catecholamines high 
blanks were obtained, possibly due to auto-oxidation, so 
that multiple blanks of standard solutions had to be run to 
ensure accurate correction.
5.5.3 Effect of catecholamines on microsomal drug metabolism
TABLE 8
Catecholamines and hexobarbitone, aniline and aminopyrine metabolism by
microsomal subcellular fraction
The microsomal fraction was incubated with the compound shown at the con­
centration indicated. Figures are mean ± S.E.M. of six determinations.
*P < 0.05 compared to control microsomes.
Hexobarbitone Aniline Aminopyrine
metabolism metabolism metabolism
my mol/mg pro- my mo]./mg pro- mymol/mg pro­
tein/30 min tein/30 min tein/30 min
Control 49.6± 2.6 5.9 ± 0.5 85.9± 1.9
-3Adrenaline 10 M 54.6± 3.7 7.1± 1.2 88.5 ± 0.6
-4Adrenaline 10 M 51.3 ±1.1 5.6 ± 0.3 78.7 ± 4.1
-5Adrenaline 10 M 44.0± 2.5 5.4 ± 0,.7 85.8 ± 1.0
Adrenaline 10 ^M 48.8 ± 0.9 6.1± 0.2 84.2 ± 0.7
Noradrenaline 10 •3m 58.3 ± 6.2 6.9 ± 0.6 86.8 ± 0.6
Noradrenaline 10 ■4m 46.1± 0.4 6.2 ± 0.2 85.7 ± 2.2
Noradrenaline 10 ■5m 46.3 ± 1.5 5.4 ± 0.4 86.1± 1.1
Noradrenaline 10 -6m 48.8 ± 1.0 • 5.5±0.3 87.7 ± 1.8
-3Cyclic AMP 10 M 51.0± 3.0 - -
-4
Cyclic AMP 10 M 48.2 ± 0.7 - -
-5
Cyclic AMP 10 M 45.9 ± 2.1 - -
Cyclic AMP 10 ^M 48..9 ± 3.2 - « -
Dibutyryl cyclic AMP 10"•3m 49.7 ± 1.8 ‘ - -
Dibutyryl cyclic AMP 10~'4m 53.9 ± 5.7 - -
Dibutyryl cyclic AMP io‘■5m 51.7 ± 2.1 ■ - -
Dibutyryl cyclic AMP io'-6m 52.1± 1.9 - -
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Figure 29
Microsomal difference spectra of catecholamines. Difference spectra were 
obtained with adrenaline 5 mM (broken line) and noradrenaline 5 mM (solid 
line) in microsomal suspensions from male rats.
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Figure 30
Lineweaver-Burke plot of the spectral changes caused by catecholamines.
The reciprocal of the absorbance difference between 417 mP and 430 mjj
(— ) is plotted against the reciprocal of the concentration (~) of adren- 
V S
aline (•) and noradrenaline (o) producing the change.
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The results are shown in Table 8. Neither cyclic AMP
— finor dibutyryl cyclic AMP, in concentrations from 10 M to
-3
10 M, had any significant effect upon the metabolism of 
hexobarbitone. Similar findings were recently reported by 
Weiner et al (1972a).
The catecholamines adrenaline and noradrenaline, in
-3concentrations up to 10 M, had no significant effect upon 
the metabolism of the three substrates investigated, aniline, 
hexobarbitone and aminopyrine.
5.5.4 Difference spectra of catecholamines
Both adrenaline and noradrenaline produced changes in
the microsomal difference spectrum as shown in Fig. 29. The
difference spectrum caused by adrenaline resembles that of a
type I compound with X . at 418 my but with no real X * * m m  H • max
Noradrenaline produced a typical type II difference spectrum
with X . 405 my and X at 428 my. Neither cyclic AMP norm m  max u
dibutyryl cyclic AMP produced any difference spectrum in the 
microsomal fraction.
When a Lineweaver-Burke plot was constructed using the 
changes in absorption at varying concentrations of catechol­
amines (Fig. 30) noradrenaline was found to have a K of 1 mM.s
However adrenaline produced a line that had a positive inter­
cept on the X-axis which would result in a negative Kg.
Since this is not possible in Michaelis-Menton kinetics it 
may be that the spectral difference caused by adrenaline is 
due to non-specific binding, possibly of a product of auto-
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Figure 31
Hepatic microsomal drug metabolism after pre-treatment of rats with 
catecholamines. Male rats were pre-treated with adrenaline 1 mg/Kg 
(open symbols) or noradrenaline 1 mg/Kg (closed symbols) and microsomes 
prepared at various times thereafter. Metabolism of aniline (A,A) and 
aminopyrine (o,») was determined. Values are mean (± S.E.M.) of ten 
animals.
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oxidation.
5.5.5 Effect of catecholamines on the difference spectra 
produced by other compounds
The difference spectra produced by the type I compound 
hexobarbitone and the type II compound aniline were not 
affected by cyclic AMP, dibutyryl cyclic AMP, or adrenaline. 
However noradrenaline at 1 mM was an inhibitor of aniline 
binding and at even higher concentrations of 4 mM, of hexo­
barbitone binding.
5.6 Effect of pre-treatment of rats with catecholamines on 
microsomal drug metabolism
5.6.1 Effect on microsomal metabolism of aniline and amino- 
PYr ine
Pre-treatment of male rats with noradrenaline, 1 mg/Kg 
caused an increase in the metabolism of both aniline and 
aminopyrine by the hepatic microsomal fraction maximal at 
30 min after injection (Fig. 31). Aminopyrine metabolism 
was increased by 45 ±8% (P < 0.001) and aniline metabolism 
by 54 ±7% (P < 0.001). The metabolism of both substrates 
was not significantly different from control values after 2 h.
In contrast pre-treatment of rats with adrenaline, 1 mg/ 
Kg, caused an inhibition in the microsomal metabolism of both 
substrates, apparent within 15 min after the injection (Fig.
31). Aniline metabolism was inhibited by 18.5 ± 5.5% (P < 0.05)
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Figure 32 .
Hepatic microsomal cytochrome content and NADPH-cytochrome c reductase 
activity after pre-treatment of rats with catecholamines. Male rats were 
pre-treated with adrenaline 1 mg/Kg (A,A) or noradrenaline 1 mg/Kg (□,*). 
The upper panel shows the cytochrome content. Cytochrome b,_ content 
(open symbols) and cytochrome P-450 content (closed symbols). The lower 
panel shows NADPH-cytochrome c reductase activity. Values are mean 
(± S.E.M.) of six animals.
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and aminopyrine metabolism by 12.0 ± 1.7% (P < 0.005) at 
30 min. The metabolism of aminopyrine had returned to control 
values within 60 min whereas that of aniline was still in­
hibited after 2 h, although not significantly different from 
control values at this time.
5.6.2 Effect on the components of the microsomal electron 
transport chain
The possibility that catecholamine pre-treatment was 
causing changes in the microsomal drug-metabolising activity 
by affecting some component of the microsomal electron trans­
port system was also investigated.
Pre-treatment with adrenaline or noradrenaline did not 
produce any significant alteration in the microsomal content 
of cytochrome P-450, but caused a significant decrease in 
cytochrome b^ within 30 min, of 54 ± 5% (P < 0.01) and of 50 
± 5% (P < 0.01) respectively (Fig. 32). In both cases 
cytochrome b^ levels had returned to control values within 
60 min and remained constant thereafter. Pre-treatment with 
either adrenaline or noradrenaline produced no significant 
alteration in the activity of NADPH-cytochrome c reductase 
(Fig. 32).
5.6.3 Distribution of 3H-noradrenaline in the rat after 
injection
Although pre-treatment of rats with catecholamines had 
no significant effect upon the main components of the electron
TABLE 9
Distribution of label after injection of 3H-noradrenaline into rats
Rats were injected with 3H-noradrenaline, 1 mg/Kg, at time 0 and groups 
of animals sacrificed at the times indicated. Figures are concentrations 
of label assuming no metabolism and are mean ± S.E.M. of four animals.
Plasma conc. 
ng/ml
Liver conc. 
ng/g of liver
Microsomal conc, 
pg/mg protein
0 min 
15 min 
30 min 
60 min 
120 min
0
203 ± 17 
267 ± 23 
514 ± 27 
395 ± 19
0
2383 ± 104 
1171 ± 87 
3583 ± 236 
1926 ± 188
0
14.4 ±0.7 
14.3 ±0.6 
7.2 ± 1.1 
4.6 ±0.3
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transport chain it was considered possible that adrenaline 
and noradrenaline, or their metabolites, might be bound to 
the microsomal fraction and remain after isolation of this 
fraction. This was tested by injecting rats with 3H- 
labelled noradrenaline, 1 mg/Kg and measuring the label 
present in various fractions at different time intervals 
(Table 9) .
Within 15 min after the injection label was detectable 
in the plasma at a concentration of 203 ng/ml and in the 
liver at a concentration of 2383 ng/g of tissue. However 
since no distinction was made between noradrenaline and its 
metabolites it is possible that a large fraction of this 
concentration was made up of metabolites, especially in the 
liver which is the primary site of metabolism of circulating 
catecholamines (Lightman and Hems, 1973) . Only small amounts 
of label could be detected in the microsomal fraction and it 
appeared that noradrenaline was not bound to any significant 
extent to the microsomal fraction during its isolation.
5.7 Further studies on microsomal drug metabolism
5.7.1 Effect of washing microsomes with catecholamines on 
drug metabolism
In view of the high concentrations of label found in the 
liver soon after an injection of noradrenaline it was thought 
possible that catecholamines might have been exerting their 
effects upon the microsomes during the homogenisation pro­
cedure. This was investigated by re-suspending the micro­
somal fraction, from female rat liver prepared in the normal
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Effect of washing microsomes in catecholamines on drug metabolism. Micro­
somes were prepared as normal (control), washed in sucrose (sucrose wash),
-3 -3adrenaline, 10 M (adrenaline wash) or in noradrenaline, 10 M (noradren­
aline wash). The' upper panel shows aminopyrine metabolism and the lower 
panel shows aniline metabolism. NADPH was generated by isocitrate de­
hydrogenase. Values are mean (± S.E.M.) of six determinations.
*P < 0.05 **p < 0.01 compared with control microsomes.
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Effect of washing microsomes in sucrose or EDTA on drug metabolism.
Microsomes were prepared as normal (control), .washed in sucrose
-3(sucrose wash) or washed in EDTA 10 M (EDTA wash). The upper panel 
shows aminopyrine metabolism and the lower panel shows aniline 
metabolism. NADPH was generated by isocitrate dehydrogenase. Values 
are mean (± S.E.M.) of six determinations.
*P < 0.05 **P < 0.01 compared with control microsomes.
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manner, in sucrose containing catecholamine and then sub­
jecting it to a second high-speed spin.
The results obtained are shown in Fig. 33. Washing the 
microsomal fraction in sucrose caused no significant alter­
ation of aniline metabolism but a 17% inhibition of amino-
_ -3
pyrine metabolism (P < 0.05). Noradrenaline, 10 M, prevented 
any loss of aniline or aminopyrine metabolising activity 
whereas adrenaline, although preventing the loss of amino­
pyrine metabolising activity caused a loss of aniline meta­
bolising activity of 35% (P < 0.01).
/
5.7.2 Effect of washing microsomes on drug metabolism
The loss of activity observed on washing microsomes in 
sucrose was studied in more detail and the effect of other 
possible protective compounds investigated.
Aniline metabolism was unaffected after washing the 
microsomes in sucrose but aminopyrine metabolism was reduced 
by 28% (P < 0.05) (Fig. 34). This is almost twice as great 
an effect as observed in the initial experiments (Section 
5.7.1). When microsomes were washed in sucrose containing
_3
EDTA, 10 M both aniline and aminopyrine metabolism were in­
creased by about 60% over the control values (P < 0.01). 
Similar changes were also observed when NADPH was added 
directly to the incubation instead of employing a£ generating 
system. This indicated that none of the observed effects 
could be ascribed to changes in activity of the NADPH- 
generating system.
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Acetone enhancement of aniline metabolism in .washed microsomes. Microsomes
were prepared as normal (control), washed in sucrose (sucrose wash) or 
-3
washed in EDTA 10 M (EDTA wash). Open columns show aniline metabolism 
with no acetone and filled columns aniline metabolism in the presence of 
acetone, 0.5 M. NADPH was generated by isocitrate dehydrogenase. Figures 
are mean (± S.E.M.) of six determinations.
*P < 0.05 **P < 0.01 compared with metabolism in the absence of acetone.
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One finding that proved of interest was that the 
enhancement of aniline metabolism by acetone (Anders, 19 68) 
was almost abolished by washing the microsomes. Peak 
enhancement of aniline metabolism occurred between 0.5 M 
and 0.7 5 M acetone. The percentage increase in aniline 
metabolism was 240 ± 9% at 0.5 M acetone. Inhibition of 
aminopyrine metabolism was also observed, as already re­
ported by Anders (1968), 23% inhibition with acetone, 0.5 M.
When microsomes were washed in sucrose, acetone enhance­
ment of aniline metabolism was only 21 ± 3% (Fig. 35). How-
-3
ever when EDTA, 10 M was added to the washing sucrose there 
was complete protection against any relative loss of acetone 
enhancing ability, even though the absolute value of aniline 
metabolising activity was increased compared to the control 
incubations.
Similar changes in acetone enhancement were observed
after washing in sucrose or EDTA when NADPH was added
directly to the incubation medium, thus showing that the
effects were other than at the level of the NADPH-generating
system. This finding was used to check whether acetone
enhancement was reversible. It was found that microsomes
exposed to 0.5 M acetone then washed by re-centrifuging to
remove the acetone no longer responded to acetone. However 
_ 3
when EDTA, 10 M was added to the acetone to which the micro­
somes were exposed it was found that they retained full 
susceptibility to acetone enhancement. Thus acetone enhance­
ment is a reversible phenomenon.
TABLE 10
Effect of washing with activators and inhibitors of lipid peroxidation on
microsomal drug metabolism
Microsomes were washed in a solution of the compound in shcrose buffer. 
BHT and vit E were first dissolved in 0.1 ml absolute ethanol which had 
no effect on drug-metabolising activity itself. NADPH was generated by 
isocitrate dehydrogenase. Acetone enhancement of aniline metabolism was 
determined in the presence of acetone 0.5M and the figures in parentheses 
show the percentage increase in aniline metabolism compared with the 
corresponding control. Values are mean ± S.E.M*. of six determinations.
*P < 0.05 **P < 0.01 compared to control microsomes. (Comparisons not
shown for acetone column).
Aniline metabolism Aminopyrine metabolism
mvimol/mg protein/30 min mymol/mg protein/30 min
No acetone Acetone 0.5M
Control 6.2 ± 0.2 14.01 0.2 (+125) 67.314.7
Washed microsomes
Sucrose 5.8 ± 0.2 8.11 0.1 (+ 39) 53.812.7*
EDTA 10“3M
* *
9.2±0.4 21.0 1 0.3(+130)
* *
95.61 3.4
-3BHT 10 M
**
5.5 ± 0.1 7.9 1 0.2 (+ 43) 57.2 1 3.9
-3Vitamin E 34x10 M
**
5.1± 0.1 6.6 1 0.3(+ 29) 52.5 1 2.0
EGTA 10"3M 5.8 ± 0.2 8.9 1 0.1(+ 53) 65.3 1 2.7
2+ —3 Mn 10 M 6.9 ± 0.3* 10.4 1 0.1 (+ 50) 70.012.0
-3
Vitamin C 10 M
**
5.4 ± 0.1 7.1 1 0.2(+ 32) -
2+ -3 Fe 10 M 6.510.2 10.3 1 0.2(+ 58)
**
45.3 1 2.0
TABLE 11
Effect of second post-microsomal supernatant on drug-metabolising activity
Supernatant obtained from washing microsomes in sucrose was added to the 
incubation medium where indicated. Controls were carried out by adding 
sucrose to the incubation. Figures in parentheses show percentage enhance­
ment of aniline metabolism by acetone, 0.5M compared with values obtained
/
with no acetone. NADPH was added directly to the incubations. Figures 
are mean ± S.E.M. of six•determinations.
*P < 0.05 **P < 0.01 compared with aniline metabolism with no acetone
Aniline Metabolism 
mymol/mg protein/30 min
No acetone Acetone 0.5M
13.41 0.4 29.9 1 0.5**(+123)
'k'k
5.3±0.2 12.4 10.2 (+134)
3.3 10.1 10.9 1 0.2** (+227)
5.0 1 0.3 6.1 1 0.3* (+ 22)
4.4 1 0.5 5.7 1 0.1* (+ 30)
present,
Microsomes Additions to 
incubation
Control
Control
Control
Sucrose washed 
Sucrose washed
None
Sucrose
Supernatant
Sucrose
Supernatant
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5.7.3 Effect of washing the microsomal fraction in anti­
oxidants
Since EDTA is an inhibitor of lipid peroxidation the 
effect of other drugs, affecting lipid peroxidation, upon 
washed microsomes was investigated. The results are shown 
in Table 10. EDTA, EGTA, BHT and Mn^ + prevented any sig­
nificant reduction of aminopyrine metabolising activity 
after washing, but only EDTA provided much protection against 
the loss of acetone enhancement of aniline metabolism that 
normally occurred after washing the microsomes. Vitamin E, 
either in the natural form, or as the acid succinate or 
acetate salts had no protective effect on drug metabolism.
2+Vitamic C and Fe which stimulate lipid peroxidation 
failed to significantly potentiate the changes occurring on 
washing.
5.7.4 Effect of washing the microsomal fraction in post— 
microsomal supernatant
When control microsomes were incubated during the assay 
with sucrose there was over 60% reduction in aniline metabolism 
but the percentage increase in aniline metabolism due to 
acetone enhancement was unaffected (Table 11). When either 
control microsomes or those washed in sucrose were incubated 
with the supernatant from this wash aniline metabolism was 
even further reduced than with sucrose alone. This may be an 
effect on the detection of p-aminophenol rather than its 
. formation possibly due to an interaction with haemoglobin in
TABLE 12
Drug metabolism in microsomes washed in first post-microsomal supernatant
Microsomes were washed in the supernatant, obtained from the first isolation 
of the microsomes, where indicated. Figures in parentheses show percentage 
enhancement of aniline metabolism by acetone 0.5M compared with activity 
with no acetone present. NADPH was generated by isocitrate dehydrogenase. 
Figures are mean ± S.E.M. of six determinations.
*P < 0.05 **P < 0.01 compared with control microsomes.
Aniline metabolism Aminopyrine metabolism
mymol/mg protein/30 min mymol/mg protein/30 min
No acetone Acetone 0.5M
Control 7.1± 0.2
Washed microsomes 
Sucrose 6.9 ±0.4
Supernatant 7.1 ±0.3
18.3 ±0.9 (+130)
**
10.3 ±0.5 (+ 27)
22.3 ±0.7 (+205)
Heated supernatant 5.5 ±0.2 10.2±0.4 (+ 85)
74.5 ± 3.1
56.4 ±4.3
81.9 ± 2.3
* *
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the supernatant. Acetone enhancement in control microsomes 
was unaffected by this post—microsomal supernatant but there 
was no reversal of the loss of activity that occurred after 
washing in sucrose. Thus it was unlikely that during washing 
of the microsomes some component of the microsomal fraction 
was lost into the supernatant which could be added back to 
restore activity.
Another possibility was that during the normal isolation 
of the microsomal fraction some soluble endogenous compound 
prevented the loss of activity that occurred on washing 
microsomes in the absence of post—microsomal supernatant.
Thus microsomes were washed in the supernatant obtained after 
their first isolation. This was found to prevent any loss 
of aminopyrine metabolising activity, and even to increase 
it slightly (Table 12). Similarly the acetone enhancement 
of aniline metabolism was even greater than before washing, 
in contrast to the loss of activity that occurred after 
washing in sucrose alone. These results are very similar 
to those observed with EDTA.
When the post—microsomal supernatant was boiled for 10 
min and filtered to remove the precipitate it provided only 
some protection against the loss of acetone enhancement..
5.7.5 Effect of storing microsmes on drug-metabolising 
activity
A loss of aminopyrine metabolising activity with very 
little loss of aniline metabolising activity has been
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Figure 3 6
Effect of storage of microsomes on drug metabolism. .Microsomes were
-3
suspended in sucrose buffer, EDTA 10 M or the post-microsomal supernatant 
from the first spin, and assayed for aminopyrine metabolism (upper panel) 
and aniline metabolism (lower panel) on the day of preparation (open 
columns). The microsomes were also assayed after storage at 4°C for 90 h 
(stippled columns). NADPH was added directly to the incubation. Figures 
are mean (± S.E.M.) of four determinations.
*P<0.05 **P < 0.01 compared with metabolism before storage.
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reported to occur in the microsomal fraction when stored for 
more than a few hours at 4°C (Leadbeater and Davies, 1964; 
Hewick and Fouts, 1970). Because of the similarities in 
effects produced by this treatment and washing of the micro­
somes, the effect of storing microsomes in EDTA and the post- 
microsomal supernatant were investigated. To avoid possible 
•complications of EDTA interacting with the NADPH-generating 
system reduced NADPH was added directly to the incubation 
medium.
Storing microsomal fraction at 4°C suspended in sucrose
resulted in a much greater loss of aminopyrine metabolism,
/
reduced by 86.4%, compared with aniline metabolism which was 
reduced by 52.1% (Fig. 36). The enhancement of aniline 
metabolism by acetone was almost completely abolished by 
storage (results not shown).
Suspension of microsomal fraction in sucrose containing 
-3EDTA 10 M caused a significant increase in both aniline and 
aminopyrine metabolism, 18.5% and 34.8% respectively. After 
storage at 4°C these microsomes showed less reduction of drug- 
metabolising activity when compared with microsomes stored 
in sucrose, both in absolute terms and in percentage changes. 
Aminopyrine metabolism was reduced by 73.1% and aniline meta­
bolism by only 32.6%.
Microsomes suspended in post-microsomal supernatant 
obtained after the first spin exhibited a 27.6% increase in 
aminopyrine metabolism but aniline metabolism was reduced by
TABLE 13 •
Microsomal metabolism in presence of EDTA
Drug metabolism was determined in microsomes in the presence and absence 
-5of EDTA 2.5 x 10 M. Microsomes were treated as shown. Drug-metabolising 
activity is expressed as mymol/mg protein/30 min. NADPH was generated by 
glucose-6-phosphate dehydrogenase. Figures are mean ± S.E.M. of six 
determinations.
*P < 0.05 **P < 0.01 compared with values in absence of EDTA.
Aniline metabolism Aminopyrine metabolism
mymol/mg protein/30 min mymol/mg protein/30 min
No acetone Acetone 0.5M
No EDTA EDTA No EDTA EDTA No EDTA EDTA '
Control 7.110.2 7.2 ± 0.1 19.7 ± 0.3 22.9 ± 0.5** 89.91 2.5 98.4 1 1.6**
Washed micro­
somes
Sucrose 5.210.3 5.210.2 -7.210.4 8.010.3 . 79.71 1.3 85.612.1
EDTA 10*" M 9.8 10.4 10.2 +0.3 29.4 + 0.3 32.8 10.7 117.1 1 5.2 133.9 1 3.3
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47.1%, probably due to interference in the assay of p-amino- 
phenol. When these microsomes were stored at 4°C some 
protection of aminopyrine metabolism was evident, the loss 
of activity being 74.3%. Aniline metabolism was also 
protected when compared to the appropriate control, but this 
was complicated by the inhibitory effect of post-microsomal 
supernatant itself.
It was concluded that many parallels existed between 
the effects of storage of microsomes and of washing.
^•7.6 Effect of EDTA on drug metabolism
-3
As reported previously EDTA at 10 M appeared to increase
the metabolism of both aniline and aminopyrine when included
in the incubation medium. This was further investigated at
a lower concentration of EDTA, and the results are shown in
-5Table 13. At 2.5 x 10 M EDTA increased aminopyrine metabolism, 
by 10% in control microsomes, and by 7.5% and by 14% in 
sucrose washed and EDTA washed microsomes respectively. How­
ever at this concentration of EDTA there was no significant 
effect upon aniline metabolism although in the presence of 
0.5 M acetone EDTA did cause a light increase in aniline 
metabolism over and above that caused by acetone enhancement 
(P < 0.01).
This effect of EDTA was insufficient to account for its 
protective effect against loss of acetone enhancement or 
aminopyrine metabolism occurring after washing in EDTA, if
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Figure 37
Lipid peroxidation in washed microsomes. Lipid peroxidation was measured
in control microsomes (open columns), microsomes washed in sucrose (filled
-3
columns) and microsomes washed in EDTA 10 M (stippled columns). Measure­
ments were performed after isolating the microsomes, after incubation for
30 min with NADPH generated by glucose-6-phosphate dehydrogenase, and
-5after incubation as before but m  the presence of EDTA 2.5 x 10 M. Values 
are mean (± S.E.M.) of six determinations. No measurement taken.
*P < 0.05 **P < O.Ol compared with control microsomes.
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this was only due to a carry-over of EDTA into the microsomal
pellet. This was confirmed by incubating sucrose washed
microsomes with varying concentrations of EDTA in the presence
of 0.5 M acetone. In the absence of EDTA, acetone increased
aniline metabolism slightly to 10.7.mymol/mg/30 min. EDTA,
-2at most, increased this to 13.0 mymol/mg/30 min at,10 M.
This was insufficient to account for the observed enhancement
-3after washing in EDTA, 10 M in which aniline metabolism was 
increased to 29.0 mymol/mg/30 min.
5.7.7 Effect of washing microsomes on lipid peroxidation
The effects of washing microsomes in sucrose could be 
prevented by adding certain inhibitors of lipid peroxidation.
It was therefore possible that these effects of washing were 
due to lipid peroxidation occurring during washing. Malon- 
aldehyde formation was used as a measure of lipid peroxidation 
(Bidlack et al, 1973) .
After washing microsomes in sucrose there was signif­
icantly more malonaldehyde present than in control microsomes
-3
(Fig. 37). When EDTA, 10 M was included in the sucrose this 
increase in malonaldehyde was largely prevented. Similarly, 
after incubation of the washed microsomes for 30 min, more 
lipid peroxidation occurred in washed microsomes than in con­
trol microsomes and this increase did not occur in microsomes
-3 -5washed in 10 M EDTA. Although the inclusion of 2.5 x 10 M
EDTA in the incubation medium of either control or sucrose 
washed microsomes resulted in a reduction of lipid peroxidation 
there were still significant amounts of malonaldehyde formed.
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Effect of the duration of incubation on drug metabolism by washed
microsomes. Aniline metabolism was determined in the absence of
acetone (•) and in the presence of acetone, 0.5 M (A). NADPH was
generated by isocitrate dehydrogenase. Microsomes were incubated
after their first isolation (control) or washed in sucrose (sucrose 
-3
wash) or EDTA 10 M (EDTA wash). Aniline metabolism is expressed 
as the rate of formation of p-aminophenol per 30 min. Values are 
mean (± S.E.M.) of six determinations.
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The effect of incubating EDTA washed microsomes was not tested 
since the experiment was designed to detemine if EDTA, carried 
over from washing the microsomes, could inhibit lipid peroxid­
ation.
5.7.8 Effect of the duration of incubation of washed 
microsomes on drug metabolism
The possibility that the loss of drug-metabolising 
activity that was apparent after washing the microsomes in 
sucrose was due to a loss of activity during the incubation 
at 4°C rather than during the washing procedure was investigated.
When the period of, washing, before isolating the micro­
somes, was increased from 30 min to 2 h or reduced to 5 min 
no significant change in the loss of aminopyrine metabolism 
or of acetone enhancement was evident, when compared with 
that occurring after 30 min. Similarly the protection afforded
-3
by EDTA, 10 M was not significantly affected by altering 
the time between spins. It was also found that increasing 
the temperature of the incubation from 4°C to 37°C had no 
significant effect upon the extent of the activity lost after 
washing in sucrose or upon the protective effect of EDTA.
Thus it appeared that the changes that were evident after 
washing in sucrose occurred either during the second spin or 
after it. Fig. 38 shows the results obtained from experiments 
designed to judge the latter possibility.
In control microsomes the rate of aniline metabolism fell 
slightly, by 15% between 10 and 30 min of incubation. However
TABLE 14
Effect of washing microsomes on components of electron transport chain
Microsomes were washed as shown. Cytochrome b_ and P-450 content are5
expressed as mymol/mg protein, NADPH-cytochrome c reductase is expressed 
as mymol cytochrome c reduced/min/mg protein and NADPH-cytochrome P-450 
reductase is expressed as mymol cytochrome P-450 reduced/mg protein/min. 
Figures are mean ± S.E.M. of four determinations.
*P < 0.05 **P < 0.01 compared to control microsomes.
Cytochrome b Cytochrome NADPH-cyto- NADPH-cyto- 
P-450 chrome c
reductase
chrome P-450 
reductase
Control 0.463 10.030 0.799 10.020 0.245 10.024 0.286 10.057
Washed microsomes
Sucrose
-3
EDTA 10 M
0.408 +0.035 0.744 10.039 0.205 10.020 0.400 10.086
"k k k
0.551 + 0.028 1.144 +0.022 0.18010.033 0.343 10.029
TABLE 15
Difference spectra after washing microsomes in sucrose
Microsomes were treated as shown. Difference spectra were obtained as 
described in the text. Results are AOD (Peak-trough)/mg protein and are 
expressed as a percentage of the values obtained with control microsomes, 
Symbols in parentheses indicate the type of spectral change produced. 
Figures are mean ± S.E.M. of six determinations.
*P < 0.05 **P < 0.01 compared with control microsomes.
SKF 525-A (I)
Substrate
Aniline (II) Acetone (II)
Control
Washed microsomes 
Sucrose
-3
EDTA 10 M
100 ± 2
73 ± 3
140 ± 5
100 ± 4
98 ± 2
121 ± 8
100 ± 9
0 ± 3
72 ±11
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over this period the percentage enhancement of aniline metabol­
ism caused by acetone did not change. Similar results were
- 3
obtained with microsomes previously washed in EDTA, 10 M.
Incubation of microsomes washed in sucrose caused a fall 
in aniline metabolising activity of only 8% between 10 and 
30 min, while over the same period percentage acetone enhance­
ment was reduced from 57% to 40%. These changes were insuffic­
ient to completely account for the effect of washing micrsomes 
in sucrose.
5.7.9 Effect of washing microsomes on the components of the 
electron transport chain
Washing the microsomal fraction in sucrose produced no 
significant change in the microsomal content of cytochrome b^ 
or cytochrome P-450 nor was there any significant alteration 
in the activity of NADPH-cytochrome c reductase or NADPH-cyto- 
chrome P-450 reductase (Table 14). Microsomes that were
-3
washed in sucrose containing EDTA, 10 M had a significant 
increase in both cytochrome b^ levels and in cytochrome P-450 
levels. The activity of NADPH-cytochrome c reductase and 
NADPH-cytochrome P-4 50 reductase was not significantly affected 
in these microsomes.
Microsomes washed in sucrose displayed a 17% reduction 
in cytochrome P-4 50 binding of the type I substrate, SKF 525-A 
but did not have significantly altered binding of type II 
substrates such as aniline (Table 15). In contrast microsomes 
washed in EDTA showed significant increases in the binding of
TABLE 16
Mierosomal protein yield after washing in sucrose
Microsomes were treated as shown. Protein was determined in both the
/
microsomal pellet and the supernatant after washing. Figures are mean 
± S.E.M. of twenty determinations.
Protein in Protein in
pellet mg supernatant mg Total
Control 30.5 ±1.0 - 30.5 ±1.0
Washed microsomes
Sucrose 24.0 ±0.8 6.7 ±0.2 30.7 ±1.0
EDTA 10“3M 21.1 ±0.4 9.2 ±0.3 30.3 ±0.7
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both type I substrates, increased by 40%, and of type II 
substrates, increased by 21%.
In agreement with an observation by Vainio and H&nninen 
(1972) acetone was found to produce a typical type II spectral 
change in microsomal suspensions, though the magnitude of this 
change was small. Microsomes washed in sucrose showed no 
binding of acetone (Table 15).
5.7.10 Effect of washing on microsomal protein yield
All the washing procedures were found to cause a reduction
/
in the amount of protein recovered from the microsomal pellet. 
Microsomes washed in sucrose yielded only 7 9 ± 2% of the 
protein obtained from control microsomes and washing in EDTA 
reduced the yield further, to 71 ± 3% of the control (Table 
16). The protein lost from the pellet could be recovered 
from the supernatant, both after washing in sucrose and in 
EDTA.
CHAPTER 6
Discussion
TABLE 17
Values obtained for various tests of function of the isolated perfused rat
liver
The values obtained in the present study are compared with those found by
other workers and with the values found in vivo in1 the rat. - indicates
no value quoted.
Initial Peak
glucose
“T"
K Haemo­ bile
production L:P pH change release lysis flow
Source mg/g/h ratio pH units/h ymol/g/h %/h ml/h
This work 3.3 8.0 0.00 10 0.2 0.7
In vitro
Woods & Krebs, 1971 5.4 8.5 — 0.7
Schimassek, 1963a 4.9 10.0 - - - • -
Mortimore, 1961 8.0 - - 17 - -
Brauer et al, 1951 - - - - - 0.38
Craig, 1966 2.4 - ‘ -0.08 7 2.0 -
Ostashever et al, 1960 - - 0.00 - 0.4 0.45
Northrop & Parks, 1964 7.0 - - - - -
Hems et al, 1966 2.4 - - - - 0.40
Exton & Park, 1967 9.0 10.0 0.00 10 0.0 0.30
Ryoo & Tarver, 1968 - - - - - 0.40
Kaiser et al, 1965 2.0 - . - - - • 0.60
Penhos et alf 1966 1.4 - - - - -
Fisher & Kerly, 1964 1.5 - -0.03 19 - 0.50
Levine et al, 1964 0.6 - - - - 0.75
Flock & Owen, 1965 - - - - - 0.50
John & Miller, 1969 - — - - - 0.65
Herz et al, 1973 - 7.7 - 4 2.6 -
In vivo 
Ross, 1972 10.0 0.00 0 0.0 0.75
6.1 Viability of the perfused liver
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The operative procedure used in isolating the liver was 
designed to be quick, and to avoid any period of anoxia to the 
liver, so characteristic of many previous perfusion experi­
ments (see review by Ross, 1972). The viability of the liver 
was assessed for periods of up to six hours of perfusion.
Within a few minutes of the transfer of the liver to the 
perfusion chamber its appearance corresponded closely with 
that normally observed in vivo and in successful perfusions 
a similar appearance was still evident at the end of the 
experiment. Electron microscopy of the liver after 4 h per­
fusion revealed none of the characteristic signs of cell 
damage or necrosis or even of the reversible changes occurring 
during hypoxia (Bock et al, 1972). There were none of the 
changes caused by the increased lysosomal activity associated 
with high oxygen tensions (Abraham et al, 1968).
A comparison of the values obtained for the various tests 
of liver function in the present study with those reported by 
other workers is shown in Table 17. It is only by comparison 
with the in vivo values and with those reported for successful 
perfusions that an assessment of the viability of the liver 
can be made.
Glucose production is expressed over the initial period 
of perfusion during which glycogenolysis occurs due to 
operative trauma (Bartosek et al, 1972b). The values are 
well within the range of values reported by others for the
successfully functioning perfused liver. Changes in the 
perfusate pH, extent of haemolysis, and K+ efflux from the 
liver correlate well with the results of others. The lactate 
pyruvate ratio, which has been described as one of the most 
sensitive tests of liver function (Ross, 1972) was maintained 
between 8 and 10 after the first 60 min of perfusion for 
periods of up to 5 h. This is similar to the ratio measured 
in vivo (Schimassek, 1963a) and in the functioning perfused 
liver (Schimassek, 1963a; Woods and Krebs, 1971). In anoxia 
(Schimassek, 1963a; Faupel, Seitz, Tarnowski, Thiemann and 
Weiss, 1972) or inadequate perfusion (Woods and Krebs, 1971) 
the ratio increases rapidly to values above 25.
Although bile flow is not regarded as a good test of 
liver function (Ostashever et al, 1960) it was found that 
flow rates agreed with most reported values and the initial 
rate was similar to that observed in vivo. The bile flow 
was initially high but then declined over the duration of 
perfusion. This is probably a reflection of the loss of 
bile salts from the system which, in vivo, would enter an 
entero-hepatic circulation and stimulate bile production 
(O'Maille, Richards and Short, 1966). Addition of bile salts 
to the perfused liver has been found to increase bile pro­
duction to near in vivo rates (Kendler, Bassan and Zimmerman, 
1971; Liersch, Barth, Hackenschmidt, Ullmann and Decker,
1973).
Thus the isolated liver could be maintained in a viable 
condition for periods of up to 6 h as judged by various tests 
' of morphology, and biochemical and physiological function.
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Little evidence of bacterial contamination was found making 
it unnecessary to add antibiotics. A period of 60 min was 
allowed for equilibration after transfer of the liver to the 
perfusion chamber during which time the lactate:pyruvate ratio 
attained a steady value and most of the other parameters 
tested reached a steady state.
6.2 Drug metabolism in the perfused liver
6.2.1 Hexobarbitone metabolism
The metabolism of hexobarbitone by the isolated perfused 
rat liver was found to be a first order reaction, which con­
firms the findings of Cumming and Mannering (1970) and Bock 
et al (1972).
#
The half-life of hexobarbitone during the first pulse 
of substrate in the perfused liver was 29.7 ± 2.0 min. This 
correlates well with values for the half-life of hexobarbitone 
in vivo which has been variously reported as 3 6 min (Anders, 
1966) , 28 min (Axelrod, Reichenthal and Brodie, 1954) and 30 
min (Bush and Weller, 1972). It has been shown by von Bahr 
et al (1970) that the half-life of‘ those drugs with a small 
volume of distribution in vivo closely resembles the half-life 
in the perfused liver. The volume of distribution of hexo­
barbitone in the rat is relatively small (Cumming and Mannering, 
1970; Bush and Weller, 1972). It is thus not unreasonable 
that the half-life of this substrate in the perfused liver 
closely resembles the half-life in vivo.
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The half-life of hexobarbitone in the perfused liver 
reported by other workers (Stitzel et al, 1968; Weiner et al, 
1972a) is lower than the values found in the present study. 
However this is possibly due to the abnormally high oxygen 
tensions used by these workers. Hexobarbitone metabolism is 
very sensitive to changes in oxygen tension (Cumming and 
Mannering, 1970).
The half-life of hexobarbitone during the second pulse 
was significantly greater than during the first pulse.
Stitzel et al (1968) also found that there was a small but 
significant increase in the half-life of hexobarbitone from 
the first to the second pulse. The reason for this decrease 
in drug-metabolising activity is unknown. It may be due to 
the depletion of some essential co-factor or the destruction 
of some essential component of the drug-metabolising system.
The levels of the components of the microsomal electron 
transport chain cytochrome P-450, cytochrome b^ and NADPH- 
cytochrome c reductase have, however, been reported to remain 
stable over 4 h perfusion (Bock et al, 1972? Bartosek et al,
1974).
It has recently been reported that the metabolism of the 
type I substrate aminopyrine by the 9,000 x G fraction isolated 
from perfused rat liver was reduced by 50% whereas that of 
aniline, a type II substrate, was reduced by less than 20% 
after 2 h perfusion (Bartosek et al, 1974). The loss in 
aminopyrine metabolising activity could be partially prevented 
by the infusion of nicotinic acid, a precursor of NADP, during 
perfusion. A loss of NADP (H) may explain the loss of
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hexobarbitone metabolising activity observed in the perfused 
liver.
6.2.2 Aniline metabolism
It has been known for some time that the metabolism of 
aniline by the microsomal fraction is slower than the meta­
bolism of hexobarbitone (Dixon et al, 1964). This has been 
explained in terms of the inhibition and activation of the 
rate of reduction of cytochrome P-450 by the two substrates 
respectively (Gigon et al, 1968, 1969). It has also been 
found that in vivo the metabolism of hexobarbitone (Bush and 
Weller, 1972) is much faster than the metabolism of aniline 
(Parke, 1960). The metabolism of aniline by the perfused 
liver has now been shown to be much slower than that of hexo­
barbitone. Three hours after the addition of aniline to the 
perfused liver 20% of it remained unmetabolised in the per­
fusion medium whereas almost all the hexobarbitone had been 
metabolised within 90 min.
The phase I metabolism of aniline in vivo is largely to 
p-aminophenol (Parke, 1960). In the present study although 
p-aminophenol could be liberated from the perfusion medium by 
strong acid hydrolysis no free p-aminophenol could be detected. 
Separate studies with red cell suspensions revealed that free 
p-aminophenol was bound to some component of the erythrocytes, 
most probably haemoglobin, so that it could not be detected. 
Further studies with 3H-aniline showed that over 7% of the 
label could be detected bound to haemoglobin. This may rep­
resent free p-aminophenol that has reacted with haemoglobin. 
Kiese and Pekis (1964) have shown that p-aminophenol reacts
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with haemoglobin to convert it to hemiglobin while there is 
a coupled oxidation of the p-aminophenol itself, and the 
hemiglobin, by molecular oxygen. It then no longer forms 
an indo-phenol complex.
The main metabolites of aniline produced by the perfused 
liver are an acid-labile conjugate of aniline, accounting for 
33% of the aniline added, and conjugates of p-aminophenol, 
accounting for 13% of the aniline added. If the haemoglobin- 
bound form of p-aminophenol is taken into account 20% of the 
aniline is metabolised to p-aminophenol.
Smith and Williams (194 9) found that rabbits fed aniline 
excreted almost 50% of the dose as an acid-labile conjugate 
which it was suggested could have been a glucuronide. In 
contrast Parke (1960) reported that rabbits fed aniline ex­
creted over 50% of a dose as p-aminophenol or its conjugates 
and only 5.5% could be detected as the aniline-N-glucuronide.
It was observed however that large quantities of free 
glucuronic acid were excreted in the urine of these animals 
(Parke, 1960).
In the present study, mild acid hydrolysis liberated free 
aniline from the perfusion medium, possibly from an acid- 
labile conjugate, which may be aniline-N-glucuronide. Al­
though aniline-N-glucuronide can be produced as a result of 
enzymatic activity it-can also be formed spontaneously (Parke, 
1960). In the present study SKF 525-A, which has been reported 
to inhibit the enzymes of glucuronide formation (Anders, 1971), 
reduced the formation of the acid-labile aniline conjugate by 
62%.
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After 3 h, 7% of the aniline administered was present 
in the perfusion medium in an unidentified form. Since only 
certain of the possible metabolites were being assayed it is 
probable that this fraction represents one or more of these 
other metabolites known to be formed. Traces of acetanilide 
and m-aminophenol are produced by rabbits fed aniline (Parke, 
1966) and o-aminophenol is produced- in the rat in the ratio 
of 1:6 to p-aminophenol (Parke, 1960). o-aminophenol could 
thus account for 3 to 4% of the aniline, remaining in the 
perfusate, after 3 h perfusion. Phenylsulphamic acid accounted 
for 5.5% of a dose of aniline fed to rabbits (Parke, 1960) 
and so may form part of the unidentified metabolites in the 
perfused liver of the rat.
Over 7% of the aniline was excreted in the bile produced 
by the perfused rat liver over 3 h. Almost half of this was 
as an acid-labile conjugate of aniline. Hirom, Millburn,
Smith and Williams (1972) have shown that the threshold for 
active excretion of compounds into the bile of the rat is 
325 ± 50. Thus aniline, with a molecular weight of 93, is 
well below the threshold and most free aniline in the bile 
probably results from passive diffusion into the cannuliculi. 
The molecular weight of aniline-N-glucuronide is 2 69 and is 
thus on the threshold for active excretion. Compounds can 
enter the bile both from the hepatocytes and from the blood 
(Back and Calvey, 1972). Thus the presence of a trace of 
free p-aminophenol in the bile may derive from compound that 
has diffused from the hepatocyte, and supports the hypothesis 
that most free p-aminophenol is either.conjugated in the cell
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or binds with haemoglobin in the perfusion medium.
After 3 h perfusion 10% of the 3H-aniline added to the 
perfused liver had been lost by non-metabolic processes, and 
was not recoverable from the perfusion medium in any form. 
Krieglstein, Krieglstein and Urban (197 2) have shown that 
lipophilic drugs are readily adsorbed on to many types of 
plastic, particularly silicone rubber, and as much as 50% is 
adsorbed on to polyethylene in the case of very lipophilic 
compounds. When the polyethylene and silicone rubber of the 
perfusion circuit were extracted after perfusion with 3H- 
aniline a total of less than 1% of that added could be re­
covered. Thus neither aniline nor its metabolites are 
adsorbed to any appreciable extent by the material of the 
perfusion circuit. Over half of the aniline lost by non- 
metabolic processes was lost by transexudation across the 
liver capsule into the liquid paraffin in the perfusion 
chamber. This loss may represent free aniline or a metabolite, 
its identity was not investigated. It has been suggested 
that transexudation across the liver may occur in man after 
perfusion of actinonycin D directly into the liver (Mulcare, 
Solis and Fortner, 1973). The rest of the aniline lost in 
this non-metabolic fraction could*be quantitatively accounted 
for as residue remaining in the sampling pipettes, glassware 
and perfusion apparatus. This was assessed by soaking all 
contaminated material, after perfusion with 3H-aniline, in a 
large volume of detergent and determining the activity in the 
extract.
As already discussed in the Results (Section 5.2.2) the
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A suggested model to describe the distribution and metabolism of aniline 
in the isolated perfused rat liver. The points in the upper panel show
the experimental data on which the model was constructed as described in
Appendix I. Aniline removal (©), acid-labile conjugate appearance (B) 
and the appearance of p-aminophenol conjugates (A), bars represent S.E.M. 
of four perfusions. The lines are the theoretical predictions based on 
the model shown in the lower panel. The rate constants, K, are in min \
No predicted curve could be obtained for p-aminophenol.
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removal of aniline from the perfusion medium falls into two 
phases. Kinetic analysis of the data enabled a model to be
derived as described in Appendix I. This model is shown in
Fig. 39. The experimental data for both the removal of 
aniline and the formation of its metabolites were in close 
accord with the predicted values, as also shown in Fig. 39.
All of the processes of metabolism and excretion of aniline 
appeared to occur from compartment 1. Thus compartment 1 
probably corresponds to the whole system, the intracellular 
water being in rapid equilibrium with the perfusion medium, 
so that it does not represent' a separate compartment. A 
similar situation has been shown to exist for propranolol in
the perfused liver (Evans et al, 197 3)/ Thus access of
substrate to the microsomal enzymes does not appear to be 
rate limiting in this system.
This leaves compartment 2 unaccounted for. It seems 
most probable that it represents some form, of binding of free 
aniline. Non-specific binding to hepatic tissue proteins 
has been reported for propranolol (Evans et al, 1973; Shand, 
Branch, Evans, Sies and Wilkinson, 1973). It has been shown 
that aniline does not bind to serum albumin (Bickel and Bovet, 
1962). Aniline is a type II substrate (Schenkman, 1967) and 
so will bind to cytochrome P-450 at the non-metabolic type II 
site. This site could represent compartment 2 for aniline in 
the perfused liver although this remains highly speculative.
SKF 525-A inhibits many drug-metabolising enzymes in­
cluding glucuronyl transferase (Anders, 1971). In the per­
fused liver it inhibits p-aminophenol formation completely,
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i.e. Kp = 0. Kinetic analysis showed-that the rate constant,
K^ ,, for the formation of the acid-labile aniline conjugate
was reduced to 0.0016 min Using these new values of
and Kp in the equations of Appendix I it was found that Kq
was reduced to 0.0170 min  ^ and K. was increased to 0.0086
i
min Thus SKF 525-A had inhibited the two main pathways
of aniline metabolism in the perfused liver and increased the 
size of compartment 2 by almost 100%. Schenkman (1970) has 
suggested that at increasing concentrations of aniline, 
binding of this substrate to the non-metabolic type II site 
may be facilitated, possibly due to a solvent effect. SKF 525-A, 
by inhibiting aniline metabolism, would increase the con­
centration of aniline present and might thus increase type 
II binding. It has also been shown that compounds such as 
SKF 525-A, that produce a type I difference spectrum, can 
increase the binding of type II compounds, probably by pre­
venting the small degree of binding to type I sites that 
normally occurs with these substrates (Schenkman, 1970;
Gorrod and Temple, 197 3). Although the type I component of 
the difference spectrum of type II substrates is not very 
great, it has been shown by these authors that blocking it 
results in a large increase in type II binding. This could 
thus possibly account for the increase in the size of com­
partment 2 caused by SKF 525-A.
6.3 Effect of catecholamines on drug metabolism
6.3.1 The isolated perfused rat liver
The effect of catecholamines on drug metabolism in the
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perfused liver has not previously been reported. Both adren­
aline and noradrenaline inhibit the metabolism of hexo­
barbitone but have no effect on the metabolism of aniline.
The known differences in the binding of these two substrates 
to cytochrome P-450 and the effect this has on their respec­
tive metabolism (Anders, 1971) might explain the different 
effects of catecholamines on the metabolism of the two sub­
strates. However the mechanism whereby catecholamines might 
produce this effect is not known.
Most of the metabolic effects of catecholamines are 
mediated by cyclic AMP and.it has recently been shown that 
cyclic AMP inhibits hexobarbitone metabolism in the perfused 
liver (Weiner et al, 1972a). Catecholamines could thus be 
acting by the liberation of cyclic AMP.
Although no significant direct effect of catecholamines 
on drug metabolism by the microsomal fraction was found 
(Dixon et al, 1964) Cooper and Rosenthal (1962a) found that 
noradrenaline would increase steroid hydroxylation by a micro­
somal oxidase of adrenal homogenates. Catecholamines may 
therefore be acting by a direct interaction with the enzymes 
of drug metabolism.
Long term pre-treatment of rats, for 24 h or more, with 
adrenaline (Fouts, 1962) or noradrenaline (Dixon et al, 1964) 
inhibits the metabolism of both aniline, aminopyrine•and 
hexobarbitone by the hepatic microsomal fraction although 
Kato and Gillette (1965) found that adrenaline inhibited the 
microsomal metabolism of only type I substrates whilst the
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metabolism of type II substrates was unaffected in male rats.
Although the effects of catecholamines on drug metabolism 
have not previously been described several workers have in­
vestigated the influence of catecholamines on the clearance 
of a number of substances by the liver. Both adrenaline and 
noradrenaline were found to reduce the clearance of brom- 
sulphthalein in the isolated dog liver (Andrews, Maegraith 
and Richards, 1956) and it was later shown that the extraction 
of CrPO^ was reduced by catecholamines in the perfused rat 
liver (Brauer, Leong, McElroy and Holloway, 1956). A similar
effect of catecholamines upon the hepatic extraction of indo-
/
cyanine green has recently been reported in the anaesthetised 
cat (Krarup, 1973). Catecholamines may be acting on drug 
metabolism by a similar mechanism, either by reducing sub­
strate uptake or by causing vasoconstriction and thus reducing 
the supply of substrate.
Thus it was concluded from these known effects of catechol­
amines that their effect on hexobarbitone metabolism in the 
isolated perfused rat liver could be attributed to one or 
more of the following effects.
a) Direct inhibition of hexobarbitone binding to cyto­
chrome P-450 or some component of the microsomal electron 
transport chain.
b) Liberation of cyclic AMP which could then inhibit 
drug metabolism.
c) Alteration in uptake of substrate at the site of 
metabolism.
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d) Alteration in supply of substrate or other co-factor 
through an effect on blood flow.
These possibilities will be considered individually.
6.3.2 Direct effect of catecholamines on drug metabolism
Although Dixon et al (1964) reported that catecholamines 
caused a slight and non-significant increase in the rate of 
microsomal drug metabolism when added directly, the current
-3
work has shown that even at concentrations as high as 10 M
catecholamines have no direct effect upon the metabolism of
either aniline or hexobarbitone by the microsomal fraction.
/
Hepatic drug metabolism thus differs from adrenal steroid 
hydroxylation which is stimulated by noradrenaline (Cooper 
and Rosenthal, 1962a).
It was found that high concentrations of noradrenaline 
could inhibit the binding of type II substrates to cytochrome 
P-450 in microsomal suspensions. Even higher concentrations 
of noradrenaline were necessary to inhibit the binding of 
hexobarbitone, and it may be that at these concentrations the 
effect was non-specific. Inhibition of the binding of type 
II substrates rarely affects their metabolism (Jefcoate et al, 
1969). Noradrenaline itself produced a type II difference 
spectrum with a of 1 mM and Liebman, Hildebrandt and 
Estabrook (1969) have shown that type II substrates produce 
competitive inhibition of the binding of type I substrates, 
although they never produce competitive inhibition of the 
binding of type II substrates rather a non-competitive in­
hibition. However it was clearly shown that catecholamines
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did not inhibit the microsomal metabolism of hexobarbitone, 
either directly or by inhibition of the enzymes of the micro­
somal electron transport chain.
6.3.3 Possible effect through the release Of cyclic AMP
The effects of cyclic AMP on hepatic drug metabolism have
been reviewed in Section 2.5. Many of the metabolic effects
of catecholamines are mediated through the release of cyclic
AMP (Sutherland and Robison, 1966). Therefore it could be
that catecholamines were inhibiting drug metabolism through
this mechanism. Cyclic AMP is thought to act at the level of
/
the intact cell membrane to liberate some inhibitory substance, 
possibly free fatty acids, and this then inhibits the enzymes 
of drug metabolism (Weiner, 197 3). In agreement with the 
findings of Weiner et al (1972b) it was shown in the present 
study that although cyclic AMP does not inhibit microsomal 
drug metabolism directly, even at high concentrations, it does 
inhibit metabolism by liver slices.. However in the present 
study catecholamines had no effect on the metabolism of either 
type I or type II substrates by this system. Weiner and his 
associates (Weiner et al, 1970, 1972a, b) investigated the 
effects of cyclic AMP on the metabolism of type I substrates 
only, p-chloromethylaniline which they used as a type II sub­
strate is probably a type I substrate in rat microsomes (Ross 
and Oppelt, 1973) despite findings to the contrary with guinea 
pig liver (Kupfer and Orrenius, 1970). However it has been 
clearly shown that cyclic AMP administered to male rats in­
hibits the metabolism of both type I and type II substrates 
(Ross and Oppelt, 1971, 1973; Ross et al, 1973) . In contrast,
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in the present study, with the perfused liver, catecholamines 
inhibit the metabolism of type I substrates only.
Papaverine is a potent inhibitor of phosphodiesterase 
(Goren and Rosen, 1972). It should therefore potentiate the 
effects of any cyclic AMP released by catecholamines in the 
perfused liver by preventing its metabolism. However in the 
presence of high concentrations of papaverine adrenaline 
failed to have any further inhibitory effect on hexobarbitone 
metabolism, and it did not develop any inhibitory effect on 
aniline metabolism. If adrenaline was inhibiting hexo­
barbitone metabolism by the release of cyclic AMP, then
y
blocking the breakdown of cyclic AMP should potentiate the 
action of adrenaline. This has been observed when glucagon, 
which also liberates cyclic AMP (Sutherland and Robison, 1966) 
was added to the perfused liver in the presence of the 
phosphodiesterase inhibitor theophylline (Weiner et al, 1972a). 
Glucagon alone produced a slight inhibition of hexobarbitone 
metabolism but was much more potent.in the presence of 
theophylline (Weiner et al, 1972a).
How can the difference on drug metabolism be explained
between adrenaline and glucagon, both of which liberate cyclic
AMP? Weiner et al (1972a) found that a relatively high
threshold concentration of cyclic AMP was necessary to produce
inhibition of drug metabolism. A perfusate concentration of 
—73 x 10 M glucagon could only produce a 20? reduction in the
metabolism of hexobarbitone by the perfused liver and the
concentration of dibutyryl cyclic AMP necessary to produce a
-450% inhibition was 10 M. In the isolated perfused rat liver
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-9glucagon, at concentrations as low as 3 x 10 M, will
produce a thirty-fold increase in cyclic AMP levels (Kuster,
Zapf and Jakob, 197 3). Exton, Robison, Sutherland and Park
(1971) found that maximum cyclic AMP production occurred at
—  8a glucagon concentration of 2 x 10 M, with an 85-fold 
increase in cyclic AMP levels (Kuster et al, 197 3). In 
contrast, a maximum two-fold increase in cyclic AMP levels
-7
was produced by adrenaline, 5 x 10 M, (Exton et al, 1971).
This increase was transient, lasting only five minutes unlike
the glucagon effect, which lasted for over 30 min (Exton et
al, 1971; Kuster et al, 1973). Cyclic AMP levels could not
be elevated further even by the addition of theophylline
/
(Exton et al, 1971). In the perfused liver noradrenaline 
was slightly less potent than adrenaline at releasing cyclic 
AMP (Exton et al, 1971).
Thus although catecholamines release cyclic AMP in the 
perfused liver, the amount of nucleotide released is very low. 
To produce inhibition of drug metabolism levels of cyclic AMP 
about 25-fold above normal are necessary. All the evidence 
thus seems to preclude the possibility that the mode of action 
of catecholamines on inhibition of drug metabolism in the 
perfused liver is through the release of cyclic AMP.
6.3.4 Alteration of substrate uptake by hepatocytes
Among several possibilities suggested by Andrews et al 
(1956) to explain the decrease in bromsulphthalein clearance 
observed in the perfused liver after the addition of catechol­
amines was that catecholamines could be altering the uptake
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of bromsulphthalein into the hepatocytes. Such a mechanism 
could explain some of the results observed in this study if 
different uptake mechanisms exist for aniline and hexo­
barbitone, or alternatively if uptake is rate limiting for 
hexobarbitone metabolism but not for aniline metabolism. 
However in the studies of Cooper et al (19 54) there was no 
evidence of an uptake process for hexobarbitone across the 
plasma membrane in liver slices. In the present study 
catecholamines had no effect on the rate of disappearance 
of aniline or hexobarbitone in liver slices. Thus the 
effects of catecholamines on drug metabolism cannot be due
to the reduction in uptake of substrate into the hepatocyte,
/
even if such a process exists.
6.3.5 Effect on blood flow
2 +It has been found that Ca is necessary for the con-
2 +traction of smooth muscle (Bohr, 1964). When Ca was omitted 
from the perfusion medium the pressor effects of catechol­
amines were almost completely abolished. Similarly there was 
a loss of the inhibitory effects of catecholamines upon 
hexobarbitone metabolism. It was considered possible there­
fore, that*this effect on drug metabolism might be related 
to the vascular effects of catecholamines in the perfused 
liver.
In almost all previous studies in which the effects of 
sympathomimetics on hepatic blood flow have been studied in 
the perfused liver, a constant pressure system has been 
employed (Brauer, 1963; Greenway and Stark, 1971) and those 
studies carried out in vivo have involved anaesthetised
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animals in which vasomotor reflexes are abolished (Ho, 1972). 
Catecholamines cause a pronounced vasoconstriction of the 
hepatic.vasculature, and in a constant pressure system this 
will result in a considerable reduction in total blood flow 
through the liver (Northrop and Parks, 1964). However when 
catecholamines are administered in vivo there is a reflex 
change in blood flow to the liver so that the total blood 
flow through the organ is unchanged or even increased, de­
spite a splanchnic vasoconstriction (Andrews, 1957). In his 
review Brauer (1963) likened the liver in vivo to the organ 
in a perfusion system in which the total blood flow through
the organ is determined externally. Circulatory regulation
/
within such a system would then depend on modifications of 
blood flow distribution within the organ. Thus the liver 
perfused at a constant flow rate provides a system that more 
closely resembles the situation in vivo than perfusion at a 
constant pressure. It also enables the effects of catechol­
amines on blood flow distribution to be investigated, rather 
than just measuring changes in the total blood flow through 
the organ.
Considerable controversy exists as to whether catechol­
amines can cause a redistribution of blood flow within the 
liver. Several workers have reported that such a phenomenon 
does occur (Daniel and Prichard, 1951c; McCuskey, 1966) 
whereas others claim that there is no such phenomenon 
(Greenway and Oshiro, 1972b). The evidence available to date 
has been reviewed in'Appendix II.
The possibility that catecholamines were causing a
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redistribution of hepatic blood flow has been investigated in 
the present study. X-radiography of the liver perfused with 
adrenaline revealed that adrenaline does, indeed, cause a 
change in the distribution of perfusate flow within the liver, 
and perfusion of the liver with Indian ink and adrenaline 
followed by histology showed that this effect is manifest as 
a redistribution of perfusate away from peripheral areas of 
the lobes to more central regions, with many small blood 
vessels in the periphery no longer being perfused.
How can a redistribution of blood flow by catecholamines
explain their selective inhibitory effect on hexobarbitone
/
metabolism in the perfused liver? There are several possible 
explanations. The perfusion medium in the isolated liver is 
responsible for the transport of both substrates and molecular 
oxygen to the hepatocyte. Molecular oxygen is necessary for 
the oxidative metabolism of both hexobarbitone and aniline 
(Estabrook, 1971).
If a reduced supply of substrate to peripheral hepato- 
cytes is responsible for the inhibitory effects of catechol­
amines it might be expected that the metabolism of both aniline 
and hexobarbitone would be inhibited. However compounds that 
are rapidly cleared by the perfused liver are susceptible to 
changes in blood flow whereas for those compounds whose 
clearance is slow changes in blood flow are offset by increases 
in clearance (Branch, Shand and Nies, 1973a, b; Nies, Evans 
and Shand, 197 3; Branch, Nies and Shand, 1973). Hexobarbitone 
is metabolised at more than three times the rate of aniline 
in the perfused liver so that it is possible that during the
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restricted circulation caused by catecholamines aniline rneta- 
bolism by the central hepatocytes increases to compensate for 
decreased metabolism by peripheral cells whereas hexobarbitone 
metabolism could already be maximal and so would not increase 
further to offset decreased metabolism in the periphery. It 
would be fortuitous however if the two effects were to exactly 
balance out, as they would have to, since no net change in 
aniline metabolism occurs.
Another possibility is that the enzymes responsible for 
aniline and hexobarbitone metabolism are distributed unevenly 
throughout the lobes. If the enzymes of aniline metabolism 
are located in the centre of the lobes and those of hexobarbi­
tone metabolism in the periphery the redistribution of blood 
flow caused by catecholamines would result in a selective in­
hibition of hexobarbitone metabolism. However a search of 
the literature failed to reveal any evidence that any micro­
somal drug-metabolising enzymes are unevenly distributed 
throughout the lobes, although there is.good evidence that at 
least some of the enzymes of drug metabolism are unevenly 
distributed throughout the liver lobule (Wattenburg and Leong, 
1962; Rappaport, 1973).
The third possibility to be considered is that a peri­
pheral hypoxia caused by a redistribution of blood flow 
selectively inhibits hexobarbitone metabolism. Exposure of 
rats to hypoxia causes a subsequent decrease in the metabolism 
of type I substrates by the microsomal fraction whereas the 
metabolism of type II substrates is unaffected (Kato and 
Gillette, 1965). Incubation of the microsomal fraction in 
graded oxygen concentrations has shown that aniline metabolism
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is relatively resistant to the effects of hypoxia, even at 
very low Pq values, whereas the metabolism of type I com­
pounds is inhibited at values even slightly below normal
(Kampffmeyer and Kiese, 1964). The metabolism of hexobarbi­
tone is also reduced in the perfused liver by hypoxia (Cumming 
and Mannering, 1970; Bock et al, 1972). However no studies 
have been carried out on the effects of hypoxia on the meta­
bolism of a type II substrate by the perfused liver.
The liver in vivo receives blood with a low oxygen con­
tent so that it may normally be close to hypoxia (Cumming and 
Mannering, 1970). The total oxygen content of arterial blood, 
measured by the Lex-C^-Con total oxygen analyser, is between 
10 and 12 vol% and in venous blood between 5 and 7 vol% 
(Valeri, Zaroulis, Marchionni and Patti, 1972). The hepatic 
artery accounts fpr less than 20% of blood flow to the liver 
(Fischer, 1963), thus the mean oxygen content of blood reach­
ing the liver is no more than 6.8 vol%. In the present study 
the total oxygen content of the perfusion medium measured in 
the same way is 8.6 vol%. Since the liver is perfused at a 
flow rate similar to that in vivo (Ross, 1972) the level of 
oxygenation of the liver must closely resemble that in vivo 
since, in vivo, blood entering the* sinusoids is almost 
entirely mixed venous blood (Greenway and Stark, 1971) .
Thus catecholamines, by causing a redistribution of blood 
flow within the liver, may cause hypoxia of peripheral hepato- 
cytes, which would result in a selective inhibition of hexo­
barbitone metabolism since the metabolism of hexobarbitone is 
'very susceptible to hypoxia and that of aniline is not. In
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liver slices, which by their nature are not dependent on 
blood flow, oxygen being supplied by diffusion, the metabolism 
of neither substrate was affected by the catecholamines 
adrenaline and noradrenaline.
It has been suggested that drug metabolism in the perfused 
liver may compete with intermediary metabolism for the 
available molecular oxygen (Cumming and Mannering, 1970; Bock
et al, 1972) and evidence to this effect was provided by 
Scholz, Hansen and Thurman (1973) who found that the metabolism 
of type I substrates in the perfused liver reduced gluconeo- 
genesis by competing for molecular oxygen. Although the re­
verse effect has not been reported, at high rates of inter­
mediary metabolism oxygen utilisation in the perfused liver 
can increase three-fold (Woods and Krebs, 1972). Both adren­
aline and noradrenaline stimulate intermediary metabolism 
(Sutherland and Robison, 1966) and increase oxygen utilisation 
in the liver (Andrews and Glockling, 1956) adrenaline being 
the more potent compound. Since the liver is normally close 
to hypoxia such an overall increase in oxygen utilisation 
would enhance an hypoxia caused by the blood flow redistribu­
tion caused by catecholamines and would explain why adrenaline 
causes a greater inhibition of hexobarbitone metabolism in 
the perfused liver than noradrenaline, despite the similarity 
in the magnitude of the pressor response caused by the two 
catecholamines.
One possible criticism of the present investigation is 
2 +that removal of Ca from the perfusion medium would affect 
the metabolic effects of catecholamines as well as the vascular 
effects. There is evidence that the mechanism of stimulation
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of adenyl cyclase by glucagon in the liver differs from that
• 2 +  for adrenaline, the glucagon system not requiring Ca unlike
that for adrenaline (Bitensky, Russell and Robertson, 1968;
Marinetti, Ray and Tomasi, 1969). However more recent evidence
in other tissues suggests that stimulation of adenyl cyclase
2 ~h 2 +by catecholamines does not depend upon Ca , and that Ca may
in fact inhibit the enzyme (Andersson, 1972; Matsuzaki and
Dumont, 1972). In the isolated perfused rat liver the metabolic
2 +effects of catecholamines were not affected by omitting Ca
from the perfusion medium (Exton et al, 1971). It was con-
2 +eluded from this that if Ca was necessary for the metabolic
effects of catecholamines there was sufficient in the tissue
2 +and the removal of Ca from the perfusion medium would only 
affect the vascular effects of these compounds.
The vessels of the portal tree have been shown to be 
sensitive to sympathomimetic compounds, which cause a redis­
tribution of blood flow. In addition many of the vessels of 
the hepatic portal tree have a sympathetic innervation 
(Brauer, 1963) and the possibility that this innervation plays 
a role in regulating blood flow distribution within the liver 
in vivo is discussed in Appendix II. It seems reasonable to 
suggest that a mechanism for the redistribution of blood flow 
could exist in vivo which would be sensitive to catecholamines 
released from the adrenals, sympathetic nerve endings, or both. 
This would either directly or indirectly modify the activity 
of the drug-metabolising system. It has recently been found 
that hypoxic hypoxia decreases drug metabolism to a greater 
extent than CO-hypoxia and it was suggested that this could 
be due to alterations in blood flow within the liver (Montgomery 
and Rubin, 1973a, b). During enzyme induction by phenobarb'itone
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part of the increase in in vivo drug metabolism has been 
attributed to an increased blood flow through the liver 
(Ohnhaus/ Thorgeirsson, Davies and Breckenridge, 1971) which 
may be caused by relaxation of sphincteric tone in the liver 
blood vessels.
An interesting finding by Vainio (197 3) is that in
endotoxin shock the metabolism of type I substrates by the
microsomal fraction was immediately inhibited whereas that
of type II substrates was initially elevated. The author
suggested that this decreased metabolism of drugs could also
decrease the metabolism of naturally occurring steroids which
/
have a therapeutic effect in this syndrome. It may be that 
there is a reduction in drug metabolism as part of the body's 
defence mechanism to maintain elevated levels of circulating 
steroids. In stress, as well as a release of steroids, there 
is an increase in circulating catecholamines released from 
the adrenals (Irvine, Cullen, Stewart, Ewart and Baird, 1968) 
and it may be that one of the roles, of the catecholamines is 
to cause redistribution of blood flow within the liver and 
thereby limit the destruction of these steroids.
6.3.6- Pre-treatment of rats with catecholamines
When rats were pre-treated with noradrenaline the meta­
bolism of both aniline and aminopyrine by the microsomal 
fraction was increased within 30 min, whereas pre-treatment 
with adrenaline caused a slight inhibition in the metabolism 
of both substrates. It has been found previously that pre­
treatment of rats with adrenaline (Fouts, 1962) or noradren­
aline (Dixon et al,. 19 64) increased the microsomal metabolism
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of type I substrates within 2 h. The metabolism of type II 
substrates was not investigated at time intervals less than 
2 h. These findings were not pursued as the authors were 
concerned with the longer term effects of catecholamine pre­
treatment on drug metabolism.
Although Gielen and Nebert (1972) found that noradrenaline
induced benzpyrene hydroxylase in cultured foetal rat liver
cells the short time course of events in the present study,
maximum effect within 30 min, almost certainly precludes
enzyme induction as the mechanism of action (Conney, 1967).
Thus catecholamines must be acting by either a direct effect
/
on some component of the microsomal drug-metabolising system 
to cause an alteration in activity, or affecting the release 
of some endogenous compound which in turn is responsible for 
modifying the activity of some portion of the microsomal 
fraction.
Since drug-metabolising activity was studied in an isolated 
microsomal fraction, to which was added optimum concentrations 
of all the necessary co-factors for drug metabolism, catechol­
amines could not be acting by altering the endogenous levels 
of some co-factor. Examination of the components of the micro­
somal electron transport chain revealed that catecholamine 
pre-treatment does not affect cytochrome P-4 50 levels or the 
activity of NADPH-cytochrome c reductase. Cytochrome b^ levels 
are reduced 30 min after pre-treatment with either adrenaline 
or noradrenaline. The significance of this finding to the 
effects of catecholamines on drug metabolism is unknown. The 
role of cytochrome b^ in drug metabolism is however debatable
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and has been discussed in Section 2.2.4. It appears unlikely 
that catecholamines are affecting drug metabolism by directly 
modifying some component of the drug-metabolising system.
An alternative mechanism is that catecholamines were 
altering the levels of some endogenous modifier of drug 
metabolism. This is quite possible. For example, cortico­
sterone inhibits drug metabolism (Radzialowsky and Bousquet, 
1968) and noradrenaline inhibits the secretion of ACTH in the 
rat, thereby reducing the plasma levels of corticosterone 
(Scapagnini, Van Loon, Moberg, Preziosi and Ganong, 1972).
Thus noradrenaline, acting by reducing the levels of an in­
hibitor, might appear to stimulate drug metabolism. However 
adrenalectomy did not alter the effects of pre-treatment with 
either adrenaline or noradrenaline (Boobis and Powis, 197 3) 
so that adrenal steroids do not appear to be involved. 
Catecholamines may act, however, by altering the levels of 
some other modifier but how this would act without affecting 
the components of the microsomal drug-metabolising system is 
not clear.
Experiments with 3H-noradrenaline revealed that high con­
centrations of the catecholamine or its metabolites were 
present in the liver at the time of isolation of the micro­
somal fraction, although very little of the label was.bound 
to the microsomes themselves. It was therefore unlikely that 
catecholamines were exerting their effects on drug metabolism 
by direct interaction with the microsomal enzymes after pre- 
oaration of the microsomes. This was further supported by 
incubating the microsomal fraction with catecholamines. There
137
was no significant alteration in the metabolism of either 
aniline or aminopyrine.
The presence of catecholamines in the liver homogenate 
during preparation may have some effect on the activity of 
the microsomal fraction. This was investigated by washing 
the microsomal fraction in sucrose containing catecholamine. 
This caused changes in drug-metabolising activity similar 
to those observed after pre-treatment of rats with catechol­
amines. Washing microsomes in sucrose alone resulted in a 
reduction in drug-metabolising activity, which was prevented 
by noradrenaline. Adrenaline however increased the loss of 
activity that occurred on washing the microsomes. The effects 
of catecholamines on drug metabolism during washing of the 
microsomes could not be properly evaluated until the effects 
of washing itself had been studied in more detail. The re­
maining part of the study was concerned with an investigation 
into this aspect of drug metabolism.
6.4 Effect of washing microsomes
6.4.1 Metabolism of type I and type II substrates
Washing microsomes in sucrose buffer causes a reduction 
in the metabolism of type I substrates but very little change 
in the metabolism of type II substrates. Catecholamines 
largely prevent this loss of activity. Catecholamines are 
known inhibitors of lipid peroxidation (Privett, 1962) so 
the effects of another inhibitor of lipid peroxidation, EDTA 
(Chatterjee and McKee, 1965) were investigated. When micro-
138
somes were washed in EDTA no loss of drug metabolism occurred 
and the metabolism of both type I and type II substrates was 
even increased compared to control values. It may be that 
EDTA, either itself or by some chelating action, alters the 
configuration of the type I binding site to increase the 
binding of substrates, and in fact increased binding of type 
I substrates was observed in microsomes washed in EDTA.
2 +When other inhibitors of lipid peroxidation were tested Mn ,
BHT and EGTA had some protective effect but this was less
than that of EDTA. However vitamin E and its salts and BHT
are not water soluble so that there may have been insufficient
2+compound in solution to have much of an effect. Mn , although 
inhibiting enzymatic lipid peroxidation, has little effect on 
non-enzymatic lipid peroxidation (Kitabchi, McCay, Carpenter, 
Trucco and Caputto, 1960).
Several reports in the past have shown that there is 
competition between some hepatic microsomal mixed function 
oxidase reactions and enzymatic lipid peroxidation (Orrenius 
etal, 1964; Gram and Fouts, 1966; Lewis et al, 1967; 
Carpenter, 1972). However in most instances, although drug 
metabolism was shown to inhibit lipid peroxidation, an in­
hibition of the lipid peroxidation did not stimulate drug 
metabolism as might have been expected (Gram and Fouts, 1966; 
Carpenter, 1972). More recently Kamataki and Kitagawa (1973) 
have shown that inhibition of lipid peroxidation can stimulate 
the microsomal metabolism of foreign compounds. Lewis et al 
(1967) had already shown that microsomal epoxidation could be 
increased by inhibitors of lipid peroxidation but that if 
microsomes were pre-incubated with NADPH the loss of epoxi­
dation activity could not be completely reversed by inhibitors
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of lipid peroxidation. It appears that there may thus be 
two different components of inhibition, one a simple com­
petition between enzymatic lipid peroxidation and drug meta­
bolism, for NADPH or oxygen, and the second a structural 
alteration caused by either enzymatic or non-enzymatic 
peroxidation of the lipid of the microsomal membrane that
results in loss of activity.
Although it was found that inhibitors of lipid peroxida­
tion did cause some increase in drug metabolism during 30 
min incubation at 37°C, and would inhibit the formation of 
malonaldehyde, a product of lipid peroxidation, this effect 
was insufficient to account for the effect of washing the 
microsomes. Peroxidation of the. microsomal lipid increased 
during the washing of microsomes in sucrose, and was in­
hibited by EDTA. Because of the absence of NADPH during
the washing process and because it occurred at 2°C, it is 
probable that the process was non-enzymatic. A similar 
process occurs when microsomes from vitamin E deficient rats 
are incubated with the post-microsomal supernatant (Kitabchi 
et al, 1960). In this instance material in the supernatant 
stimulated lipid peroxidation by the microsomes, and the
process was non-enzymatic. It was suggested.that some ion in
2 +the supernatant, possibly Fe is an activator. In the present 
investigation it was found that none of the components of the 
microsomal electron transport chain were affected by washing. 
Hochstein and Ernster (1964) found that NADPH-cytochrome c 
reductase was not affected by lipid peroxidation but both 
cytochrome b^ (Tappel and Zalkin, 1960) and cytochrome P-450 
(Levin, Lu, Jacobson, Kuntzman, Poyer and McCay, 1973) have
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been shown to exhibit lability to prolonged incubation during 
which lipid peroxidation occurs.
In the present study the relatively specific loss of the 
metabolism of type I substrates, the lack of effect on the 
components of the electron transport chain and, in addition, 
the changes observed in the binding of substrates by cyto­
chrome P-450 led to the conclusion that perhaps lipid 
peroxidation and the binding of substrates by cytochrome P-450 
were connected. Phospholipids have recently been shown to 
be involved in the type I binding site of cytochrome P-450
and the phospholipid involved was identified as phosphatidyl-
/
choline (Chaplin and Mannering, 1970). Lipid peroxidation 
may therefore cause degradation of phosphatidylcholine with 
loss of type I binding, and if lipid peroxidation is pre­
vented type I binding is protected.
Although type I binding is not obligatory for metabolism,
it is facilitative (Chaplin and Mannering, 1970) so that a
reduction in type I binding will cause a reduction in the
metabolism of type I substrates. Washing microsomes increases
non-enzymatic lipid peroxidation, perhaps because some
endogenous inhibitor in the post-microsomal supernatant is
lost, and this causes decreased binding of type I substrates .
resulting in a decreased metabolism. EDTA, by inhibiting
2 +lipid peroxidation, perhaps by chelation of Fe , prevents these 
effects.
This raises the question of whether there is a similar 
loss of activity during the original isolation of the micro-
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somal fraction. It was found that the post-microsomal 
supernatant had similar protective effects to EDTA during 
the washing process. There thus appears to be an endogenous 
inhibitor of lipid peroxidation present in the post-micro­
somal supernatant. Grimwade, Lav/son and Boyd (1971) found a 
heat-stable, thiol-containing, inhibitor of enzymatic lipid 
peroxidation in rat liver supernatant and Grinna and Barber 
(197 3) have found a heat-labile inhibitor of lipid peroxida­
tion, possibly protein, in rat hepatic post-microsomal super­
natant. It may be that several different compounds can 
cause inhibition of lipid peroxidation, all acting by non­
specific binding of ions normally necessary for peroxidation.
/
It may be, however, that specific modes of action are in­
volved. Although there are inhibitors present it is pro­
bable that some non-enzymatic lipid peroxidation does occur 
during the original isolation of microsomal fraction. If 
this were inhibited by catecholamines or their metabolites, 
which are present in the liver supernatant in high concentra­
tions after pre-treating rats with,catecholamines, then 
there would be an apparent increase in drug-metabolising 
activity. If adrenaline has such an effect it appears to be 
masked by an additional inhibitory effect present during 
preparation of the microsomes, which is not observed when 
microsomes are incubated with adrenaline. This mode of 
action of catecholamines remains a possibility in view of 
the observed results and the known effects of the compounds, 
but it is as yet unproven, and some other ‘mechanism may be, 
in part or totally, responsible for the observed effects of 
catecholamine pre-treatment on drug metabolism. Inhibition 
of lipid peroxidation by catecholamines has been suggested 
as their mode of action in stimulating steroid hydroxylation
in adrenal microsomes (Lewis et al, 1967).
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The similarity between the effects of washing the micro­
somes and storage of the microsomes at 0°C leads to specula­
tion that a common mechanism is involved in the loss of drug- 
metabolising activity. Both processes lead to a decreased 
metabolism of type I substrates and loss of type I binding. 
Similar effects of storage have been found by other workers 
(Shoeman et al, 1969; Hewick and Fouts, 1970). Chan and 
Terriere (1969) have shown that storage of microsomes at 4°C 
causes increased lipid peroxidation and that the decreased 
drug-metabolising activity in stored microsomes was due to 
degradation of lipid rather than an inhibitory effect of 
accumulated product of the reaction. In the present study 
EDTA and post-microsomal supernatant, both of which inhibit 
lipid peroxidation, prevented some of the loss of type I 
drug-metabolising activity after storage. It is thus possible 
that during storage lipid peroxidation occurs and the reaction 
causes degradation of phosphatidylcholine, necessary for the 
integrity of the type I site, and thereby causing a reduction 
in the metabolism of type I compounds.
6.4.2 Acetone enhancement of aniline metabolism
In the past few years considerable interest has centred 
on a group of compounds with the ability to enhance drug 
metabolism. These compounds will increase the specific 
activity of the microsomal fraction in metabolising type II 
compounds, such as aniline (Anders, 1971). The mechanism of 
action of most enhancers is not known. One of the most
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widely investigated enhancers is acetone, and since this
compound is the only enhancing agent found endogenously,
-2it can reach concentrations of 10 M in untreated diabetes 
(Solway, Trotter, Trotter and Malins, 1971) , it was thought 
earlier in the investigation that the effects of catechol­
amine pre-treatment of rats on hepatic microsomal drug- 
metabolising activity could be due to enhancement in a 
manner analogous to that of acetone. However subsequent 
work soon revealed that catecholamines had no direct effect 
on drug metabolism. It is still possible that some endogenous 
compound liberated by catecholamines and present in liver 
homogenates can enhance drug metabolism.
Because of these early lines of thought the effect of 
washing on the acetone enhancement of aniline metabolism 
was investigated. Rather surprisingly acetone enhancement 
was affected in a manner similar to the metabolism of type I 
compounds. Washing the microsomes almost completely 
abolished acetone enhancement, and EDTA or post-microsomal 
supernatant prevented this loss of activity. Storage of the 
microsomal fraction, while not causing a great reduction in 
aniline metabolism, completely abolished acetone enhancement.
Recently it has been shown that acetone promotes the 
type I binding of type II substrates and that degradation of 
phosphatidylcholine, which causes loss of type I binding, 
also inhibits acetone enhancement (Vainio and H&nninen, 1972). 
Thus the increase in aniiine metabolism caused by acetone 
more closely resembles the metabolism of type I compounds in 
properties than it does the metabolism of type II substrates.
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It is therefore probable that acetone causes enhancement 
of type II substrates by promoting their binding to type I 
sites, and since type I binding stimulates the reduction of 
the cytochrome P-450 - substrate complex (Gigon et al, 1969) 
this will cause increased metabolism.
Although acetone was reported not to cause a spectral 
change (McLean, 1967; Anders, 1972) in the present investiga­
tion it was found to produce a type II spectral change, an 
observation that was subsequently substantiated in a paper by 
Vainio and H&nninen (1972). Since type II substrates inhibit
the reduction of the cytochrome P-450 - substrate complex
/
(Gigon et al, 1969) it is possible that acetone inhibits the 
metabolism of type I compounds by this mechanism. The in­
hibitory effect of acetone on aniline metabolism could be 
more than overcome by the enhancing effect of type I binding 
of a substrate that was previously inhibiting its own 
metabolism.
APPENDIX I
Curve stripping and model fitting
This appendix describes the derivation of a model for 
the removal of aniline by the isolated perfused liver.
I.1 Symbols used
The symbols used in the equations that follow are: 
t time, min
n number of compartments in the system
amount of compound in compartment j, ymol 
K rate constant for transport from a compartment, min  ^
q^(0 )amount of compound in compartment j at t = 0 , ymol 
coefficient of the ith exponential term 
X ' constant of the ith exponential term
rate constant for transport into compartment 2 , min ^
Kq rate constant for transport out of compartment 2 , min
rate constant for transport leading to loss, min ^
The other symbols used are explained in the text.
1.2 Curve stripping
In a multi-compartment system, the mathematical model for 
the distribution of a compound can be expressed (Atkins, 19 69)
.t
q^  = EX^e (j = 1 , . .. . , n)
As t tends to a large value, so
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Taking log^Q
log q1 = log X^ - 0.4343Ant (1 )
If the data are plotted semi-logarithmically against t then
a straight line through the last few points has an intercept
_A t
X at t = 0 and a gradient A . If the term X e n is n  ^ n n
subtracted from the remaining data points not fitted to the 
line this gives the curve
_A.t
qj = ZX_.e 3 (j = 1, . . . . , . n-1)
The points are re-plotted and the prQcess is repeated until 
all the terms have been resolved. The Equation of the curve 
is now
A t A t
q = X, e” +   + X e~ n^ 1 n
1.3 Model fitting
Graphical analysis of the data by curve stripping revealed 
that aniline disappearance was biphasic, and followed the 
equation
-0.0343t , -0.0067tq = 50e + lOOe
with q(0) = 150 ymol
50 and 1 0 0 were the intercepts of two exponentials on the
Y-axis and 0.034 3 and 0.0067 were the gradients of the two
exponentials calculated from the expression
2.303 (log Y (0)-log Y(t)) m =  —   ------
This means that aniline is probably distributed throughout a 
two compartment system. The simplest model that can be 
postulated, allowing for a loss of aniline from the system by 
metabolism, is represented thus, with rate constants as shown.
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K.l
1 2
Ko
K
Let the amount of aniline in compartment 1 =
and the amount of aniline in compartment 2 = q2
d(q )
The rate of change of substrate may be represented —
then the differential equations for the amount of aniline in
each compartment at steady state can be represented
d(qx)
dt = KQq2 - (K, + K j qe'^1
d (q2)
dt = K.qn - K q0 1^1 0^2
Since q^ is a function of time it may be represented by the 
function f^  (t).• Rewriting the expressions above 
with q^ = f-^ (t) 
and q2 = f2 (t), then
dfn (t)
- 3 E -  = Kof2 (t) - Kifl (t) - Kefl (t)
df.(t)
gt-  = K±fi (t) “ Kof2 (t)
Now use the Laplace transformation
F(s) for f(t) 
and s.F(s) - f(0) for -3 -^—
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and substitute, then
S.F^s) - f1 (0) = KqF2 (s) - K±F1 (s) - KeF1 (s) 
s.F2 (s) -  f2 (O) =  KiF1 (s) -  KqF2 (s)
At t = 0 aniline will only be present in compartment 1 so
fx (0 ) = (0 ) and (0 ) = 0
Substitute to give
s.F1 (s) - qi(0) = KqF2 (s) - KiF1 (s) - KeF1 (s) 
s.F2 (s) = KiF1 (s) - KqF2 (s)
Rearrange
(s + K. + Kj.F^s) - KqF2 (s) = qjL(0)
- KiF1 (s) + (s + KQ).F2 (s) = 0 
Solution of these equations gives *
F, (s) =
q1 (0 ). (s + Kq)
l v ' (s + K. + K ) (s + K ) - K.K l e o i.o
and Fn (s) =
qx (0).K.
2 (s + K. + K ) (s + K ) - K.Ki e q i o
These equations can be resolved into partial fractions which 
gives the result
ql (0)-(Al “ V  qx (0 ).(Ko - X2)
F l (s) (X1 - X2) (S +  Xx ) +  (Xx -  X2) (s  +  X 2 )
q 1 (o)Ki  q1 (o)Ki
F2 (S) - x2> (s + Xi) (X1 " X2) (s + A2*
- (K + K. + K ) - /(K + K. + K ) + 4K K. o i e o i e e o
where 1 =  :------------------ 2----------------------
- (K + K. + K ) + /(K + K. + K ) 2 + 4K KX o l e • o l e e o
Now performing the inverse Laplace transformation
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q-. (o) x t  x t
*i = . iq ;■-  x-2> • {(xi - Ko)e + (K0 - X2 )e" }
ql(0)K. r _Xxt _X2t; 
2 (X x - X2) ' {e " e }
These may be reduced to the form
X , t X
q-L = X ie “ 1 + X 2e" /  (2)
X t X pt
q2 = X3e“ 1 - X3e” Z (3)
where
q^Q) (XX - Ko)
xi = ■- (X, - x2) <«>
qi(°)(Ko - X2)
X 2 = --- (X----X-—  ' (5)
q , ( o ) K
X3 = (X1 - X2) <6>
In addition the equations for X ^  and X 2 can be reduced so that
X1X 2 = KeKo (7)
and X, + X - = K .  + K + K (8 )
1 2 i o e
I.4 Experimental results
-0.0343t , -0.0067tq.. = 50e + lOOe
1
So that from (2)
X^ = 50 ymol 
X2 = 1 0 0 ymol 
X^ = 0.034 3 min  ^
X2 = 0.0067 min  ^
and q(o) = 150 ymol
150
150 x (0.0343 - K )
From (4) - ( 0 > 0 3 4 3 0 .0067) = 5 0
Hence K = 0.0251 min 10
From (7) 0.0343 x 0.0067 = K x 0.0251e
So K = 0.0091 min""1e
From (8 ) 0.0343 + 0.0067 = 0.0251 + 0.0091 + K
So K. = 0.0068 min 11
By substituting these values for the rate constants back 
into the equations for and it is possible to obtain the 
predicted values of these constants.
Using equations (4), (5) and (6 ) to obtain predicted
values of X^, and X^ it is possible to solve equations 
(2) and (3) to obtain a predicted curve for the amount of 
aniline in compartment 1 and compartment 2 at different times.
If the formation of acid-labile aniline conjugate, C is 
assumed to be first order the rate of formation is given by 
the expression
dq
-d§ = Kc %
qr is known experimentally and q. can be obtained from the 
solution already described. Solving this expression by the 
type of analysis above yields
Kc = 0.0042 min 1
If it is initially assumed that Kg represents all the 
metabolic loss of aniline from the perfusion medium 
(compartment 1 ) then Ke ~ Kc = other losses apart from the 
formation of acid-labile conjugate of anilne.
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An estimate of the remaining rate constants for aniline 
loss by processes such as bile formation can be obtained from 
the general expression
Amount of aniline lost by process a (A) a
Amount of aniline lost by process b (B)
A, B etc. are obtained from the values in the histogram shown 
in Fig. 14.
The results are
K = 0.0010 min  ^Aniline lost in bile B
= 0.0013 min  ^Aniline lost by transexudation
and sampling errors
= 0.0008 min  ^Aniline lost by metabolism to 
unidentified metabolites
KP = Ke ' KC " (KB + KL ^  V
Hence Kp = 0.0018 min  ^ Aniline lost by metabolism
to p-aminophenol
Para-aminophenol formation must be estimated by subtraction 
because the binding of free p-aminophenol to haemoglobin does 
not permit an experimental value for the total formed in 3 h 
to be determined
However from Kp and the amount of p-aminophenol detected 
in the medium it can be estimated that ^3 3% of the p-amino­
phenol formed is bound to haemoglobin and the remaining 67% 
is detected as a conjugate. These two processes may be zero 
order since a first order reaction results in an appearance 
curve which begins to plateau after 3 h whereas the experimental 
data indicates an almost linear formation of p-aminophenol 
after 60 min (Fig. i4). “
Since the experimental data correlates so closely with 
the predicted curves from the model (Fig. 39) it is apparent 
that the data is not inconsistant with the postulated model.
APPENDIX II
The Hepatic Circulation
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II.1 Introduction
When it was realised that the effects of catecholamines 
on hexobarbitone metabolism in the perfused liver were 
possibly due to an effect of hepatic blood flow the literature 
was consulted to determine the known effects of catecholamines 
on blood flow in the liver. However•it was soon found that a 
considerable controversy exists as to whether or not there is 
any regulatory mechanism of blood flow distribution within 
the liver, and from this it follows that there is little 
agreement on what effects catecholamines have on blood flow 
in the liver. This appendix has been designed to review the 
information available to date on this subject. A short review 
on the anatomy of the hepatic circulation is included, against 
which background the effects of sympathomimetics is discussed.
II-• 2 The anatomy of the hepatic circulation
The liver receives two supplies of blood, one from the 
portal vein and one from the hepatic artery. The former 
normally supplies 80% of the blood to the liver (Fischer, 1963). 
The portal venous tree branches considerably (Elias and Petty, 
1952) and these branches can give off side branches of all 
the higher orders down to terminal vessels, along their entire 
path through the liver, unlike other veins which terminate in 
two or three branches of the next higher order (Elias and 
Petty, 1952; Elias and Gershbein, 1954; Knisely, Harding and 
Debacker, 1957). These offshoots of the portal vein finally 
supply blood to the sinusoid bed, which.is also extremely 
complex, consisting of a series of interconnected blood spaces
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(Elias, 1949, 1953). The sinusoids of one lobe of the 
mammalian liver are in direct communication with all other 
similar vessels of that lobe (Hyrtl, 1873) .
Much controversy still exists as to the detailed anatomy
of the hepatic arterial supply to the liver (Brauer, 1963;
Greenway and Stark, 1971) and the role of the hepatic artery
is still in question. Friedman, Milrod, Frank and Fine (1953)
ligated the hepatic artery of a dog without any apparent
adverse effects. However, more recently, the possible role
of the hepatic artery in providing a functional reserve of
oxygen has been put forward (Nakata and Kinosita, 1963; Fischer,
/
1963), although in small animals such as the rat this does not 
appear to be an important consideration and the liver of the 
rat has been shown to function normally in the absence of an 
arterial blood supply even during metabolic stimulation at 
which time oxygen uptake would be greatly increased (Hems et al, 
1966; Powis, 1970). It has been established that the hepatic 
artery does not provide a significant supply of blood outside 
of the portal tracts (Olds and Stafford, 1930; Cameron and 
Mayes, 1930; Julian and De Ome, 1948; Andrews, Maegraith and 
Wenyon, 1949; Elias and Petty, 1953; Nakata and Kinosita,
1963). Studies on bromsulphthalein clearance (Brauer et al,
Q [T
1959) Kr washout curves (Hollenberg and Dougherty, 196 6 ) and 
later with tagged serum albumin and red cells (Cohn and 
Pinkerson, 1969) led to the conclusion that most of the 
arterial blood is mixed with portal venous blo.od before enter­
ing the sinusoids, .though some direct arteriole pathways may 
supply unmixed arterial blood direct to the proximal end of a 
few sinusoids (Chenderovitch and Caroli, 1956; Greenway and 
Stark, 1971). In addition to admixing with portal blood and
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supplying a few sinusoids directly the hepatic artery is 
thought to supply the capillary network round the bile duct 
which drains into the portal vein (Andrews et al, 194 9; Elias 
and Petty, 1953; Elias and Sherrick, 1969).
II.3 The regulation of the intrahepatic distribution of blood 
flow
In his excellent review on liver circulation Brauer (1963) 
makes the important point that blood flow through the normal 
liver in vivo is not determined by intrahepatic factors, so 
that the liver behaves like an organ in a perfusion system, 
the system determining externally the rate of blood flow through 
the tissue, with other parameters stabilising at associated 
values. Circulatory regulation within such a system would 
depend on modifications of the blood flow distribution within 
the organ rather than changes in the total resistance to flow.
The existence of sphincteric mechanisms within the hepatic 
vasculature capable of causing a redistribution of blood flow 
is still in dispute (review by Greenway and Stark, 1971). In 
his prior review, Brauer (1963) cited considerable evidence 
that constriction of the portal vein prior to the major sinu­
soidal bed could occur as well as constriction of arterioles, 
selected portal and hepatic venules and possibly some parts 
of the sinusoids themselves. More recently Elias and Sherrick 
(1969) proposed that the weight of evidence suggested the 
presence of sphincters in-the portal venous inlet branches, 
in the sinusoidal outlets, at the entrance of the central into 
sublobular vein and, in addition, at several different arteriolar
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sites. It was further suggested that Kupfer cells in the 
walls of the sinusoids may act to regulate blood flow, a 
suggestion which has been repeated by Conway and Saba (1972) 
and Rappaport (1973).
Sphincters have been described at the ends of sinusoids 
by many groups (Irwin and MacDonald, - 1953; Bloch, 1955; 
Knisely et al, 1957).
McCuskey (1966) used direct transillumination of the 
in vivo liver, coupled with video recording, to demonstrate 
the apparent presence of both pre- and post- sinusoidal 
sphincters and, in addition, sphincters at the junction of 
intrasinusoidal sinusoids. He claimed that the sphincters 
consisted of reticuloendothelial cells and that they may 
act by contraction of intracellular fibres. Reticular fibres 
had already been reported from electron microscopic studies 
of the sinusoid wall (Wasserman, 1958). In what was an 
extremely explicit, demonstration, by a direct means, of 
apparent sinusoidal sphincters McCuskey (1966) attributed 
the failure of other workers to observe such structures in 
transilluminated livers to poor resolution caused by movement 
of the liver or low magnification (Seneviratne, 1949; 
Maegraith, 1958; Brauer, 1963). Although Ho and Ma (197.2) 
have shown considerable evidence to the contrary they were 
unable to visualise the presence of sphincters at these sites. 
These authors concluded that this was due to an abolition of 
vasomotor tone by the anaesthetic.
There is a large pressure drop between the portal venule
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and the hepatic venule (Nakata, Leong and Brauer, 1966).
This they attributed to possible deviations of the sinusoids 
from Poiseuille assumptions, since it had been concluded 
that there were no sinusoidal contractile elements due to the 
failure to demonstrate the existence of such structures 
photographically both by themselves and by several other 
groups. However subsequent work has provided apparent photo­
graphic proof of the presence of sphincters in the hepatic 
sinusoids and this has led several workers to point out that, 
in the light of this evidence, the pressure drop across the 
sinusoids could be explained simply, in terms of such struct­
ures (McCuskey, 1966; Noguchi and Plaa, 197,0) .
/
It is thus apparent that at present the anatomical 
evidence for the existence of regulatory sphincters in the. 
hepatic vasculature is in considerable dispute. Some groups 
accept that sufficient evidence exists to establish beyond 
doubt the presence of such a system for control of the dis­
tribution of blood flow whereas other groups deny this and 
cite the negative results, of other papers to support their 
claim that no such system operates in the mammalian liver.
II.4 The effect of nerve stimulation and vasoactive compounds
on the flow of blood and its distribution within the liver
Early work had indirectly shown that sympathetic nerve 
stimulation caused vessels of the portal tree to constrict 
(Bayliss and Starling, 1894; Francois-Franck and Hallion,
1897; Burton-Opitz, 1912a, b, 1914; Griffith and Emery, 1930; 
Eckardt, 1935). Adrenaline was reported to cause constriction 
of portal venules, sinusoids and efferent venules (Loeffler
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and Nordmann, 1925), portal venules and sinusoids (Seneviratne, 
1941) and sinusoids only (Wakim, 1944).
In the rat Daniel and Prichard (1951a, b) observed that 
sometimes the liver showed a restricted circulation. It was 
surmised that this could be due to sympathetic nerve activity. 
Daniel and Prichard, using X-radiography, (1951c) then showed
that direct stimulation of the hepatic sympathetic nerves, or 
the portal venous administration of adrenaline, produced a 
restricted intrahepatic blood flow.
In his review, Brauer (1963) concluded that catecholamines
/
caused active vasoconstriction of the portal venous tree thus 
causing a transition from a diffuse to a restricted intra­
hepatic circulation, so that the total number of hepatic vascular 
channels perfused is reduced. The total blood flow will be 
relatively unaffected. Andrews (1957) and Greenway and Stark 
(1971) have since again made the point that« the administration 
of catecholamines to the general circulation results in either 
no change in the total blood flow to the liver or in an in­
crease in flow. They demonstrated that this was the result 
of a reflex initiated by the aortic and carotid sinus receptors.
Direct transillumination of the rat liver revealed that 
catecholamines cause constriction of what were apparently 
sinusoidal sphincters (McCuskey, 1966). Later it was demonstr­
ated in the in vivo transilluminated rat liver, that the con­
tractile elements of the portal venous circulation were under 
control of the sympathetic nervous system (Ho, 1972).
Recent work by Greenway and his colleauges (Greenway and
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Lautt,. 1970; Greenway and Stark, 1971; Greenway and Lautt, 
1972; Greenway and Oshiro, 1972b) suggests that there is no 
pre-sinusoidal sphincter in the liver of the cat. Although 
it was concluded that catecholamines had not been shown to 
cause a marked intrahepatic redistribution of portal blood 
flow it was stressed that this had by no means been positively 
established. In addition it may be of some relevance that all 
of these studies were performed on either cats or dogs. It 
was also reported that in dogs histamine causes a redistribu­
tion of portal blood flow in the liver, the flow being de­
creased at the free ends of the lobes and redistributed to
t-he hilar ends (Greenway and Oshiro, 1972a) . This was ascribed
/
to pressure changes at the hilar and free ends of the lobes.
In a subsequent paper the same authors (Greenway and Oshiro, 
1972b) concluded that sympathetic nerve stimulation did not 
cause a significant redistribution of blood flow in the liver 
of cats or dogs.
A survey of the literature reveals that catecholamines 
cause vasoconstriction of several elements of the portal 
venous system with a concomitant increase in portal venous 
pressure. In vivo, net blood flow to the liver is unaltered 
or reflexly increased. Considerable controversy exists as to 
whether vasoactive stimuli initiate a redistribution of 
portal blood flow within the liver. Evidence exists from 
transillumination studies that such a phenomenon does occur 
but in other studies, such as the use of radio-active micro­
spheres (Greenway and Oshiro, 1972b), no such redistribution 
could be observed. Several groups have generalised their 
results from a study of one, or possibly two, species.
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Whether or not species differences exist in the control of 
hepatic distribution of blood flow is still a matter of con-, 
jecture but if it did it would help to resolve some of the 
contradictions in the literature.
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